Pharma & Biotech Sector Financials, Performance and Ratios
-
Sector Score
38.1 /100
Rank 12 out of 27 Sectors -
Advance/Decline
184/489
-
No. of Companies673
-
Avg. Market Cap8,853
-
Price to Earning Ratio10.75
-
Price to Earning Growth Ratio0.87
-
Price to Book Ratio20.01
-
Return on Equity10.95
-
Return on Capital Employed-
-
Return on Assets6.99
-
Dividend yield 1 year %0.62 %
-
Net Profit Growth Annual YoY %16.41 %
-
Net Profit Growth Qtr YoY %4.26 %
-
Net Profit Growth Qtr QoQ %40.85 %
Show more
*All values are market cap weighted averages.
*All Financial parameters are in Million USD.
Pharma & Biotech Sector Market Breadth
- < -5%
- -2 to -5%
- 0 to -2%
- 0 to 2%
- 2 to 5%
- > 5%
Pharma & Biotech Peer comparison
Compare all stocks in Pharma & Biotech industry listed on stock exchanges
| Stock Name | 3M Price Chart | Market Cap | LTPLast Traded Price | Day High Low (%) | Week High Low (%) | Month High Low (%) | Qtr High Low(%) | 1 Year High low(%) | 3 Year High low(%) | 5 Year High low(%) | 10 Year High low(%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AbbVie |
|
443,359.0
|
250.9
|
L
 -2.5%
H
247
255.5
|
L
 -3.3%
H
247
267.5
|
L
 -0.1%
H
243.1
267.5
|
L
 21.5%
H
200.0
267.5
|
L
 28.5%
H
190.8
267.5
|
L
 68.9%
H
135.9
267.5
|
L
 115.8%
H
105.6
267.5
|
L
 274.9%
H
55.1
267.5
|
| Adc Therapeutics SA |
|
133.6
|
1.1
|
L
 -5.4%
H
1.0
1.1
|
L
 -8.7%
H
1.0
1.2
|
L
 -7.9%
H
1.0
1.5
|
L
 -72.6%
H
0.8
4.1
|
L
 -61.0%
H
0.8
5.0
|
L
 -30.5%
H
0.4
6.0
|
L
 -95.0%
H
0.4
32
|
L
H
0.4
56.6
|
| Amneal Pharma Inc (Class A) |
|
5,850.2
|
18.3
|
L
 -1.0%
H
17.9
18.4
|
L
 2.2%
H
17.7
19.3
|
L
 8.0%
H
16.5
19.3
|
L
 42.8%
H
11.8
19.3
|
L
 134.0%
H
7.8
19.3
|
L
 477.9%
H
3.1
19.3
|
L
 271.6%
H
1.2
19.3
|
L
 -41.2%
H
1.2
31.9
|
| Annovis Bio Inc |
|
74.4
|
1.8
|
L
 -1.1%
H
1.7
1.8
|
L
 5.4%
H
1.6
1.8
|
L
 -8.9%
H
1.6
2.2
|
L
 -12.5%
H
1.6
2.5
|
L
 -30.3%
H
1.5
5.5
|
L
 -87.1%
H
1.1
22.5
|
L
 -94.9%
H
1.1
43.4
|
L
H
1.1
132
|
| Bausch Health Companies Inc |
|
2,576.8
|
6.9
|
L
 14.3%
H
6.0
6.9
|
L
 55.5%
H
4.5
6.9
|
L
 44.4%
H
4.3
6.9
|
L
 22.0%
H
4.3
6.9
|
L
 20.7%
H
4.3
8.7
|
L
 -27.2%
H
4.0
11.5
|
L
 -76.4%
H
4.0
30.0
|
L
 -67.0%
H
4.0
34.8
|
| Bristol-Myers Squibb |
|
133,409.7
|
65.3
|
L
 0.7%
H
63.5
65.7
|
L
 5.2%
H
62.2
65.7
|
L
 17.0%
H
56.4
65.7
|
L
 12.2%
H
53.4
65.7
|
L
 47.7%
H
42.5
65.7
|
L
 6.1%
H
39.4
65.7
|
L
 -3.8%
H
39.4
81.4
|
L
 -14.3%
H
39.4
81.4
|
| Bellring Brands Inc |
|
1,440.7
|
12.4
|
L
 -5.8%
H
12.2
13.2
|
L
 -4.3%
H
12.2
14.2
|
L
 -7.2%
H
11.8
14.3
|
L
 -28.0%
H
7.8
18.3
|
L
 -77.1%
H
7.8
54.7
|
L
 -65.5%
H
7.8
80.7
|
L
 -62.5%
H
7.8
80.7
|
L
H
7.8
80.7
|
| Emergent Biosolutions Inc |
|
372.5
|
7.2
|
L
 -0.6%
H
7.1
7.3
|
L
 -0.6%
H
7.1
7.5
|
L
 -12.8%
H
7.1
8.5
|
L
 -14.8%
H
7.1
9.7
|
L
 28.2%
H
5.6
14.1
|
L
 -8.7%
H
1.4
15.1
|
L
 -89.0%
H
1.4
66.8
|
L
 -76.7%
H
1.4
137.6
|
| Elanco Animal Health Inc |
|
13,170.5
|
26.4
|
L
 -0.3%
H
25.8
26.5
|
L
 5.9%
H
25.1
26.9
|
L
 9.5%
H
23.7
26.9
|
L
 17.2%
H
19.4
26.9
|
L
 91.2%
H
13.8
27.7
|
L
 120.3%
H
8.0
27.7
|
L
 -27.7%
H
7.9
36.8
|
L
H
7.9
37.6
|
| GSK PLC (ADR) |
|
103,558.1
|
51.7
|
L
 -0.7%
H
51.4
52.0
|
L
 0.7%
H
51.4
55.8
|
L
 0.8%
H
49.9
55.8
|
L
 0.2%
H
48.6
55.8
|
L
 37.6%
H
36.8
61.7
|
L
 48.0%
H
31.7
61.7
|
L
 26.5%
H
28.5
61.7
|
L
 12.2%
H
28.5
61.7
|
| IQVIA |
|
38,684.3
|
235.0
|
L
 -1.2%
H
230.9
237.9
|
L
 13.0%
H
206.9
251.4
|
L
 15.7%
H
197.6
251.4
|
L
 49.0%
H
156.6
251.4
|
L
 28.8%
H
154.5
251.4
|
L
 7.3%
H
134.6
261.7
|
L
 -5.1%
H
134.6
285.6
|
L
 199.0%
H
70.1
285.6
|
| Johnson & Johnson |
|
617,777.5
|
256.4
|
L
 0.2%
H
253.3
258.5
|
L
 -2.7%
H
253.3
274.9
|
L
 0.9%
H
245.5
274.9
|
L
 12.8%
H
220.4
274.9
|
L
 53.2%
H
166.6
274.9
|
L
 51.8%
H
140.7
274.9
|
L
 48.9%
H
140.7
274.9
|
L
 104.4%
H
109.2
274.9
|
| Eli Lilly |
|
1,024,468.2
|
1,148.8
|
L
 -0.5%
H
1119
1150.6
|
L
 -4.0%
H
1119
1232
|
L
 -3.6%
H
1119
1249.5
|
L
 19.3%
H
943.3
1249.5
|
L
 50.7%
H
623.8
1249.5
|
L
 153.6%
H
446.9
1249.5
|
L
 371.8%
H
220.2
1249.5
|
L
 1281.1%
H
64.2
1249.5
|
| Merck & Company |
|
321,571.1
|
130.2
|
L
 0.3%
H
128.1
131.0
|
L
 -0.7%
H
127.3
135.1
|
L
 3.9%
H
120.2
135.1
|
L
 16.1%
H
110.8
135.1
|
L
 64.2%
H
77.6
135.1
|
L
 23.7%
H
73.3
135.1
|
L
 69.4%
H
70.9
135.1
|
L
 132.6%
H
50.4
135.1
|
| Nuvation Bio Inc (Class A) |
|
2,204.1
|
6.3
|
L
 -5.5%
H
6.3
6.7
|
L
 -1.4%
H
6.3
6.8
|
L
 16.8%
H
5.3
6.8
|
L
 41.0%
H
4.1
6.8
|
L
 183.9%
H
2.2
9.8
|
L
 234.9%
H
1.0
9.8
|
L
 -26.7%
H
1.0
10.5
|
L
H
1.0
15.2
|
| Novo Nordisk (ADR) |
|
208,182.8
|
47.1
|
L
 -8.8%
H
46.4
47.6
|
L
 -3.5%
H
46.4
52.1
|
L
 -3.5%
H
46.4
52.1
|
L
 7.3%
H
41
52.1
|
L
 -2.3%
H
35.1
64.2
|
L
 -41.8%
H
35.1
148.2
|
L
 1.7%
H
35.1
148.2
|
L
 65.1%
H
15.5
148.2
|
| Novartis AG (ADR) |
|
296,796.6
|
156.2
|
L
 -1.5%
H
155.0
157.1
|
L
 0.7%
H
155.0
160.3
|
L
 1.3%
H
149.3
160.6
|
L
 6.5%
H
142.3
160.6
|
L
 35.4%
H
113.5
170.5
|
L
 51.1%
H
92.2
170.5
|
L
 69.0%
H
74.1
170.5
|
L
 112.6%
H
59.2
170.5
|
| Organon & Co. |
|
3,558.4
|
13.6
|
L
H
13.5
13.6
|
L
 0.2%
H
13.5
13.6
|
L
 0.2%
H
13.5
13.6
|
L
 2.0%
H
13.3
13.6
|
L
 39.0%
H
5.7
13.6
|
L
 -37.6%
H
5.7
24.1
|
L
 -53.3%
H
5.7
39.5
|
L
H
5.7
39.5
|
| Prestige Consumer Healthcare Inc |
|
2,379.0
|
50.2
|
L
 0.5%
H
49.0
50.5
|
L
 1.1%
H
49.0
52.5
|
L
 4.3%
H
47.0
52.5
|
L
 -8.8%
H
42.6
56.6
|
L
 -31.9%
H
42.6
75.3
|
L
 -23.2%
H
42.6
90.0
|
L
 -4.4%
H
42.6
90.0
|
L
 -6.3%
H
26.3
90.0
|
| Pfizer |
|
142,543.1
|
25.0
|
L
 0.4%
H
24.7
25.2
|
L
 1.9%
H
24.4
25.5
|
L
 4.7%
H
23.6
25.7
|
L
 -5.0%
H
23.6
26.8
|
L
 6.5%
H
23.4
28.7
|
L
 -29.8%
H
20.9
37.2
|
L
 -41.6%
H
20.9
61.7
|
L
 -29.2%
H
20.9
61.7
|
| Perrigo Co PLC |
|
1,398.9
|
10.1
|
L
 -1.9%
H
10
10.3
|
L
 0.2%
H
10
10.6
|
L
 -1.9%
H
9.8
11.6
|
L
 -15.2%
H
9.4
12.6
|
L
 -62.1%
H
9.2
27.2
|
L
 -72.2%
H
9.2
40.3
|
L
 -79.0%
H
9.2
50.9
|
L
 -88.9%
H
9.2
99.1
|
| Arcus Biosciences Inc |
|
3,545.5
|
28.2
|
L
 -0.2%
H
27.3
28.4
|
L
 -0.8%
H
26.2
29.6
|
L
 -2.5%
H
25.7
31.2
|
L
 9.8%
H
21.8
31.7
|
L
 207.8%
H
8.9
31.7
|
L
 44.5%
H
6.5
31.7
|
L
 -10.3%
H
6.5
49.1
|
L
H
6.3
49.1
|
| Dr. Reddy`s Laboratories Ltd (ADR) |
|
9,871.1
|
11.9
|
L
 0.2%
H
11.7
11.9
|
L
 0.5%
H
11.6
11.9
|
L
 -15.3%
H
11.4
14.7
|
L
 -13.6%
H
11.4
15.7
|
L
 -15.0%
H
11.4
15.7
|
L
 -14.5%
H
11.4
74.9
|
L
 -5.3%
H
9.6
74.9
|
L
 33.1%
H
5.6
74.9
|
| Takeda pharma Co (ADR) |
|
54,577.0
|
17.1
|
L
 -0.9%
H
16.9
17.2
|
L
 -0.9%
H
16.9
17.8
|
L
 7.2%
H
16.2
17.8
|
L
 2.8%
H
14.8
17.8
|
L
 20.7%
H
13.0
18.9
|
L
 13.0%
H
12.6
18.9
|
L
 3.6%
H
12.3
18.9
|
L
 -27.1%
H
12.3
30.6
|
| Teva- pharma Ind Ltd (ADR) |
|
40,797.0
|
35.0
|
L
 -1.1%
H
34.6
35.7
|
L
 13.6%
H
30.9
35.9
|
L
 4.7%
H
29.6
35.9
|
L
 0.2%
H
29.6
37.0
|
L
 127.6%
H
15.5
37.3
|
L
 322.3%
H
8.1
37.3
|
L
 262.8%
H
6.8
37.3
|
L
 -34.7%
H
6.1
55.8
|
| Usana Health Sciences Inc |
|
408.2
|
22.1
|
L
 -0.3%
H
21.7
22.3
|
L
 3.7%
H
21.4
23.6
|
L
 1.8%
H
20.5
23.6
|
L
 14.3%
H
16.9
23.6
|
L
 -23.4%
H
16.6
32.3
|
L
 -65.4%
H
16.6
67.3
|
L
 -76.8%
H
16.6
104.0
|
L
 -67.8%
H
16.6
138.0
|
| Zoetis (Class A) |
|
32,402.1
|
77.3
|
L
 1.7%
H
74.9
77.5
|
L
 2.6%
H
74.9
79.4
|
L
 6.7%
H
72.9
79.4
|
L
 -32.3%
H
71.5
115.1
|
L
 -47.6%
H
71.5
160.5
|
L
 -58.3%
H
71.5
201.9
|
L
 -61.9%
H
71.5
249.3
|
L
 53.4%
H
46.9
249.3
|
| Biohaven Ltd |
|
2,032.6
|
13.5
|
L
 -2.3%
H
13.3
13.9
|
L
 -5.7%
H
13.1
14.9
|
L
 -14.3%
H
13.1
17.3
|
L
 40.2%
H
8.2
17.3
|
L
 -8.2%
H
7.5
18.6
|
L
 -31.3%
H
7.5
62.2
|
L
H
5.5
62.2
|
L
H
5.5
62.2
|
| Haleon PLC (ADR) |
|
43,465.5
|
9.9
|
L
 -2.4%
H
9.8
9.9
|
L
 0.9%
H
9.8
10.3
|
L
 5%
H
9.6
10.3
|
L
 5.2%
H
8.7
10.3
|
L
 2.2%
H
8.7
11.3
|
L
 15.4%
H
7.7
11.4
|
L
H
5.6
11.4
|
L
H
5.6
11.4
|
| Whitehawk Therapeutics Inc |
|
190.4
|
3.9
|
L
H
3.8
3.9
|
L
 3.8%
H
3.4
3.9
|
L
 -10.5%
H
3.4
4.5
|
L
 -3.5%
H
3.4
5.5
|
L
 121.3%
H
1.6
5.5
|
L
 -26.7%
H
1.2
7.2
|
L
 -87.3%
H
1.2
40.2
|
L
H
1.2
101.3
|
| AbCellera Biologics Inc |
|
1,743.7
|
5.7
|
L
 0.4%
H
5.5
5.9
|
L
 7.5%
H
5.0
5.9
|
L
 -24.9%
H
5.0
8.4
|
L
 28.9%
H
3.9
8.4
|
L
 34.7%
H
2.7
8.4
|
L
 -21.5%
H
1.9
8.4
|
L
 -62.4%
H
1.9
22.6
|
L
H
1.9
71.9
|
| Abeona Therapeutics Inc |
|
365.9
|
6.4
|
L
 -0.8%
H
6.2
6.6
|
L
 6.1%
H
5.8
6.6
|
L
 6.1%
H
5.8
7.4
|
L
 18.2%
H
5.1
7.4
|
L
 -1.1%
H
4
7.5
|
L
 94.0%
H
2.9
9.0
|
L
 -79.0%
H
2.2
34
|
L
 -90.9%
H
2.2
568.8
|
| Oruka Therapeutics Inc |
|
5,820.7
|
96.5
|
L
 -1.4%
H
92.7
99
|
L
 4.7%
H
85.1
99
|
L
 3.5%
H
80.7
99
|
L
 54.2%
H
53.6
99
|
L
 609.6%
H
12.8
99
|
L
 292.3%
H
2.2
99
|
L
 154.5%
H
2.2
99
|
L
 -85.6%
H
2.2
693.4
|
| Acumen Pharma Inc |
|
155.3
|
2.2
|
L
 -0.9%
H
2.1
2.3
|
L
 0.9%
H
2.1
2.4
|
L
 -17.0%
H
2.1
2.8
|
L
 -9.7%
H
2.1
2.8
|
L
 59.3%
H
1.2
3.6
|
L
 -70.4%
H
0.9
7.6
|
L
 -86.1%
H
0.9
19.5
|
L
H
0.9
27.0
|
| Absci Corp |
|
1,317.9
|
7.8
|
L
 1.8%
H
7.4
8.1
|
L
 2.9%
H
6.7
8.1
|
L
 -30.0%
H
6.7
12
|
L
 58.1%
H
4.5
12.1
|
L
 168.3%
H
2.2
12.1
|
L
 281.4%
H
1.1
12.1
|
L
 -72.7%
H
1.1
31.5
|
L
H
1.1
31.5
|
| Arbutus Biopharma Corp |
|
857.3
|
4.3
|
L
 -1.6%
H
4.3
4.5
|
L
 -0.9%
H
4.3
4.5
|
L
 -8.3%
H
4.3
5.4
|
L
 0.5%
H
4.1
5.4
|
L
 32.7%
H
3.3
5.4
|
L
 99.1%
H
1.7
5.4
|
L
 61.3%
H
1.7
6.5
|
L
 4.1%
H
0.8
12.6
|
| ABVC BioPharma Inc |
|
26.3
|
1.0
|
L
 -6.5%
H
1.0
1.1
|
L
 -12.2%
H
1.0
1.2
|
L
 -42.9%
H
1.0
2.2
|
L
 -1.9%
H
1.0
2.2
|
L
 -63.3%
H
0.9
3.4
|
L
 -72.0%
H
0.4
5.5
|
L
 -98.0%
H
0.4
116.9
|
L
 -99.7%
H
0.4
378
|
| Acadia Pharma Inc |
|
4,429.9
|
25.9
|
L
 -2.6%
H
25.3
26.4
|
L
 4.2%
H
25.0
26.6
|
L
 2.7%
H
24.2
26.6
|
L
 17.9%
H
20.3
27.3
|
L
 9.9%
H
19.7
28.4
|
L
 -10.6%
H
13.4
32.6
|
L
 19.6%
H
12.2
33.9
|
L
 -30.5%
H
12.2
58.7
|
| Adicet Bio Inc |
|
85.2
|
9.1
|
L
 0.6%
H
8.5
9.2
|
L
 16.9%
H
7.7
9.2
|
L
 5.7%
H
7.7
9.4
|
L
 11.1%
H
7.0
9.5
|
L
 -15.2%
H
6.0
17.4
|
L
 -77.5%
H
6.0
60.3
|
L
 -92.3%
H
6.0
349.9
|
L
H
6.0
349.9
|
| Achieve Life Sciences Inc |
|
659.1
|
6.4
|
L
 1.9%
H
6.1
6.5
|
L
 5.3%
H
5.9
6.5
|
L
 0.3%
H
5.8
6.7
|
L
 46.6%
H
4.3
7.1
|
L
 151.8%
H
2.4
7.1
|
L
 14.0%
H
1.8
7.1
|
L
 -12.2%
H
1.8
10.3
|
L
 -99.7%
H
1.8
2156
|
| AC Immune SA |
|
222.9
|
2.2
|
L
 -7.6%
H
2.2
2.4
|
L
 -1.8%
H
2.2
2.4
|
L
 -8.0%
H
2.1
2.6
|
L
 -26.5%
H
2.1
3.2
|
L
 3.3%
H
2.0
4
|
L
 -25%
H
1.4
5.1
|
L
 -69.9%
H
1.4
12.6
|
L
H
1.4
20.0
|
| Aclaris Therapeutics Inc |
|
726.3
|
5.2
|
L
 -2.3%
H
5.1
5.3
|
L
 -0.6%
H
5.0
5.6
|
L
 -2.6%
H
5.0
5.9
|
L
 17.9%
H
4.1
5.9
|
L
 239.9%
H
1.5
5.9
|
L
 -47.0%
H
0.6
10.2
|
L
 -65.2%
H
0.6
20.0
|
L
 -73.7%
H
0.6
33.3
|
| Acrivon Therapeutics Inc |
|
64.2
|
1.5
|
L
 -1.3%
H
1.5
1.6
|
L
 -6.3%
H
1.4
1.6
|
L
 -13.3%
H
1.4
2.2
|
L
 -28.2%
H
1.4
2.2
|
L
 19.1%
H
1.2
3.6
|
L
 -88.0%
H
1.1
12.9
|
L
H
1.1
25.5
|
L
H
1.1
25.5
|
| Acelrx Pharma Inc |
|
21.7
|
1.3
|
L
 -5.9%
H
1.3
1.4
|
L
 -5.2%
H
1.2
1.4
|
L
 21.9%
H
1
1.5
|
L
 39.1%
H
0.8
1.5
|
L
 220%
H
0.4
1.6
|
L
 26.7%
H
0.4
1.6
|
L
 -94.6%
H
0.4
25
|
L
 -98.2%
H
0.4
115
|
| Grace Therapeutics Inc |
|
33.8
|
2.1
|
L
 0.5%
H
2.0
2.2
|
L
 -10.7%
H
1.9
2.4
|
L
 -7.1%
H
1.9
2.6
|
L
 -11.1%
H
1.9
2.7
|
L
 -27.5%
H
1.8
5.2
|
L
 -19.4%
H
1.7
5.2
|
L
 -90.5%
H
1.7
27.1
|
L
 -97.2%
H
1.7
161.1
|
| Acurx Pharma Inc |
|
6.2
|
1.4
|
L
 1.4%
H
1.4
1.4
|
L
 1.4%
H
1.3
1.5
|
L
 -5.9%
H
1.3
1.9
|
L
 -33.3%
H
1.3
2.2
|
L
 -76.6%
H
1.3
8.3
|
L
 -96.4%
H
1.3
176.4
|
L
 -98.7%
H
1.3
176.4
|
L
H
1.3
176.4
|
| Adial Pharma Inc |
|
7.3
|
3.3
|
L
 1.5%
H
3.2
3.4
|
L
 20.1%
H
2.7
3.4
|
L
 18.9%
H
2.5
3.4
|
L
 115.5%
H
1.3
5.2
|
L
 -70.7%
H
1.3
11.5
|
L
 -98.0%
H
1.3
167.5
|
L
 -99.8%
H
1.3
3175
|
L
H
1.3
5900
|
| Adma Biologics Inc |
|
1,960.8
|
8.5
|
L
 -2.4%
H
8.4
8.7
|
L
 2.3%
H
8.4
8.9
|
L
 -1.7%
H
8.2
9.3
|
L
 -19.6%
H
7.5
10.7
|
L
 -56.2%
H
7.2
20.5
|
L
 103.9%
H
3.1
25.7
|
L
 445.8%
H
1.0
25.7
|
L
 30.4%
H
1.0
25.7
|
| Adaptive biotech Corp |
|
3,590.0
|
22.6
|
L
 -6.7%
H
22.4
24.6
|
L
 1.4%
H
21.7
24.6
|
L
 -74.8%
H
20.9
91.2
|
L
 -60.5%
H
20.9
91.2
|
L
 -45.4%
H
20.9
91.2
|
L
 -31.6%
H
9.1
91.2
|
L
 -84.6%
H
9.1
160
|
L
H
9.1
285
|
| Agenus Inc |
|
312.3
|
7.5
|
L
 -5.2%
H
7.3
8.0
|
L
 25.4%
H
5.9
8.0
|
L
 119.9%
H
3.1
8.7
|
L
 95.3%
H
2.9
8.7
|
L
 39.9%
H
2.7
8.7
|
L
 -74.3%
H
1.4
196
|
L
 -92.6%
H
1.4
196
|
L
 -93.2%
H
1.4
196
|
| Agios Pharma Inc |
|
1,792.3
|
30.0
|
L
 -8.3%
H
29.9
33.3
|
L
 -17.4%
H
29.2
38.7
|
L
 -19.0%
H
29.2
44.1
|
L
 6.6%
H
26.4
44.1
|
L
 -14.2%
H
22.2
46
|
L
 12.1%
H
19.8
62.6
|
L
 -37.6%
H
16.8
62.6
|
L
 -34.3%
H
16.8
99.8
|
| Aeglea BioTherapeutics Inc |
|
398.1
|
98.3
|
L
 -3.1%
H
95.3
100.6
|
L
 -3.7%
H
92.4
105.1
|
L
 10.6%
H
85.2
105.1
|
L
 41.7%
H
64.7
105.1
|
L
 504.7%
H
14.5
105.1
|
L
 613.1%
H
8.4
105.1
|
L
 -35.8%
H
2.7
212.5
|
L
 -17.5%
H
2.7
300
|
| Akebia Therapeutics Inc |
|
354.1
|
1.3
|
L
 -2.2%
H
1.3
1.4
|
L
 8.2%
H
1.2
1.4
|
L
 9.1%
H
1.2
1.5
|
L
 -5.7%
H
0.8
1.5
|
L
 -64.5%
H
0.8
3.8
|
L
 -28.3%
H
0.8
4.1
|
L
 -46.6%
H
0.2
4.1
|
L
 -85.3%
H
0.2
20.3
|
| Change Agents Corp |
|
2.5
|
0.2
|
L
H
0.2
0.2
|
L
 -20.8%
H
0.2
0.2
|
L
 -34.5%
H
0.2
0.3
|
L
 -54.8%
H
0.2
0.4
|
L
 -91.2%
H
0.2
2.9
|
L
 -86.3%
H
0.2
11.7
|
L
 -98.1%
H
0.2
11.9
|
L
H
0.2
135
|
| Aldeyra Therapeutics Inc |
|
92.9
|
1.5
|
L
 -3.8%
H
1.5
1.6
|
L
 1.3%
H
1.5
1.7
|
L
 -36.6%
H
1.5
2.5
|
L
 -3.1%
H
1.5
2.5
|
L
 -68.0%
H
1.1
6.2
|
L
 -80.8%
H
1.1
8.4
|
L
 -82.7%
H
1.1
12.0
|
L
 -74.3%
H
1.1
16.7
|
| Alector Inc |
|
167.6
|
1.5
|
L
 -6.8%
H
1.5
1.6
|
L
 2.0%
H
1.5
1.7
|
L
 -24.9%
H
1.4
2.1
|
L
 -36.0%
H
1.4
2.7
|
L
 4.1%
H
1.1
3.4
|
L
 -78.1%
H
0.9
9.1
|
L
 -93.7%
H
0.9
29.3
|
L
H
0.9
43.3
|
| Aligos Therapeutics Inc |
|
26.2
|
4.2
|
L
 -2.1%
H
4.2
4.5
|
L
 3.7%
H
4.0
4.5
|
L
 -22.4%
H
4.0
7.1
|
L
 -30.5%
H
4.0
7.1
|
L
 -43.3%
H
4.0
13.7
|
L
 -80.8%
H
3.8
46.3
|
L
 -98.8%
H
3.8
449.3
|
L
H
3.8
937.8
|
| Alkermes PLC |
|
8,218.7
|
49.0
|
L
 -2.1%
H
48.5
49.8
|
L
 -7.4%
H
47.7
53.8
|
L
 -5.3%
H
47.7
55.7
|
L
 46.8%
H
33.2
55.7
|
L
 84.5%
H
25.2
55.7
|
L
 71.7%
H
22.0
55.7
|
L
 89.4%
H
21.2
55.7
|
L
 -1.2%
H
12.0
71.2
|
| Allogene Therapeutics Inc |
|
648.9
|
1.9
|
L
 -4.6%
H
1.9
2
|
L
 8.1%
H
1.6
2
|
L
 -10.9%
H
1.6
2.2
|
L
 -12.6%
H
1.6
2.4
|
L
 74.1%
H
1.0
4.5
|
L
 -60.8%
H
0.9
5.8
|
L
 -91.4%
H
0.9
27.9
|
L
H
0.9
55
|
| Allarity Therapeutics Inc |
|
19.3
|
1.2
|
L
 -1.6%
H
1.2
1.2
|
L
 1.7%
H
1.2
1.3
|
L
 -9.0%
H
1.0
1.4
|
L
 -6.9%
H
1.0
1.8
|
L
 19.8%
H
0.8
2.1
|
L
 -97.6%
H
0.1
116
|
L
H
0.1
509600
|
L
H
0.1
509600
|
| Alnylam Pharma Inc |
|
27,500.5
|
205.5
|
L
 0.0%
H
200.1
208.0
|
L
 -24.4%
H
197.8
290.6
|
L
 -31.9%
H
197.8
380
|
L
 -30.6%
H
197.8
380
|
L
 -48.9%
H
197.8
495.6
|
L
 8.7%
H
142.0
495.6
|
L
 14.9%
H
117.6
495.6
|
L
 186.2%
H
31.4
495.6
|
| Rein Therapeutics Inc |
|
63.3
|
0.7
|
L
 -3.9%
H
0.7
0.8
|
L
 -6.3%
H
0.7
0.8
|
L
 -24.5%
H
0.7
1.1
|
L
 -28.2%
H
0.7
1.2
|
L
 -33.3%
H
0.7
2.2
|
L
 -57.0%
H
0.7
7.4
|
L
 -96.4%
H
0.7
25.4
|
L
H
0.7
309.6
|
| Altimmune Inc |
|
552.3
|
2.8
|
L
 -4.7%
H
2.8
3.0
|
L
 2.5%
H
2.8
3.3
|
L
 -9.8%
H
2.8
3.3
|
L
 0.7%
H
2.6
3.4
|
L
 -21.3%
H
2.6
6.4
|
L
 -10.4%
H
2.1
14.8
|
L
 -68.7%
H
2.1
23.5
|
L
 -99.6%
H
1.5
1050
|
| Alvotech |
|
1,393.5
|
4.1
|
L
 15.4%
H
3.5
4.1
|
L
 34.6%
H
3.1
4.1
|
L
 15.1%
H
3.0
4.1
|
L
 19.1%
H
2.9
4.6
|
L
 -53.1%
H
2.9
9.3
|
L
 -56.9%
H
2.9
18
|
L
H
2.9
18
|
L
H
2.9
18
|
| Kalaris Therapeutics Inc |
|
83.5
|
3.5
|
L
 0.9%
H
3.4
3.6
|
L
 -5.9%
H
3.0
3.8
|
L
 -22.5%
H
3.0
6.3
|
L
 -35.7%
H
3.0
6.3
|
L
 30.5%
H
2.1
11.9
|
L
 9.7%
H
0.4
12.9
|
L
 -81.7%
H
0.4
26.4
|
L
H
0.4
49.0
|
| Alx Oncology Holdings Inc |
|
261.1
|
1.9
|
L
 -0.5%
H
1.9
2
|
L
 -4.4%
H
1.9
2.1
|
L
 -5.8%
H
1.9
2.4
|
L
 14.8%
H
1.4
2.4
|
L
 273.1%
H
0.5
2.7
|
L
 -67.4%
H
0.4
17.8
|
L
 -96.7%
H
0.4
81.2
|
L
H
0.4
117.5
|
| Alzamend Neuro Inc |
|
6.3
|
1.3
|
L
 -3.0%
H
1.3
1.4
|
L
 -1.5%
H
1.3
1.4
|
L
 17.0%
H
1.1
1.4
|
L
 17.0%
H
1
1.4
|
L
 -40.5%
H
0.8
2.7
|
L
 -99.8%
H
0.8
634.5
|
L
 -100.0%
H
0.8
6534
|
L
H
0.8
45292.5
|
| Amgen |
|
207,874.0
|
385.2
|
L
 -0.6%
H
379.3
386.8
|
L
 2.4%
H
374.4
398
|
L
 6.6%
H
354.0
398
|
L
 16.8%
H
320.5
398
|
L
 29.7%
H
269.8
398
|
L
 65.9%
H
228.2
398
|
L
 59.5%
H
198.6
398
|
L
 121.2%
H
133.6
398
|
| Amylyx Pharma Inc |
|
2,258.2
|
20.3
|
L
 -2.1%
H
19.3
20.9
|
L
 10.3%
H
18.1
20.9
|
L
 13.2%
H
16.5
20.9
|
L
 26.9%
H
12.4
20.9
|
L
 163.1%
H
7.5
20.9
|
L
 -13.1%
H
1.6
23.6
|
L
H
1.6
41.9
|
L
H
1.6
41.9
|
| Amphastar Pharma Inc |
|
879.2
|
19.9
|
L
 -2.2%
H
19.7
20.4
|
L
 6.5%
H
19.0
20.7
|
L
 -0.8%
H
18.4
20.7
|
L
 -8.9%
H
16.6
24.3
|
L
 -6.0%
H
16.6
31.3
|
L
 -67.1%
H
16.6
67.7
|
L
 -4.8%
H
16.6
67.7
|
L
 22.4%
H
12.1
67.7
|
| AnaptysBio Inc |
|
1,579.9
|
53.4
|
L
 -3.1%
H
52.2
54.5
|
L
 -1.5%
H
50.5
55.9
|
L
 -18.5%
H
49.7
70.9
|
L
 -20.1%
H
49.7
72.4
|
L
 116.1%
H
17.1
73.3
|
L
 159.5%
H
12.2
73.3
|
L
 132.2%
H
12.2
73.3
|
L
H
10
134
|
| ANI Pharma Inc |
|
1,801.5
|
79.2
|
L
 -1.5%
H
78.2
80.4
|
L
 2.1%
H
77.8
82
|
L
 -4.6%
H
76.4
87.2
|
L
 -1.4%
H
73.5
87.8
|
L
 24.0%
H
63.7
99.5
|
L
 56.0%
H
48.2
99.5
|
L
 133.5%
H
22.3
99.5
|
L
 29.8%
H
22.3
99.5
|
| Anixa Biosciences Inc |
|
116.4
|
3.4
|
L
 -3.9%
H
3.3
3.6
|
L
 -7.6%
H
3.3
3.8
|
L
 8.9%
H
2.9
3.9
|
L
 8.9%
H
2.3
3.9
|
L
 13.6%
H
2.3
5.5
|
L
 -5.8%
H
2.1
5.5
|
L
 -22.6%
H
2.1
6.5
|
L
 7.5%
H
0.6
8.1
|
| Annexon Inc |
|
835.6
|
5.1
|
L
 -3.2%
H
5.0
5.4
|
L
 -2.3%
H
4.8
5.4
|
L
 -8.1%
H
4.8
6.6
|
L
 -11.3%
H
4.5
6.6
|
L
 108.2%
H
2.0
7.2
|
L
 44.1%
H
1.3
8.4
|
L
 -75.8%
H
1.3
23.6
|
L
H
1.3
38.0
|
| AN2 Therapeutics Inc |
|
192.7
|
5.4
|
L
 0.4%
H
5.3
5.7
|
L
 8.7%
H
4.6
5.7
|
L
 13.8%
H
4.1
5.7
|
L
 14.3%
H
3.7
5.7
|
L
 404.7%
H
1
6.9
|
L
 -34.8%
H
0.9
22.2
|
L
H
0.9
23.6
|
L
H
0.9
23.6
|
| Niki BioSolutions Inc |
|
8.0
|
9.9
|
L
 -3.0%
H
9.5
10.1
|
L
 17.8%
H
7.8
10.2
|
L
 23.4%
H
6
12.2
|
L
 12.2%
H
6
13.9
|
L
 -28.0%
H
6
44.7
|
L
 -47.5%
H
4.6
174.9
|
L
 -96.2%
H
4.6
294
|
L
H
4.6
3328
|
| Aprea Therapeutics Inc |
|
7.7
|
0.6
|
L
 -3.1%
H
0.6
0.7
|
L
 -1.6%
H
0.6
0.7
|
L
 -16.2%
H
0.6
0.8
|
L
 -24.4%
H
0.6
1.1
|
L
 -62.7%
H
0.6
1.8
|
L
 -80%
H
0.6
8.9
|
L
 -99.3%
H
0.6
113.4
|
L
H
0.6
1062.2
|
| Aptevo Therapeutics Inc |
|
5.1
|
4.1
|
L
 -0.5%
H
4.1
4.1
|
L
 -6.4%
H
3.9
4.5
|
L
 -7.6%
H
3.7
4.9
|
L
 -16.5%
H
3.7
5.6
|
L
 -91.5%
H
3.7
50.4
|
L
 -100.0%
H
3.7
399904.7
|
L
 -100.0%
H
3.7
12940587.7
|
L
 -100.0%
H
3.7
52102512
|
| AquaBounty Tech Inc |
|
4.7
|
0.9
|
L
H
0.9
0.9
|
L
H
0.9
0.9
|
L
 -15.0%
H
0.9
1.1
|
L
 -2.2%
H
0.9
1.3
|
L
 26.4%
H
0.7
3.0
|
L
 -87%
H
0.5
7.4
|
L
 -99.1%
H
0.5
100.7
|
L
H
0.5
610
|
| Aquestive Therapeutics Inc |
|
464.2
|
3.7
|
L
 -0.5%
H
3.6
3.8
|
L
 0.5%
H
3.6
3.9
|
L
 -12.7%
H
3.6
4.4
|
L
 -11.9%
H
3.6
5.2
|
L
 -3.1%
H
2.9
7.6
|
L
 65.2%
H
1.3
7.6
|
L
 13.8%
H
0.6
7.6
|
L
H
0.6
20.7
|
| Arcturus Therapeutics Holdings Inc |
|
163.7
|
5.8
|
L
 -2.7%
H
5.6
6.0
|
L
 4.2%
H
5.6
6.0
|
L
 -16.4%
H
5.5
8.3
|
L
 -33.3%
H
5.5
9.6
|
L
 -53.2%
H
5.5
24.2
|
L
 -83.5%
H
5.5
45
|
L
 -81.6%
H
5.5
65
|
L
 -80.9%
H
4.1
129.7
|
| Ardelyx Inc |
|
1,222.8
|
5.0
|
L
 -1.8%
H
4.9
5.1
|
L
 -1.6%
H
4.9
5.2
|
L
 -4.1%
H
4.9
5.6
|
L
 -28.1%
H
4.9
7.4
|
L
 14.3%
H
4.2
8.4
|
L
 28.9%
H
3.2
10.1
|
L
 184.5%
H
0.5
10.1
|
L
 -52.9%
H
0.5
16.3
|
| Arcutis Biotherapeutics Inc |
|
3,359.7
|
26.9
|
L
 -4.0%
H
26.3
28.0
|
L
 -1.8%
H
26.3
28.6
|
L
 4.0%
H
25.3
29.8
|
L
 15.0%
H
19.3
29.8
|
L
 88.0%
H
13.7
31.8
|
L
 154.1%
H
1.8
31.8
|
L
 15.1%
H
1.8
31.8
|
L
H
1.8
40.9
|
| Artelo Biosciences Inc |
|
2.7
|
0.8
|
L
 1.3%
H
0.8
0.8
|
L
 -24.5%
H
0.7
1.1
|
L
 -30%
H
0.7
1.2
|
L
 -77.3%
H
0.7
3.6
|
L
 -97.5%
H
0.7
31.7
|
L
 -97.8%
H
0.7
85.8
|
L
 -99.7%
H
0.7
356.4
|
L
H
0.7
46656
|
| Arvinas Inc |
|
518.1
|
8.0
|
L
 -3.3%
H
7.9
8.2
|
L
H
7.9
8.4
|
L
 -2.1%
H
7.9
8.9
|
L
 -23.6%
H
7.0
11
|
L
 8.2%
H
6.1
14.5
|
L
 -67.7%
H
5.9
53.1
|
L
 -92.1%
H
5.9
103.5
|
L
H
5.9
108.5
|
| Arrowhead Pharma Inc |
|
11,923.5
|
84.7
|
L
 -3.1%
H
84.5
87.1
|
L
 -1.1%
H
82.8
88.2
|
L
 5.2%
H
69.9
95.5
|
L
 13.2%
H
69.3
95.5
|
L
 431.4%
H
15.0
95.5
|
L
 151.3%
H
9.6
95.5
|
L
 22.2%
H
9.6
95.5
|
L
 1344.5%
H
1.2
95.5
|
| Assembly Biosciences Inc |
|
497.6
|
25.1
|
L
 -3.7%
H
24.7
26.0
|
L
 -1.7%
H
24.5
26.6
|
L
 -5.9%
H
24.5
29.9
|
L
 -8.3%
H
21.8
32.5
|
L
 36.5%
H
18.0
39.7
|
L
 92.0%
H
7.7
39.7
|
L
 -39.7%
H
7.7
47.3
|
L
 -62.2%
H
7.7
808.3
|
| ASP Isotopes Inc |
|
503.6
|
4
|
L
 0.5%
H
3.9
4.2
|
L
 3.4%
H
3.5
4.2
|
L
 -35.2%
H
3.5
6.5
|
L
 -22.3%
H
3.5
8.5
|
L
 -55.2%
H
3.5
14.5
|
L
 217.5%
H
0.9
14.5
|
L
H
0.3
14.5
|
L
H
0.3
14.5
|
| ATAI Life Sciences N.V. |
|
2,656.3
|
7.2
|
L
H
7.2
7.2
|
L
H
7.2
7.2
|
L
 47.1%
H
4.8
7.2
|
L
 73.4%
H
3.7
7.2
|
L
 72.2%
H
3.3
7.2
|
L
 250.2%
H
1.0
7.2
|
L
 -53.7%
H
1.0
17.9
|
L
H
1.0
22.9
|
| LeonaBio Inc |
|
66.3
|
7.1
|
L
 -3.2%
H
7
7.3
|
L
 -4.5%
H
6.7
7.6
|
L
 -15.8%
H
6.7
10.1
|
L
 -20.0%
H
6.7
11.4
|
L
 90.8%
H
3.5
14.2
|
L
 -75.7%
H
2.2
43.0
|
L
 -92.7%
H
2.2
166.5
|
L
H
2.2
347.9
|
| ETHZilla Corp |
|
68.2
|
5.2
|
L
 -3.9%
H
5.2
5.6
|
L
 -10.0%
H
5.1
6.0
|
L
 -7.4%
H
5.1
7.2
|
L
 -11.8%
H
3.6
7.2
|
L
 -85.4%
H
1.8
174.6
|
L
 -97.1%
H
1.8
212.8
|
L
 -100.0%
H
1.8
33820
|
L
H
1.8
49571
|
| Atossa Therapeutics Inc |
|
20.6
|
2.1
|
L
 -5.5%
H
2.1
2.2
|
L
 -10%
H
2.1
2.5
|
L
 1.5%
H
2.0
2.6
|
L
 -61.2%
H
1.7
6.2
|
L
 -83.2%
H
1.7
19.4
|
L
 -87.5%
H
1.7
34.7
|
L
 -95.4%
H
1.7
64.7
|
L
 -99.7%
H
1.7
779.4
|
| Atara Biotherapeutics Inc |
|
75.5
|
8.4
|
L
 2.6%
H
7.9
8.7
|
L
 6.1%
H
7.4
8.7
|
L
 -26.3%
H
7.4
12
|
L
 71.0%
H
4.6
12.5
|
L
 -27.5%
H
3.9
19.1
|
L
 -84.4%
H
0.4
63.4
|
L
 -97.4%
H
0.4
501
|
L
 -98.6%
H
0.4
1361.3
|
| Aurinia Pharma Inc |
|
1,913.6
|
14.9
|
L
 -0.8%
H
14.4
15.3
|
L
 -3.1%
H
14.4
15.8
|
L
 -5.8%
H
14.4
16.7
|
L
 -3.1%
H
14.4
19.3
|
L
 41.9%
H
10.3
19.3
|
L
 42.4%
H
4.7
19.3
|
L
 9.7%
H
4.1
34.0
|
L
 313.3%
H
1.7
34.0
|
| Aura Biosciences Inc |
|
725.1
|
7.0
|
L
 -1.4%
H
6.9
7.1
|
L
 -0.6%
H
6.8
7.3
|
L
 4.2%
H
6.6
7.9
|
L
H
6.0
9.5
|
L
 4.0%
H
4.7
9.5
|
L
 -40.9%
H
4.3
12.4
|
L
H
4.3
26.2
|
L
H
4.3
26.2
|
| Atea Pharma Inc |
|
376.1
|
4.7
|
L
 -0.8%
H
4.7
5.0
|
L
 -0.6%
H
3.8
5.0
|
L
 -1.7%
H
3.8
5.0
|
L
 -15.8%
H
3.8
5.8
|
L
 35.5%
H
2.8
6.5
|
L
 37.8%
H
2.5
6.5
|
L
 -81.2%
H
2.5
46.9
|
L
H
2.5
94.2
|
| Tectonic Therapeutic Inc |
|
528.9
|
28.0
|
L
 -1.7%
H
27.2
28.6
|
L
 -7.7%
H
27.2
31.5
|
L
 -14.4%
H
27.2
39.5
|
L
 -3.5%
H
26.3
39.5
|
L
 35.2%
H
14.4
39.5
|
L
 53.7%
H
1.4
61.1
|
L
 -68.3%
H
1.4
93.6
|
L
H
1.4
644.4
|
| Jade Biosciences Inc |
|
1,202.0
|
19.8
|
L
 -1.3%
H
18.6
20.0
|
L
 -1.6%
H
18.5
21
|
L
 -9.5%
H
18.5
23.4
|
L
 -18.5%
H
14.3
26.8
|
L
 186.7%
H
6.7
28
|
L
 -96.6%
H
6.6
1134.5
|
L
 -95.6%
H
6.6
1134.5
|
L
H
6.6
1134.5
|
| Avalo Therapeutics Inc |
|
965.5
|
18.3
|
L
 -5.9%
H
18.2
19.7
|
L
 -1.0%
H
18.2
20.0
|
L
 5.6%
H
17.3
20.7
|
L
 33.1%
H
12.5
24.3
|
L
 131.3%
H
7.9
24.3
|
L
 9025%
H
0.0
34.5
|
L
 -42.8%
H
0.0
38.9
|
L
 -57.6%
H
0.0
91.8
|
| Anavex Life Sciences Corp |
|
254.8
|
2.8
|
L
 1.9%
H
2.7
2.8
|
L
 14.6%
H
2.4
2.8
|
L
 6.6%
H
2.3
2.8
|
L
 -17.2%
H
2.3
3.5
|
L
 -75.5%
H
2.3
11.7
|
L
 -66.3%
H
2.3
14.4
|
L
 -84.7%
H
2.3
23.7
|
L
 -23.8%
H
1.3
31.5
|
| Axsome Therapeutics Inc |
|
11,217.7
|
218.0
|
L
 -7.1%
H
217.6
235.1
|
L
 -9.6%
H
217.6
245.5
|
L
 -9.4%
H
217.6
252.6
|
L
 5.6%
H
208.5
260.2
|
L
 111.6%
H
96.1
260.2
|
L
 181.9%
H
55.0
260.2
|
L
 348.6%
H
19.4
260.2
|
L
 2698.3%
H
1.9
260.2
|
| Aytu BioPharma Inc |
|
23.9
|
2.2
|
L
 3.7%
H
2.1
2.3
|
L
 3.2%
H
2.0
2.3
|
L
 3.2%
H
2.0
2.3
|
L
 -14.6%
H
2.0
2.6
|
L
 -7.1%
H
1.7
3.1
|
L
 22.5%
H
1.0
3.5
|
L
 -97.2%
H
1.0
81
|
L
 -100.0%
H
1.0
320000
|
| Aziyo Biologics Inc (Class A) |
|
-
|
0.9
|
L
 -4.4%
H
0.8
0.9
|
L
 -7.5%
H
0.8
1.0
|
L
 -8.5%
H
0.8
1.0
|
L
 -14.9%
H
0.8
1.3
|
L
 -57.8%
H
0.5
2.4
|
L
 -59.4%
H
0.5
2.6
|
L
 -89.9%
H
0.5
9.8
|
L
H
0.5
18.2
|
| Adagene Inc (ADR) |
|
247.8
|
3.8
|
L
 0.5%
H
3.7
4.0
|
L
 17.2%
H
3.3
4.0
|
L
 -21.6%
H
3.2
4.8
|
L
 -1.8%
H
3.1
4.9
|
L
 95.3%
H
1.3
4.9
|
L
 175.7%
H
1.1
4.9
|
L
 -75.8%
H
0.9
19.8
|
L
H
0.9
31.8
|
| Addex Therapeutics Ltd (ADR) |
|
6.6
|
5.2
|
L
 -7.1%
H
5.0
6
|
L
 -11.6%
H
5.0
6
|
L
 -9.1%
H
5.0
6.5
|
L
 -25.7%
H
5.0
7.4
|
L
 -35.8%
H
5.0
12.1
|
L
 -53.3%
H
5
27.9
|
L
 -97.4%
H
5
205.6
|
L
H
5
750.4
|
| Akari Therapeutics PLC (ADR) |
|
13.8
|
7.9
|
L
 -1.8%
H
7.8
8.1
|
L
 -9.7%
H
7.7
9.5
|
L
 -23.3%
H
7.7
15.5
|
L
 43.7%
H
3.0
29.3
|
L
 -80.5%
H
3.0
49.6
|
L
 -96.3%
H
3.0
219.8
|
L
 -99.4%
H
3.0
1504
|
L
 -99.9%
H
3.0
17759.8
|
| Amarin Corp (ADR) |
|
299.0
|
14.3
|
L
 0.2%
H
13.9
14.4
|
L
 5.2%
H
13.5
14.6
|
L
 -13.4%
H
13.5
16.8
|
L
 1.4%
H
13.5
17.3
|
L
 -5.9%
H
13.0
20.9
|
L
 1098.3%
H
0.4
20.9
|
L
 244.4%
H
0.4
20.9
|
L
 390.0%
H
0.4
26.1
|
| Argen X SE (ADR) |
|
53,415.8
|
853.8
|
L
 -2.2%
H
846.2
873.1
|
L
 -7.0%
H
846.2
919.2
|
L
 -6.1%
H
843.6
953.6
|
L
 9.0%
H
775.6
953.6
|
L
 26.7%
H
631.5
953.6
|
L
 69.4%
H
327.7
953.6
|
L
 180.5%
H
249.5
953.6
|
L
H
17.3
953.6
|
| Ascendis Pharma A/S (ADR) |
|
14,974.4
|
243.9
|
L
 -2.9%
H
243.3
252.5
|
L
 -3.9%
H
243.3
260.2
|
L
 -8.9%
H
243.3
282.2
|
L
 10.4%
H
203.8
282.2
|
L
 39.8%
H
173.3
282.2
|
L
 166.2%
H
85.3
282.2
|
L
 106.4%
H
61.6
282.2
|
L
 1633.5%
H
13.4
282.2
|
| Alterity Therapeutics Ltd (ADR) |
|
80.1
|
4.4
|
L
 -1.8%
H
4.3
4.8
|
L
 -2.6%
H
4.2
4.8
|
L
 -19.1%
H
4.2
5.9
|
L
 -6.4%
H
3.8
5.9
|
L
 -11.8%
H
2.7
5.9
|
L
 52.9%
H
1
7
|
L
 -65.7%
H
1
18.2
|
L
 -90.5%
H
1
66.9
|
| Autolus Therapeutics PLC (ADR) |
|
396.6
|
1.5
|
L
 -2.6%
H
1.5
1.6
|
L
 2.8%
H
1.4
1.6
|
L
 -5.7%
H
1.4
1.7
|
L
 1.4%
H
1.4
2.0
|
L
 -36.6%
H
1.2
2.5
|
L
 -52.7%
H
1.1
7.5
|
L
 -72.0%
H
1.1
7.9
|
L
H
1.1
53.2
|
| Astrazeneca plc |
|
525,980.2
|
169.6
|
L
 -1.0%
H
168.4
170.7
|
L
 0.2%
H
167.8
175.0
|
L
 -7.7%
H
164.1
196.4
|
L
 -8.2%
H
164.1
196.4
|
L
 -10.0%
H
164.1
212.7
|
L
 -10.0%
H
164.1
212.7
|
L
 -10.0%
H
164.1
212.7
|
L
 -10.0%
H
164.1
212.7
|
| BridgeBio Pharma Inc |
|
15,686.5
|
80.1
|
L
 -2.5%
H
79.5
82.4
|
L
 -4.7%
H
79.5
86.3
|
L
 7.5%
H
74.5
93.4
|
L
 16.8%
H
62.5
93.4
|
L
 69.1%
H
42.1
93.4
|
L
 133.7%
H
21.6
93.4
|
L
 49.8%
H
5.0
93.4
|
L
H
5.0
93.4
|
| BioAtla Inc |
|
5.5
|
3.3
|
L
 -2.7%
H
3.2
3.5
|
L
 -2.4%
H
3.2
3.5
|
L
 -19.4%
H
3.2
4.7
|
L
 -23.0%
H
3.1
5.2
|
L
 -80.1%
H
3.1
71.5
|
L
 -97.7%
H
3.1
201
|
L
 -99.8%
H
3.1
2186.5
|
L
H
3.1
3831.5
|
| BioCardia Inc |
|
12.2
|
0.8
|
L
 6.5%
H
0.8
0.8
|
L
 -3.5%
H
0.8
0.9
|
L
 -31.1%
H
0.8
1.2
|
L
 -26.1%
H
0.8
1.8
|
L
 -61.5%
H
0.8
2.3
|
L
 -94.4%
H
0.8
23.3
|
L
 -98.4%
H
0.8
59.4
|
L
 -99.6%
H
0.8
2073.6
|
| Biocryst Pharma Inc |
|
2,282.4
|
9.0
|
L
 -2.8%
H
8.9
9.3
|
L
 -3.9%
H
8.9
9.9
|
L
 -6.9%
H
8.9
11.2
|
L
 -2.3%
H
7.8
11.2
|
L
 13.0%
H
6
11.2
|
L
 28.8%
H
4.0
11.3
|
L
 -44.3%
H
4.0
20.0
|
L
 142.7%
H
1.4
20.0
|
| BriaCell Therapeutics Corp |
|
29.9
|
3.4
|
L
 -5.2%
H
3.4
3.6
|
L
 -3.9%
H
3.4
3.8
|
L
 -0.9%
H
3.1
4
|
L
 -17.7%
H
2.6
4.3
|
L
 -95.4%
H
2.6
79
|
L
 -100.0%
H
2.6
11275.5
|
L
 -100.0%
H
2.6
18526.5
|
L
 -100.0%
H
2.6
83250
|
| Black Diamond Therapeutics Inc |
|
96.8
|
1.7
|
L
 -1.7%
H
1.6
1.7
|
L
 -4.0%
H
1.6
1.8
|
L
 -8.2%
H
1.6
2.2
|
L
 -35%
H
1.6
4.0
|
L
 -34.8%
H
1.6
4.9
|
L
 -54.3%
H
1.2
7.7
|
L
 -82.3%
H
1.2
10.5
|
L
H
1.2
46.3
|
| Beam Therapeutics Inc |
|
2,625.5
|
25.5
|
L
 -3.7%
H
25.4
26.9
|
L
 1.7%
H
24.7
27.0
|
L
 -23.8%
H
24.7
38.3
|
L
 -16.9%
H
24.7
38.3
|
L
 35.5%
H
15.6
38.3
|
L
 -10.5%
H
13.5
49.5
|
L
 -72.3%
H
13.5
116.9
|
L
H
13
138.5
|
| Biofrontera Inc |
|
15.0
|
1.2
|
L
 -4.9%
H
1.1
1.2
|
L
 7.3%
H
1
1.3
|
L
 15.8%
H
1
1.3
|
L
 8.3%
H
0.7
1.3
|
L
 12.5%
H
0.6
1.3
|
L
 -90.1%
H
0.5
12.5
|
L
H
0.5
292.6
|
L
H
0.5
292.6
|
| Biogen |
|
29,986.7
|
203.0
|
L
 -2.4%
H
202.6
208.1
|
L
 0.4%
H
199.4
218.6
|
L
 -3.2%
H
186.0
219.0
|
L
 8.5%
H
184.9
219.7
|
L
 53.8%
H
127
219.7
|
L
 -24.6%
H
110.0
279.0
|
L
 -37.9%
H
110.0
351.9
|
L
 -27.0%
H
110.0
468.6
|
| BioVie Inc |
|
11.5
|
1.5
|
L
 6.3%
H
1.4
1.6
|
L
 11.0%
H
1.3
1.6
|
L
 -30.3%
H
1.3
2.3
|
L
 -9.5%
H
1.3
2.3
|
L
 -74.8%
H
1.1
6.2
|
L
 -99.7%
H
1.1
582
|
L
 -99.9%
H
1.1
1482
|
L
 -99.9%
H
1.1
5625
|
| Biomea Fusion Inc |
|
84.6
|
1.2
|
L
 -4.1%
H
1.2
1.2
|
L
 -6.4%
H
1.2
1.3
|
L
 -14.0%
H
1.2
1.5
|
L
 -14.6%
H
1.1
1.7
|
L
 -25.5%
H
0.9
3.0
|
L
 -94.4%
H
0.9
22.7
|
L
 -91.1%
H
0.9
43.7
|
L
H
0.9
43.7
|
| Biomarin pharma Inc - Registered Shares |
|
11,600.9
|
60.0
|
L
 -0.9%
H
58.9
60.8
|
L
 1.2%
H
58.9
63.1
|
L
 3.8%
H
57.4
63.1
|
L
 11.0%
H
49.3
63.1
|
L
 3.2%
H
49.3
66.3
|
L
 -32.6%
H
49.3
99.6
|
L
 -21.8%
H
49.3
117.8
|
L
 -40.1%
H
49.3
131.9
|
| Bionano Genomics Inc |
|
12.3
|
1.1
|
L
 0.9%
H
1
1.1
|
L
 -3.6%
H
1
1.1
|
L
 -8.6%
H
1
1.2
|
L
 -9.3%
H
1
1.4
|
L
 -63.7%
H
1
5.5
|
L
 -82.4%
H
0.1
11.6
|
L
 -98.2%
H
0.1
63.7
|
L
H
0.1
156.9
|
| Benitec Biopharma Inc |
|
402.3
|
11.7
|
L
 -1.3%
H
11.1
11.9
|
L
 2.1%
H
11.1
12.4
|
L
 -7.7%
H
11.1
13.8
|
L
 -2.0%
H
10
14.3
|
L
 6.8%
H
9.9
16.8
|
L
 302.4%
H
1.9
17.2
|
L
 -80.3%
H
1.9
81.3
|
L
 -97.4%
H
1.9
1371.3
|
| Bolt Biotherapeutics Inc |
|
7.7
|
4.0
|
L
 2.6%
H
3.9
4.1
|
L
 4.2%
H
3.8
4.1
|
L
H
3.8
4.5
|
L
 -21.2%
H
3.8
5.7
|
L
 -27.9%
H
3.8
7.2
|
L
 -84.9%
H
3.8
31.2
|
L
 -98.2%
H
3.8
385.7
|
L
H
3.8
861.4
|
| Bon Natural Life Ltd |
|
8.9
|
1.1
|
L
 -0.9%
H
1.1
1.2
|
L
 -3.5%
H
1.1
1.2
|
L
 -8.3%
H
1.1
1.3
|
L
 -15.4%
H
1.1
1.5
|
L
 -15.4%
H
1.1
3.4
|
L
 -99.3%
H
1.1
180
|
L
 -100.0%
H
1.1
3530
|
L
 -100.0%
H
1.1
22532.5
|
| BioXcel Therapeutics Inc |
|
25.0
|
0.8
|
L
 2.5%
H
0.8
0.8
|
L
 -4.7%
H
0.8
0.9
|
L
 -40.9%
H
0.7
1.4
|
L
 -32.5%
H
0.7
1.5
|
L
 -40.9%
H
0.7
8.1
|
L
 -89.2%
H
0.2
8.1
|
L
 -96.8%
H
0.2
36.5
|
L
H
0.2
71.5
|
| Blue Water Biotech Inc |
|
14.8
|
0.8
|
L
 5.1%
H
0.8
0.8
|
L
 1.2%
H
0.7
0.9
|
L
 -23.2%
H
0.7
1.2
|
L
 29.7%
H
0.1
1.4
|
L
 -75.9%
H
0.1
6.7
|
L
 -23.9%
H
0.1
6.7
|
L
H
0.1
90.9
|
L
H
0.1
90.9
|
| BeyondSpring Inc |
|
47.3
|
1.2
|
L
 1.8%
H
1.2
1.2
|
L
 2.7%
H
1.1
1.2
|
L
 -37.8%
H
1.0
1.9
|
L
 -22.8%
H
1.0
1.9
|
L
 -44.4%
H
1.0
2.4
|
L
 12.7%
H
0.7
4
|
L
 -87.9%
H
0.5
33
|
L
H
0.5
48.5
|
| Bicycle Therapeutics PLC (ADR) |
|
269.5
|
3.9
|
L
 -3.7%
H
3.8
4.0
|
L
 -0.3%
H
3.8
4.0
|
L
 -8.3%
H
3.8
4.5
|
L
 -19.6%
H
3.8
5.2
|
L
 -51.7%
H
3.8
9.2
|
L
 -84.2%
H
3.8
28.7
|
L
 -87.8%
H
3.8
62.1
|
L
H
3.8
62.1
|
| Biodexa Pharma PLC (ADR) |
|
1.2
|
1.3
|
L
 -10.8%
H
1.3
1.5
|
L
 -20%
H
1.0
1.7
|
L
 -56%
H
1.0
3.0
|
L
 -56.4%
H
1.0
5.1
|
L
 -96.1%
H
1.0
59.4
|
L
 -100.0%
H
1.0
301250
|
L
 -100.0%
H
1.0
102500000
|
L
 -100.0%
H
1.0
10000000000
|
| BeiGene Ltd (ADR) |
|
33,663.3
|
316.0
|
L
 -1.9%
H
311.1
320.9
|
L
 -3.0%
H
311.1
331.7
|
L
 8.7%
H
291.9
331.7
|
L
 7.5%
H
254.0
331.7
|
L
 5.7%
H
254.0
385.2
|
L
 53.0%
H
127.0
385.2
|
L
 -0.2%
H
118.2
426.6
|
L
 1118.7%
H
25.5
426.6
|
| Bioline Rx Ltd (ADR) |
|
12.3
|
2.8
|
L
 4.4%
H
2.7
2.8
|
L
H
2.7
2.9
|
L
 -11.0%
H
2.7
3.3
|
L
 -1.4%
H
2.5
4.0
|
L
 -27.1%
H
2.2
4.6
|
L
 -95.5%
H
0.1
101.2
|
L
 -97.8%
H
0.1
133.2
|
L
 -99.4%
H
0.1
1103.9
|
| Belite Bio Inc (ADR) |
|
6,357.9
|
158.6
|
L
 -0.8%
H
155.2
161
|
L
 3.4%
H
151.5
163.0
|
L
 11.5%
H
143.5
163.0
|
L
 2.4%
H
130
163.0
|
L
 141.3%
H
60
200
|
L
 627.2%
H
20.3
200
|
L
H
6
200
|
L
H
6
200
|
| Neuphoria Therapeutics Inc |
|
21.0
|
3.9
|
L
 -1.0%
H
3.9
4
|
L
 6.6%
H
3.6
4.1
|
L
 9.3%
H
3.3
4.2
|
L
 -25.7%
H
3.2
5.5
|
L
 -51.8%
H
3.2
21.4
|
L
 129.6%
H
0.2
21.4
|
L
H
0.2
22
|
L
H
0.2
22
|
| BioNTech SE (ADR) |
|
22,906.3
|
90.6
|
L
 -2.4%
H
90.5
93.0
|
L
 1.4%
H
88.5
94.4
|
L
 -3.6%
H
88.4
98.8
|
L
 -7.1%
H
85.0
100.2
|
L
 -15.6%
H
79.5
124
|
L
 -15.4%
H
76.5
131.5
|
L
 -72.4%
H
76.5
464
|
L
H
12.5
464
|
| Biondvax Pharma Ltd (ADR) |
|
-
|
0.3
|
L
 -3.6%
H
0.3
0.3
|
L
 17.4%
H
0.2
0.3
|
L
H
0.2
0.3
|
L
 -62.0%
H
0.2
0.7
|
L
 -81.6%
H
0.2
2.0
|
L
 -80.6%
H
0.2
6.2
|
L
 -99.1%
H
0.2
99
|
L
 -99.2%
H
0.2
620
|
| Cabaletta Bio Inc |
|
437.0
|
2.7
|
L
 -1.5%
H
2.6
2.7
|
L
 -0.4%
H
2.6
2.8
|
L
 -10.4%
H
2.6
3.3
|
L
 -8.8%
H
2.6
4.2
|
L
 86.1%
H
1.3
4.2
|
L
 -78.8%
H
1.0
26.4
|
L
 -64.1%
H
0.6
26.4
|
L
H
0.6
26.4
|
| Candel Therapeutics Inc |
|
733.4
|
10.0
|
L
 1.4%
H
9.8
10.1
|
L
 4.7%
H
9.2
10.2
|
L
 1.3%
H
9.2
10.6
|
L
 54.7%
H
6.6
11.4
|
L
 59.1%
H
4.4
11.4
|
L
 853.3%
H
0.7
14.6
|
L
 31.9%
H
0.7
14.8
|
L
H
0.7
14.8
|
| CalciMedica Inc |
|
15.8
|
1
|
L
 19.1%
H
0.9
1
|
L
 31.6%
H
0.7
1
|
L
 -3.9%
H
0.7
1.1
|
L
 69.5%
H
0.5
1.2
|
L
 -66.0%
H
0.5
7.2
|
L
 -69.5%
H
0.5
8.4
|
L
 -98.3%
H
0.5
63
|
L
H
0.5
530.3
|
| Capricor Therapeutics Inc |
|
223.0
|
3.9
|
L
 -8.1%
H
3.8
4.7
|
L
 -80.5%
H
3.0
7.9
|
L
 -83.3%
H
3.0
24.6
|
L
 -87.5%
H
3.0
34.5
|
L
 -51.3%
H
3.0
40.4
|
L
 -16.1%
H
2.7
40.4
|
L
 -11.9%
H
2.6
40.4
|
L
 -89.2%
H
0.9
42.5
|
| Tvardi Therapeutics Inc |
|
19.7
|
2.1
|
L
H
2
2.1
|
L
 -16.3%
H
2
2.7
|
L
 7.7%
H
1.9
5.7
|
L
 -33.1%
H
1.5
5.7
|
L
 -92.0%
H
1.5
43.7
|
L
 -98.1%
H
1.5
117.6
|
L
 -99.5%
H
1.5
681.5
|
L
 -99.0%
H
1.5
1067.3
|
| Crescent Biopharma Inc |
|
-
|
14.5
|
L
 -3.7%
H
14.0
15.1
|
L
 -11.2%
H
14.0
17.8
|
L
 -15.3%
H
14.0
17.9
|
L
 -19.9%
H
14.0
22.5
|
L
 20.6%
H
8.7
27.4
|
L
 167.0%
H
4.8
27.4
|
L
 45.6%
H
0.9
27.4
|
L
 -72.6%
H
0.9
90.3
|
| C4 Therapeutics Inc |
|
384.8
|
3.5
|
L
 -4.9%
H
3.5
3.7
|
L
 2.4%
H
3.4
3.7
|
L
 -19.8%
H
3.4
4.4
|
L
 19.2%
H
2.8
5.2
|
L
 64.2%
H
1.7
5.2
|
L
 -6.2%
H
1.1
11.9
|
L
 -91.9%
H
1.1
51.2
|
L
H
1.1
51.2
|
| Niagen Bioscience Inc |
|
270.8
|
3.4
|
L
 2.4%
H
3.2
3.4
|
L
 5.9%
H
3.1
3.4
|
L
 2.1%
H
3.1
3.6
|
L
 -29.9%
H
3.1
5.1
|
L
 -62.4%
H
3.1
11.3
|
L
 98.8%
H
1.3
14.7
|
L
 -60.9%
H
1.2
14.7
|
L
 -12.4%
H
1.2
23.7
|
| Cullinan Oncology Inc |
|
1,014.1
|
16.5
|
L
 -5.8%
H
16.1
17.5
|
L
 -3.5%
H
16.1
18.0
|
L
 -4.5%
H
16
18.8
|
L
 22.9%
H
11.7
19.4
|
L
 115.1%
H
5.7
19.4
|
L
 59.0%
H
5.7
30.2
|
L
 -28.0%
H
5.7
30.3
|
L
H
5.7
59.9
|
| Compugen Ltd |
|
222.3
|
2.4
|
L
 0.4%
H
2.2
2.4
|
L
 3.1%
H
2.2
2.4
|
L
 10.3%
H
2.1
2.6
|
L
 -13.3%
H
2.0
3.1
|
L
 58.8%
H
1.3
3.2
|
L
 97.5%
H
0.5
3.2
|
L
 -65.4%
H
0.5
7.5
|
L
 -66.0%
H
0.5
19.9
|
| Cognition Therapeutics Inc |
|
79.7
|
0.9
|
L
 -3.3%
H
0.9
0.9
|
L
 -3.3%
H
0.9
1.0
|
L
 -21.2%
H
0.9
1.2
|
L
 -30.5%
H
0.9
1.8
|
L
 32.8%
H
0.6
3.8
|
L
 -47.0%
H
0.2
3.8
|
L
H
0.2
13.8
|
L
H
0.2
13.8
|
| Coherus Biosciences Inc |
|
217.5
|
1.4
|
L
 -4.1%
H
1.4
1.5
|
L
H
1.4
1.5
|
L
 -2.1%
H
1.4
1.7
|
L
 -21.7%
H
1.3
2.1
|
L
 60.2%
H
0.8
2.6
|
L
 -68.6%
H
0.7
5.5
|
L
 -89.2%
H
0.7
19.3
|
L
 -94.5%
H
0.7
32.0
|
| Cingulate Inc |
|
64.5
|
4.8
|
L
 0.6%
H
4.6
4.8
|
L
 3.2%
H
4.2
4.9
|
L
 -18.7%
H
4.2
6.0
|
L
 -10.8%
H
3.2
6.0
|
L
 -6.1%
H
3.2
11.9
|
L
 770.9%
H
0.2
20.8
|
L
H
0.2
20.8
|
L
H
0.2
20.8
|
| Celldex Therapeutics Inc |
|
2,987.4
|
38.1
|
L
 -1.1%
H
37.2
38.7
|
L
 7.9%
H
35
38.7
|
L
 3.5%
H
33.4
40.3
|
L
 17.8%
H
28.4
40.3
|
L
 71.5%
H
19.7
40.3
|
L
 9.5%
H
14.4
53.2
|
L
 -13.0%
H
14.4
57.2
|
L
 -45.7%
H
1.5
75.3
|
| Clene Inc |
|
64.1
|
5.0
|
L
 -0.4%
H
4.9
5.4
|
L
 -6.9%
H
4.6
5.5
|
L
 -18.1%
H
4.6
6.6
|
L
 -18.2%
H
4.6
8.7
|
L
 43.8%
H
3.5
13.5
|
L
 -66.1%
H
2.3
15.6
|
L
 -97.1%
H
2.3
196.8
|
L
H
0.5
356.4
|
| Cellectar Biosciences Inc |
|
20.5
|
2.6
|
L
 1.6%
H
2.5
2.7
|
L
 6.6%
H
2.3
2.7
|
L
 -9.2%
H
2.3
3.0
|
L
 -4.5%
H
2.2
4.7
|
L
 -45.6%
H
2.2
6.5
|
L
 -95.7%
H
2.2
133.5
|
L
 -99.2%
H
2.2
330
|
L
 -100.0%
H
2.2
10410
|
| Compass Therapeutics Inc |
|
344.0
|
1.9
|
L
 -1.6%
H
1.9
2.0
|
L
 -7.7%
H
1.9
2.2
|
L
 -12.4%
H
1.9
2.4
|
L
 -2.6%
H
1.8
2.5
|
L
 -35.3%
H
1.6
6.9
|
L
 -28.7%
H
0.8
6.9
|
L
 -61.0%
H
0.8
6.9
|
L
H
0.8
11
|
| Cns Pharma Inc |
|
8.5
|
5.8
|
L
 20%
H
4.8
5.8
|
L
 11.3%
H
4.8
5.8
|
L
 24.4%
H
4.4
6
|
L
 152.0%
H
3.9
10.5
|
L
 -24.4%
H
1.9
10.6
|
L
 -100.0%
H
1.9
4125000
|
L
 -100.0%
H
1.9
77850000
|
L
H
1.9
256050000
|
| Context Therapeutics Inc |
|
55.1
|
0.6
|
L
 -1.6%
H
0.6
0.6
|
L
 -1.6%
H
0.6
0.7
|
L
 -1.6%
H
0.6
0.7
|
L
 -73.6%
H
0.5
3.1
|
L
 -15.5%
H
0.5
3.6
|
L
 -49.2%
H
0.5
3.6
|
L
H
0.5
10.9
|
L
H
0.5
10.9
|
| Cocrystal Pharma Inc |
|
11.3
|
0.8
|
L
 -5.8%
H
0.8
0.9
|
L
 -8.9%
H
0.8
1.0
|
L
 -21.9%
H
0.8
1.1
|
L
 -40.6%
H
0.8
1.5
|
L
 -55.7%
H
0.8
2.7
|
L
 -68.1%
H
0.8
3.3
|
L
 -94.1%
H
0.8
14.8
|
L
 -99.5%
H
0.8
194.4
|
| Co-Diagnostics Inc |
|
5.3
|
1.4
|
L
 -7.7%
H
1.4
1.6
|
L
 -31.4%
H
1.4
2.2
|
L
 -53.3%
H
1.4
3.4
|
L
 -7.1%
H
1.3
13.5
|
L
 -80.7%
H
1.3
46.5
|
L
 -96.6%
H
1.3
66.9
|
L
 -99.5%
H
1.3
354.6
|
L
H
1.3
929.7
|
| Z Squared Inc |
|
253.7
|
4.8
|
L
 -7.9%
H
4.8
5.4
|
L
 -8.6%
H
4.4
5.6
|
L
 -60.0%
H
4.3
12.0
|
L
 -66.7%
H
4.3
16.9
|
L
 -55.1%
H
4.3
21.4
|
L
 -80.4%
H
2.3
27.6
|
L
 -51.2%
H
2.3
242.6
|
L
H
2.3
242.6
|
| Cogent Biosciences Inc |
|
6,651.9
|
38.9
|
L
 -5.9%
H
38.8
41.3
|
L
 -2.1%
H
38.8
42.1
|
L
 1.2%
H
37.0
42.1
|
L
 6.3%
H
30.9
42.1
|
L
 241.5%
H
10.4
43.7
|
L
 191.8%
H
3.7
43.7
|
L
 548.8%
H
3.7
43.7
|
L
H
1.2
70.6
|
| Collegium pharma Inc |
|
1,147.8
|
35.4
|
L
 -1.6%
H
34.4
36.3
|
L
 0.5%
H
34.4
36.6
|
L
 -1.3%
H
34
38.5
|
L
 3.1%
H
30.1
40.5
|
L
 17.7%
H
29.7
50.8
|
L
 55.4%
H
21.0
50.8
|
L
 42.2%
H
14.0
50.8
|
L
 198.4%
H
7.4
50.8
|
| Corcept Therapeutics Inc |
|
12,376.2
|
114.5
|
L
 -3.2%
H
111.8
118.5
|
L
 20.1%
H
90
122.2
|
L
 29.4%
H
84.9
122.2
|
L
 122.7%
H
49.8
122.2
|
L
 65.9%
H
28.7
122.2
|
L
 358.0%
H
20.8
122.2
|
L
 451.2%
H
15.8
122.2
|
L
 1884.2%
H
5.2
122.2
|
| Cosmos Health Inc |
|
13.7
|
0.2
|
L
 10%
H
0.2
0.2
|
L
 10%
H
0.2
0.2
|
L
 10%
H
0.2
0.4
|
L
 -42.1%
H
0.2
0.4
|
L
 -74.4%
H
0.2
1.3
|
L
 -85.0%
H
0.2
2.1
|
L
 -99.8%
H
0.2
150
|
L
 -99.9%
H
0.2
312.5
|
| Coya Therapeutics Inc |
|
98.3
|
4.2
|
L
 2.7%
H
4
4.2
|
L
 -1.4%
H
3.9
4.4
|
L
 -26.0%
H
3.9
6.1
|
L
 0.5%
H
3.9
6.2
|
L
 -31.2%
H
3.7
7.8
|
L
 5.5%
H
3.2
10.7
|
L
H
3.2
10.7
|
L
H
3.2
10.7
|
| Cumberland Pharma Inc |
|
100.1
|
6.7
|
L
 -0.7%
H
6.4
6.9
|
L
 1.1%
H
6.3
7.2
|
L
 -6.3%
H
5.8
8.1
|
L
 53.2%
H
4.1
8.1
|
L
 89.8%
H
1.9
8.1
|
L
 360.7%
H
1.0
8.1
|
L
 105.5%
H
1.0
8.1
|
L
 43.7%
H
1.0
8.1
|
| Corbus Pharma Holdings Inc |
|
166.2
|
9.0
|
L
 -0.9%
H
8.6
9.2
|
L
 -2.2%
H
8.6
9.5
|
L
 -1.1%
H
8.5
9.9
|
L
 -12.9%
H
7.1
12.9
|
L
 -3.7%
H
7.1
20.6
|
L
 23.9%
H
3.0
61.9
|
L
 -78.2%
H
2.1
61.9
|
L
 -89.3%
H
2.1
323.4
|
| Caribou Biosciences Inc |
|
144.8
|
1.5
|
L
 -3.3%
H
1.4
1.5
|
L
 -7.0%
H
1.4
1.7
|
L
 -17.1%
H
1.4
2.1
|
L
 -21.9%
H
1.4
2.5
|
L
 -25.1%
H
1.4
3.5
|
L
 -80.0%
H
0.7
8.3
|
L
 -91.0%
H
0.7
32.6
|
L
H
0.7
32.6
|
| Cardiol Therapeutics Inc (Class A) |
|
146.4
|
1.3
|
L
 5.0%
H
1.2
1.3
|
L
 7.6%
H
1.1
1.3
|
L
 21.0%
H
1.0
1.3
|
L
 -7.3%
H
1.0
1.4
|
L
 -8.0%
H
0.9
1.7
|
L
 17.6%
H
0.7
3.1
|
L
 -55.1%
H
0.5
5.0
|
L
H
0.5
8.5
|
| Curis Inc |
|
9.8
|
5.0
|
L
 1.2%
H
4.9
5.2
|
L
 2.7%
H
4.6
5.6
|
L
 -40.5%
H
4.4
9
|
L
 -57.6%
H
3.6
12.5
|
L
 -84.6%
H
3.6
39
|
L
 -98.5%
H
3.6
349.8
|
L
 -99.8%
H
3.6
3616
|
L
 -99.9%
H
3.6
7440
|
| CorMedix Inc |
|
590.7
|
7.5
|
L
 0.5%
H
7.3
7.6
|
L
 -4.3%
H
7.1
8.1
|
L
 -11.1%
H
7.1
9.0
|
L
 -3.3%
H
7.1
9.1
|
L
 -35.3%
H
6.1
15.0
|
L
 75.5%
H
2.6
17.4
|
L
 29.6%
H
2.6
17.4
|
L
 1.1%
H
0.9
18.8
|
| Crinetics Pharma Inc |
|
8,839.8
|
83.5
|
L
 -0.1%
H
83.5
83.8
|
L
 -0.3%
H
83.5
84
|
L
 115.9%
H
39.8
84
|
L
 114.0%
H
32.3
84
|
L
 200%
H
25.8
84
|
L
 329.4%
H
15.8
84
|
L
 364.5%
H
15.2
84
|
L
H
10.6
84
|
| Cronos Grp Inc |
|
1,057.5
|
2.8
|
L
 -2.1%
H
2.8
2.9
|
L
 0.7%
H
2.8
2.9
|
L
 -1.1%
H
2.7
2.9
|
L
 7.2%
H
2.5
2.9
|
L
 45.1%
H
1.9
3.4
|
L
 48.2%
H
1.6
3.4
|
L
 -61.6%
H
1.6
7.6
|
L
 843.3%
H
0.3
25.1
|
| CRISPR Therapeutics AG |
|
4,726.3
|
48.0
|
L
 -0.9%
H
47.3
49.0
|
L
 3.1%
H
45.9
49.0
|
L
 -13.7%
H
45.9
63.5
|
L
 -7.1%
H
45.9
63.5
|
L
 -14.4%
H
44.1
78.5
|
L
 -14.9%
H
30.0
91.1
|
L
 -60.3%
H
30.0
142.6
|
L
H
11.6
220.2
|
| Corvus Pharma Inc |
|
1,115.0
|
13.3
|
L
 0.5%
H
12.8
13.4
|
L
 1.5%
H
12.5
13.5
|
L
 -10.2%
H
12.5
16.5
|
L
 -14.2%
H
10.8
16.9
|
L
 223.4%
H
4.1
27.0
|
L
 492.0%
H
1.1
27.0
|
L
 534.4%
H
0.6
27.0
|
L
 -0.3%
H
0.6
27.0
|
| Champions Oncology Inc |
|
74.5
|
5.4
|
L
 1.9%
H
5.3
5.5
|
L
 -12.6%
H
5.2
6.5
|
L
 -11.3%
H
5.2
6.5
|
L
 -10.5%
H
5.2
7
|
L
 -13.0%
H
5.2
8.7
|
L
 -15.6%
H
3.6
12.0
|
L
 -48.7%
H
3.6
12.0
|
L
 173.5%
H
1.1
17.9
|
| CytomX Therapeutics Inc |
|
674.9
|
3.1
|
L
 -5.5%
H
3.1
3.3
|
L
 -4.3%
H
3.1
3.4
|
L
 -13.9%
H
3.1
4.0
|
L
 -25.8%
H
2.8
4.3
|
L
 31.9%
H
1.7
8.2
|
L
 83.4%
H
0.4
8.2
|
L
 -42.7%
H
0.4
8.2
|
L
 -69.8%
H
0.4
35
|
| Cue Biopharma Inc |
|
112.7
|
26.8
|
L
 -11.7%
H
25.3
29.9
|
L
 -16.4%
H
25.3
34.4
|
L
 -5.3%
H
25.3
45.5
|
L
 -11.8%
H
18.2
45.5
|
L
 21.4%
H
5.0
45.5
|
L
 -76.3%
H
5.0
115.5
|
L
 -91.4%
H
5.0
552.6
|
L
H
5.0
950.7
|
| Cadrenal Therapeutics Inc |
|
6.2
|
2.0
|
L
 -3.8%
H
2.0
2.1
|
L
 -1.5%
H
2.0
2.1
|
L
 -36.6%
H
1.9
3.9
|
L
 -68.4%
H
1.9
7
|
L
 -80.5%
H
1.9
14.6
|
L
 131.0%
H
0.4
22.9
|
L
H
0.4
22.9
|
L
H
0.4
22.9
|
| Cyclacel Pharma Inc |
|
4.9
|
0.9
|
L
 -2.2%
H
0.9
0.9
|
L
 -3.3%
H
0.9
1.0
|
L
 -19.1%
H
0.8
1.2
|
L
 -9.2%
H
0.6
2.8
|
L
 -90.8%
H
0.6
10.6
|
L
 -100.0%
H
0.6
2721.6
|
L
 -100.0%
H
0.6
21960
|
L
 -100.0%
H
0.6
784800
|
| Cyclerion Therapeutics Inc |
|
14.9
|
3.4
|
L
 -1.7%
H
3.4
3.6
|
L
 -1.7%
H
3.4
3.7
|
L
 2.1%
H
3.3
4.0
|
L
 5.5%
H
2.9
4.0
|
L
 32.8%
H
1.0
8.5
|
L
 4.2%
H
1.0
8.5
|
L
 -94.1%
H
1.0
72.5
|
L
H
1.0
457
|
| Cytokinetics Inc |
|
10,472.0
|
77.1
|
L
 -4.1%
H
77.0
80.8
|
L
 -4.5%
H
77.0
82.4
|
L
 -9.5%
H
77.0
87.9
|
L
 21.8%
H
63
88.3
|
L
 110.2%
H
32.9
88.3
|
L
 137.3%
H
26.0
110
|
L
 159.9%
H
26.0
110
|
L
 571.3%
H
5.8
110
|
| Cellectis (ADR) |
|
276.9
|
2.8
|
L
 -3.5%
H
2.7
2.9
|
L
 -3.2%
H
2.7
2.9
|
L
 -6.5%
H
2.6
3.4
|
L
 -30.4%
H
2.6
4.2
|
L
 -6.8%
H
2.5
5.5
|
L
 36.8%
H
1.0
5.5
|
L
 -78.8%
H
1.0
15.5
|
L
 -89.9%
H
1.0
38.9
|
| Chemomab Therapeutics Ltd (ADR) |
|
11.4
|
1.6
|
L
 1.3%
H
1.5
1.6
|
L
 14.0%
H
1.4
1.6
|
L
 -8.8%
H
1.4
2.8
|
L
 -3.7%
H
1.4
2.8
|
L
 -62.2%
H
1.4
4.2
|
L
 -69.7%
H
1.4
10.2
|
L
 -97.7%
H
1.4
71.2
|
L
H
1.4
736
|
| Compass Pathways PLC (ADR) |
|
1,531.7
|
11.4
|
L
 -1.9%
H
11.2
11.8
|
L
 0.8%
H
10.6
11.8
|
L
 -14.6%
H
10.6
14.6
|
L
 26.0%
H
9.0
15.4
|
L
 161.5%
H
4.0
15.4
|
L
 26.8%
H
2.3
15.4
|
L
 -68.0%
H
2.3
49.5
|
L
H
2.3
61.7
|
| Connect Biopharma Holdings Ltd (ADR) |
|
112.6
|
2.0
|
L
 -3.4%
H
2.0
2.1
|
L
 -5.6%
H
2.0
2.2
|
L
 -15.5%
H
2.0
2.8
|
L
 -18.2%
H
1.9
2.8
|
L
 1%
H
1.2
3.8
|
L
 114.9%
H
0.5
3.8
|
L
 -90.8%
H
0.5
29.3
|
L
H
0.5
29.3
|
| Dare Bioscience Inc |
|
18.3
|
1.2
|
L
 -1.6%
H
1.2
1.3
|
L
 -4.7%
H
1.1
1.4
|
L
 -42.2%
H
1.1
2.2
|
L
 -47.9%
H
1.1
3.8
|
L
 -49.6%
H
1.1
3.8
|
L
 -86.1%
H
0.3
9.5
|
L
 -93.4%
H
0.3
30.1
|
L
 -99.6%
H
0.3
429.6
|
| Journey Medical Corp |
|
175.4
|
6.4
|
L
 -1.2%
H
6.2
6.5
|
L
 2.9%
H
6.1
6.6
|
L
 -9.5%
H
6
7.5
|
L
 22.7%
H
4.8
7.5
|
L
 -8.9%
H
4.3
9.6
|
L
 231.8%
H
1.8
9.6
|
L
H
1.0
10.2
|
L
H
1.0
10.2
|
| DiaMedica Therapeutics Inc |
|
341.6
|
6.3
|
L
 -2.6%
H
6.3
6.5
|
L
 -5.9%
H
6.3
7.1
|
L
 -14.8%
H
6.3
8.5
|
L
 2.6%
H
5.2
8.5
|
L
 53.9%
H
4.2
10.4
|
L
 94.5%
H
1.9
10.4
|
L
 83.8%
H
1.1
10.4
|
L
 66.8%
H
1.1
13.8
|
| Denali Therapeutics Inc |
|
3,653.5
|
23.0
|
L
 -5.5%
H
23.0
24.4
|
L
 -0.4%
H
23.0
24.7
|
L
 -11.4%
H
22.0
27.3
|
L
 25.8%
H
17.7
27.3
|
L
 71.3%
H
12.6
27.3
|
L
 -18.7%
H
10.6
33.3
|
L
 -54.9%
H
10.6
56.8
|
L
H
10.6
93.9
|
| Dermata Therapeutics Inc |
|
4.7
|
1.2
|
L
 -0.9%
H
1.2
1.2
|
L
 -11.4%
H
1.2
1.4
|
L
 -15.2%
H
1.2
1.5
|
L
 -12.0%
H
1.2
1.5
|
L
 -81.9%
H
1.1
7.1
|
L
 -7.9%
H
0.2
7.1
|
L
H
0.2
111.2
|
L
H
0.2
111.2
|
| Bright Minds Biosciences Inc |
|
718.8
|
73.3
|
L
 -1.8%
H
71.3
74.5
|
L
 2.7%
H
68.8
75.5
|
L
 10.1%
H
63.4
79.2
|
L
 -15.8%
H
56.5
92
|
L
 117.8%
H
32.5
123.8
|
L
 1764.1%
H
0.9
123.8
|
L
 211.7%
H
0.9
123.8
|
L
H
0.9
123.8
|
| Design Therapeutics Inc |
|
760.7
|
12.2
|
L
 -3.5%
H
12.1
13.4
|
L
 3.4%
H
11.5
13.4
|
L
 -16.9%
H
11.4
15.9
|
L
 -8.4%
H
9.9
17.0
|
L
 218.9%
H
3.9
17.3
|
L
 58.2%
H
1.9
17.3
|
L
 -21.3%
H
1.9
26.3
|
L
H
1.9
50.5
|
| Precision Biosciences Inc |
|
180.4
|
7.0
|
L
 -0.1%
H
6.8
7.2
|
L
 -4.1%
H
6.7
7.7
|
L
 -11.3%
H
6.7
9.6
|
L
 -4.0%
H
6
9.6
|
L
 51.3%
H
3.5
9.6
|
L
 1105.2%
H
0.3
19.4
|
L
 -29.1%
H
0.3
19.4
|
L
H
0.3
23.7
|
| Dyne Therapeutics Inc |
|
4,702.3
|
25.2
|
L
 -2.1%
H
24.4
26.0
|
L
 3.0%
H
24.0
26.3
|
L
 15.6%
H
21.3
26.3
|
L
 44.8%
H
15.9
26.3
|
L
 150.6%
H
9.9
26.3
|
L
 112.7%
H
6.4
47.5
|
L
 39.3%
H
4.3
47.5
|
L
H
4.3
47.5
|
| DBV Tech (ADR) |
|
799.0
|
13.5
|
L
 -2.2%
H
13
13.7
|
L
 -1.0%
H
13
14.1
|
L
 -14.2%
H
13
17.4
|
L
 -32.1%
H
13
20.9
|
L
 50%
H
8.7
26.2
|
L
 -16.1%
H
0.5
26.2
|
L
 -74.0%
H
0.5
59.9
|
L
 -96.1%
H
0.5
505.7
|
| Editas Medicine Inc |
|
395.9
|
2.6
|
L
 -4.1%
H
2.5
2.7
|
L
 -0.8%
H
2.5
2.7
|
L
 -21.3%
H
2.5
3.8
|
L
 -11.0%
H
2.4
3.9
|
L
 5.7%
H
1.7
4.5
|
L
 -70.2%
H
0.9
11.7
|
L
 -93.8%
H
0.9
73.0
|
L
 -90.0%
H
0.9
100.0
|
| Edesa Biotech Inc |
|
49.2
|
5.1
|
L
 -2.7%
H
4.8
5.3
|
L
 -2.7%
H
4.5
5.6
|
L
 -34.1%
H
4.5
8.0
|
L
 -71.0%
H
4.5
19.0
|
L
 138.8%
H
0.7
20.3
|
L
 -13.1%
H
0.7
20.3
|
L
 -85.4%
H
0.7
84
|
L
 -99.4%
H
0.7
923.2
|
| Eledon Pharma Inc |
|
260.9
|
3.4
|
L
 -0.9%
H
3.3
3.5
|
L
 -5.6%
H
3.3
3.8
|
L
 -13.3%
H
3.3
4.3
|
L
 -8.4%
H
3.3
4.5
|
L
H
1.4
4.6
|
L
 160%
H
1.1
5.4
|
L
 -47.9%
H
1.1
8.5
|
L
 -98.2%
H
1.1
338.6
|
| Eloxx Pharma |
|
59.9
|
17.4
|
L
 31.1%
H
13.8
18.4
|
L
 46.0%
H
11.0
18.4
|
L
 44.1%
H
10.5
18.4
|
L
 328.3%
H
8.2
18.4
|
L
 328.3%
H
8.2
18.4
|
L
 178.4%
H
0
18.4
|
L
 -67.0%
H
0
75.6
|
L
 -87.6%
H
0
984
|
| Elicio Therapeutics Inc |
|
73.5
|
2.8
|
L
 -3.8%
H
2.7
3.0
|
L
 -6.7%
H
2.7
3.2
|
L
 -45.5%
H
2.7
3.8
|
L
 -74.0%
H
2.7
16
|
L
 -71.9%
H
2.7
16
|
L
 -72%
H
2.7
16
|
L
 -97.4%
H
2.7
141.8
|
L
H
2.7
263
|
| Enliven Therapeutics Inc |
|
3,915.5
|
54.8
|
L
 1.6%
H
53.1
55.8
|
L
 3.5%
H
52
55.8
|
L
 12.4%
H
47.5
55.8
|
L
 31.4%
H
33.5
55.8
|
L
 192.6%
H
14.8
55.8
|
L
 187.7%
H
9.8
55.8
|
L
 154.2%
H
3.9
55.8
|
L
H
3.9
250.8
|
| Climb Bio Inc |
|
681.4
|
11.9
|
L
 -1.5%
H
11.5
12.2
|
L
 -7.3%
H
11.5
14.4
|
L
 -10.5%
H
11.5
14.4
|
L
 33.6%
H
8.9
14.4
|
L
 720.7%
H
1.5
14.4
|
L
 326.5%
H
1.1
14.4
|
L
H
1.1
29.7
|
L
H
1.1
29.7
|
| Enlivex Therapeutics Ltd |
|
35.2
|
2.1
|
L
 7.2%
H
1.8
2.2
|
L
 -50.2%
H
1.8
4.3
|
L
 287.0%
H
0.4
7.6
|
L
 154.9%
H
0.4
7.6
|
L
 44.1%
H
0.4
7.6
|
L
 -22.0%
H
0.4
7.6
|
L
 -72.5%
H
0.4
14.0
|
L
 -96.8%
H
0.4
81.6
|
| Enochian Biosciences Inc |
|
-
|
1.9
|
L
 -4.0%
H
1.9
2.1
|
L
 -16.7%
H
1.9
2.4
|
L
 -37.2%
H
1.9
3.3
|
L
 506.3%
H
0.2
5.0
|
L
 646.2%
H
0.1
5.0
|
L
 198.5%
H
0.1
5.0
|
L
 -61.0%
H
0.1
13.8
|
L
 30.2%
H
0.1
13.8
|
| Ensysce Biosciences Inc |
|
3.8
|
0.3
|
L
 -3.9%
H
0.3
0.3
|
L
 -3.9%
H
0.2
0.3
|
L
 -16.7%
H
0.2
0.3
|
L
 -35.9%
H
0.2
0.4
|
L
 -87.8%
H
0.2
2.8
|
L
 -87.9%
H
0.1
9.9
|
L
 -100.0%
H
0.1
1680
|
L
H
0.1
5757.6
|
| Enanta Pharma Inc |
|
366.4
|
12.6
|
L
 -3.1%
H
12.5
13.0
|
L
 -1.4%
H
12.3
13.2
|
L
 -14.7%
H
12.3
15.5
|
L
 -12.2%
H
10.9
15.9
|
L
 77.2%
H
6.5
17.2
|
L
 -32.4%
H
4.1
20.0
|
L
 -70.2%
H
4.1
102
|
L
 -43.5%
H
4.1
127.8
|
| Entera Bio Ltd |
|
147.4
|
3.0
|
L
 1.4%
H
2.9
3.2
|
L
 45.9%
H
2.7
4.2
|
L
 76.9%
H
1.6
4.2
|
L
 171.8%
H
1.1
4.2
|
L
 53.3%
H
0.9
4.2
|
L
 273.8%
H
0.5
4.2
|
L
 -41.8%
H
0.5
5.8
|
L
H
0.5
10.2
|
| Enveric Biosciences Inc |
|
6.3
|
1.6
|
L
 9.8%
H
1.4
1.6
|
L
 21.7%
H
1.3
1.6
|
L
 4.7%
H
1.3
1.6
|
L
 -60.7%
H
1.3
4.1
|
L
 -88.6%
H
1.3
17.6
|
L
 -99.7%
H
1.3
701.6
|
L
 -100.0%
H
1.3
33660
|
L
 -100.0%
H
1.3
12150000
|
| Evolus Inc |
|
384.6
|
5.8
|
L
 -2.8%
H
5.7
6.0
|
L
 -2.3%
H
5.7
6.4
|
L
 -13.4%
H
5.4
7.2
|
L
 9.6%
H
5.3
7.3
|
L
 -36.2%
H
3.9
9.4
|
L
 -42.6%
H
3.9
17.8
|
L
 -46.0%
H
3.9
17.8
|
L
H
2.9
39.5
|
| Equillium Inc |
|
139.1
|
2.2
|
L
 -5.2%
H
2.2
2.4
|
L
 -11.7%
H
2.2
2.7
|
L
 -27.6%
H
2.2
3.3
|
L
 5.8%
H
1.8
3.5
|
L
 209.9%
H
0.5
3.5
|
L
 197.3%
H
0.3
3.5
|
L
 -59.4%
H
0.3
7.1
|
L
H
0.3
27.1
|
| Erasca Inc |
|
6,300.4
|
18.2
|
L
 -2.8%
H
17.8
18.9
|
L
 -5.0%
H
17.1
20.0
|
L
 1.3%
H
17.1
21.6
|
L
 81.0%
H
9.8
21.6
|
L
 1205.8%
H
1.3
24.3
|
L
 584.9%
H
1.0
24.3
|
L
 -13.6%
H
1.0
24.5
|
L
H
1.0
24.5
|
| Eterna Therapeutics Inc |
|
3.8
|
3.3
|
L
 -5.5%
H
3.3
3.5
|
L
 -16.5%
H
3.3
4.1
|
L
 -51.0%
H
3.3
9.9
|
L
 -13.9%
H
3.2
15.9
|
L
 -91.6%
H
3.2
71.5
|
L
 -99.7%
H
3.2
1091.3
|
L
 -100.0%
H
3.2
102225
|
L
 -100.0%
H
3.2
605025
|
| Eton Pharma Inc |
|
1,271.6
|
46.4
|
L
 -5.3%
H
46.0
49.1
|
L
 9.0%
H
42.1
50.2
|
L
 26.7%
H
35
50.2
|
L
 60.6%
H
26.7
50.2
|
L
 228.5%
H
14.0
50.2
|
L
 1546.1%
H
2.5
50.2
|
L
 803.1%
H
2.0
50.2
|
L
H
2.0
50.2
|
| Evogene Ltd |
|
5.7
|
0.5
|
L
 -4.1%
H
0.5
0.5
|
L
 -13.0%
H
0.5
0.6
|
L
 6.8%
H
0.4
0.7
|
L
 -39.0%
H
0.4
0.9
|
L
 -59.5%
H
0.4
1.5
|
L
 -95.6%
H
0.4
10.9
|
L
 -98.4%
H
0.4
35.8
|
L
 -99.3%
H
0.4
102.4
|
| Edgewise Therapeutics Inc |
|
4,134.8
|
38.4
|
L
 -6.5%
H
38.2
41.1
|
L
 -5.9%
H
38.2
42.4
|
L
 -1.8%
H
37.3
48.4
|
L
 25.6%
H
30.5
48.4
|
L
 168.6%
H
12.3
48.4
|
L
 445.1%
H
5.1
48.4
|
L
 119.5%
H
5.1
48.4
|
L
H
5.1
48.4
|
| Exelixis Inc |
|
13,329.4
|
53.0
|
L
 -5.3%
H
52.8
56.2
|
L
 -4.2%
H
52.8
56.9
|
L
 -1.7%
H
52.8
57.6
|
L
 21.4%
H
43.5
57.6
|
L
 42.3%
H
33.8
57.6
|
L
 170.1%
H
18.6
57.6
|
L
 214.7%
H
14.9
57.6
|
L
 472.1%
H
9
57.6
|
| Hyperion DeFi Inc |
|
40.0
|
2.6
|
L
 -0.8%
H
2.6
2.7
|
L
 5.2%
H
2.3
2.7
|
L
 -15.9%
H
2.3
3.5
|
L
 -36.8%
H
2.3
4.8
|
L
 -62.7%
H
2.3
15
|
L
 -98.4%
H
0.0
205.6
|
L
 -99.2%
H
0.0
530.4
|
L
H
0.0
859.2
|
| EyePoint Pharma Inc |
|
1,027.1
|
12.3
|
L
 -4.7%
H
12.0
12.8
|
L
 0.5%
H
11.6
13.0
|
L
 -7.2%
H
11.6
15.0
|
L
 -8.2%
H
11.3
15.9
|
L
 26.2%
H
9.4
19.1
|
L
 -3.5%
H
3.9
31.0
|
L
 49.0%
H
2.2
31.0
|
L
 -68.8%
H
2.2
42.5
|
| Evaxion Biotech A/S (ADR) |
|
23.5
|
2.8
|
L
 -0.4%
H
2.8
2.9
|
L
 -4.7%
H
2.8
3.1
|
L
 -11.9%
H
2.8
3.6
|
L
 -37.3%
H
2.8
4.8
|
L
 8.1%
H
2.5
12.2
|
L
 -77.6%
H
0.8
13.6
|
L
 -94.8%
H
0.8
250.4
|
L
H
0.8
250.4
|
| Fate Therapeutics Inc |
|
285.6
|
2.5
|
L
 -2.4%
H
2.4
2.6
|
L
 1.7%
H
2.3
2.6
|
L
 -18.9%
H
2.3
3.2
|
L
 60.1%
H
1.5
3.2
|
L
 129.0%
H
0.9
3.2
|
L
 -38.3%
H
0.7
8.8
|
L
 -97.0%
H
0.7
97.4
|
L
 23.1%
H
0.7
121.2
|
| Fortress Biotech Inc |
|
104.0
|
3.1
|
L
 -4.9%
H
3.1
3.3
|
L
 -6.3%
H
3.1
3.5
|
L
 1.3%
H
2.9
3.8
|
L
 34.3%
H
2.2
3.8
|
L
 72.9%
H
1.8
4.5
|
L
 -63.4%
H
1.2
9
|
L
 -93.3%
H
1.2
57.2
|
L
 -92.8%
H
1.2
91.5
|
| Forte Biosciences Inc |
|
1,569.5
|
76.6
|
L
 -0.5%
H
76.5
76.7
|
L
 39.8%
H
76.4
77.2
|
L
 259.3%
H
20.0
77.2
|
L
 171.7%
H
15.5
77.2
|
L
 697.1%
H
9.1
77.2
|
L
 200.6%
H
4.1
77.2
|
L
 -89.8%
H
4.1
786.8
|
L
H
0.0
1349.8
|
| 4D Molecular Therapeutics Inc |
|
532.2
|
10.2
|
L
 1.1%
H
9.8
10.7
|
L
 1.1%
H
9.4
10.7
|
L
 -19.8%
H
9.4
13.4
|
L
 12.0%
H
8.1
14
|
L
 58.6%
H
5.1
14
|
L
 -44.9%
H
2.2
36.3
|
L
 -59.1%
H
2.2
36.3
|
L
H
2.2
55.1
|
| Fennec Pharma Inc |
|
332.4
|
9.6
|
L
 -3.4%
H
9.4
10.1
|
L
 -4.2%
H
9.4
10.6
|
L
 -7.5%
H
9.4
11.2
|
L
 46.3%
H
6.6
11.3
|
L
 22.1%
H
5.7
11.3
|
L
 9.4%
H
4.0
11.9
|
L
 47.0%
H
3.8
11.9
|
L
 327.2%
H
1.6
15.0
|
| Kyntra Bio Inc |
|
27.2
|
6.7
|
L
 -0.9%
H
6.7
6.9
|
L
 -4.3%
H
6.7
7.2
|
L
 -10.9%
H
6.7
7.8
|
L
 -5.1%
H
6.6
8.0
|
L
 -2.3%
H
6.3
12.6
|
L
 -86.5%
H
4.5
73.3
|
L
 -97.9%
H
4.5
642.3
|
L
 -98.6%
H
4.5
1713.8
|
| Foghorn Therapeutics Inc |
|
266.0
|
4.5
|
L
 -4.4%
H
4.4
5.0
|
L
 -6.6%
H
4.4
5.3
|
L
 -9.6%
H
4.4
6.6
|
L
 -4.8%
H
3.5
6.6
|
L
 -9.2%
H
3.3
7.0
|
L
 -51.3%
H
2.7
10.2
|
L
 -50.1%
H
2.7
24.3
|
L
H
2.7
28.3
|
| Q32 Bio Inc |
|
465.8
|
15.7
|
L
 0.8%
H
15
16.0
|
L
 3.5%
H
14.4
16.6
|
L
 24.4%
H
10.8
23.6
|
L
 211.1%
H
5.0
23.6
|
L
 684%
H
1.6
23.6
|
L
 -39.1%
H
1.3
53.8
|
L
 -86.3%
H
1.3
160.2
|
L
H
1.3
572.4
|
| ZeroStack Corp |
|
3.7
|
1.5
|
L
 -1.3%
H
1.5
1.6
|
L
 4.8%
H
1.3
1.6
|
L
 -51.1%
H
1.3
3.9
|
L
 -70.7%
H
1.3
5.9
|
L
 -92.4%
H
1.3
47
|
L
 -98.3%
H
1.3
213.7
|
L
 -100.0%
H
1.3
16731
|
L
H
1.3
16731
|
| Frequency Therapeutics Inc |
|
-
|
10.4
|
L
 -0.8%
H
9.8
10.5
|
L
 -2.5%
H
9.8
11.3
|
L
 -24.0%
H
9.8
15.6
|
L
 -23.6%
H
9.1
15.6
|
L
 -25.1%
H
5.2
55.9
|
L
 -58.8%
H
5.2
55.9
|
L
 -97.5%
H
5.2
430
|
L
H
5.2
2918.5
|
| Fulcrum Therapeutics Inc |
|
273.1
|
3.6
|
L
 -3.8%
H
3.5
3.7
|
L
 -3.8%
H
3.5
3.8
|
L
 -1.7%
H
3.4
3.9
|
L
 -51.4%
H
2.8
7.6
|
L
 -47.6%
H
2.8
15.7
|
L
 -3.5%
H
2.3
15.7
|
L
 -51.0%
H
2.3
33.1
|
L
H
2.3
33.1
|
| First Wave BioPharma Inc |
|
4.5
|
2.9
|
L
 -4.9%
H
2.9
3.1
|
L
 -4.6%
H
2.6
3.2
|
L
 -34.8%
H
2.6
4.8
|
L
 15.1%
H
2.4
6.9
|
L
 590.5%
H
0.4
6.9
|
L
 -72.1%
H
0.4
22.2
|
L
 -100.0%
H
0.4
35991.6
|
L
H
0.4
235200
|
| Galectin Therapeutics Inc |
|
195.6
|
3.0
|
L
 -8.1%
H
3.0
3.3
|
L
 -14.4%
H
3.0
3.6
|
L
 -31.4%
H
3.0
5.6
|
L
 30.8%
H
2.0
5.6
|
L
 -18.6%
H
2.0
7.1
|
L
 112.1%
H
0.7
7.1
|
L
 8%
H
0.7
7.1
|
L
 54.7%
H
0.5
9.5
|
| Gain Therapeutics Inc |
|
71.7
|
1.7
|
L
 -4.6%
H
1.7
1.8
|
L
 -4%
H
1.7
1.9
|
L
 -15.6%
H
1.6
2.0
|
L
 -10.6%
H
1.5
2.2
|
L
 16.7%
H
1.4
4.3
|
L
 -57.8%
H
0.9
5.3
|
L
 -79%
H
0.9
9.8
|
L
H
0.9
17.9
|
| CytoMed Therapeutics Ltd |
|
11.0
|
0.9
|
L
 -6.1%
H
0.9
1.0
|
L
 -6.1%
H
0.7
1.2
|
L
 -6.1%
H
0.7
1.2
|
L
 -4.1%
H
0.7
1.4
|
L
 -49.2%
H
0.7
3.7
|
L
 -78.2%
H
0.7
5.5
|
L
H
0.7
9.3
|
L
H
0.7
9.3
|
| Geron Corp |
|
827.6
|
1.3
|
L
 -3.7%
H
1.2
1.4
|
L
 -9.2%
H
1.2
1.5
|
L
 1.6%
H
1.2
1.6
|
L
 -18.4%
H
1.1
1.7
|
L
 10.3%
H
1.0
2.0
|
L
 -59.8%
H
1.0
5.3
|
L
 5.7%
H
1.0
5.3
|
L
 -52.4%
H
0.8
7.0
|
| GH Research PLC |
|
1,925.9
|
28.1
|
L
 -1.1%
H
27.9
28.9
|
L
 2.9%
H
26.3
29.1
|
L
 6.3%
H
25
31
|
L
 35.5%
H
19.5
31
|
L
 104.3%
H
11.3
31
|
L
 98.4%
H
5.1
31
|
L
 42.5%
H
5.1
31
|
L
H
5.1
31
|
| Gilead Sciences |
|
161,664.8
|
130.2
|
L
 -0.8%
H
128.8
130.9
|
L
 0.7%
H
128.3
136.3
|
L
 3.4%
H
126.5
140.6
|
L
 -1.1%
H
121.4
140.6
|
L
 15.1%
H
108.5
157.3
|
L
 72.1%
H
62.1
157.3
|
L
 90.7%
H
57.2
157.3
|
L
 61.8%
H
56.6
157.3
|
| Galmed Pharma Ltd |
|
5.1
|
0.6
|
L
 3.3%
H
0.5
0.6
|
L
 21.6%
H
0.5
0.6
|
L
 -4.6%
H
0.5
0.6
|
L
 8.8%
H
0.4
0.8
|
L
 -60%
H
0.4
1.7
|
L
 -95.2%
H
0.2
13.6
|
L
 -99.9%
H
0.2
615.6
|
L
 -99.9%
H
0.2
4870.8
|
| Greenwich LifeSciences Inc |
|
198.2
|
13.5
|
L
 -3.7%
H
13.2
14.3
|
L
 4.0%
H
12.6
14.4
|
L
 -43.0%
H
12.5
24.0
|
L
 -43.0%
H
12.5
29.9
|
L
 21.7%
H
7.8
34.1
|
L
 36.5%
H
7.6
34.1
|
L
 -65.8%
H
6.8
48.5
|
L
H
3.3
158.1
|
| Galecto Inc |
|
1,784.4
|
29.0
|
L
 -0.8%
H
28.7
30.3
|
L
 0.6%
H
28.2
30.9
|
L
 7.0%
H
26.3
34.9
|
L
 14.3%
H
18.6
34.9
|
L
 805.9%
H
2.5
38.3
|
L
 935.4%
H
0.5
38.3
|
L
 575.8%
H
0.5
38.3
|
L
H
0.5
38.3
|
| Monte Rosa Therapeutics Inc |
|
1,395.6
|
16.5
|
L
 -27.2%
H
14.9
16.9
|
L
 -27.5%
H
14.9
23.7
|
L
 -31.2%
H
14.9
25.2
|
L
 -12.1%
H
14.9
25.2
|
L
 244.9%
H
4.1
25.8
|
L
 139.4%
H
2.4
25.8
|
L
 -32.6%
H
2.4
45.6
|
L
H
2.4
45.6
|
| GlycoMimetics Inc |
|
933.8
|
14.5
|
L
 -3.7%
H
14.0
15.1
|
L
 -11.2%
H
14.0
17.8
|
L
 -15.3%
H
14.0
17.9
|
L
 -19.9%
H
14.0
22.5
|
L
 20.6%
H
8.7
27.4
|
L
 -91.2%
H
8.7
353
|
L
 -92.8%
H
8.7
416
|
L
 -98.4%
H
8.7
2605
|
| Genelux Corp |
|
131.8
|
2.9
|
L
 -3.6%
H
2.9
3.1
|
L
 1.7%
H
2.8
3.1
|
L
 1.4%
H
2.8
3.2
|
L
 7.3%
H
2.7
3.3
|
L
 -16.2%
H
2.3
8.5
|
L
 -85.7%
H
1.6
30.4
|
L
H
1.6
41.0
|
L
H
1.6
41.0
|
| Genprex Inc |
|
3.0
|
6.0
|
L
 -1.2%
H
5.6
6.3
|
L
 -23.3%
H
5.6
8.3
|
L
 1030.2%
H
0.5
10.0
|
L
 551.1%
H
0.4
10.0
|
L
 2504.4%
H
0.1
13.0
|
L
 698.7%
H
0.1
13.0
|
L
 102.4%
H
0.1
13.0
|
L
H
0.1
19.5
|
| Gossamer Bio Inc |
|
83.1
|
0.2
|
L
 -5.6%
H
0.2
0.2
|
L
 21.4%
H
0.1
0.3
|
L
H
0.1
0.3
|
L
 -54.1%
H
0.1
0.4
|
L
 -91.5%
H
0.1
3.9
|
L
 -87.8%
H
0.1
3.9
|
L
 -97.8%
H
0.1
15.2
|
L
H
0.1
27.2
|
| Geovax Labs Inc |
|
3.5
|
0.7
|
L
 -2.9%
H
0.7
0.7
|
L
 -6.9%
H
0.6
0.8
|
L
 -46.0%
H
0.6
1.3
|
L
 -41.4%
H
0.6
4.4
|
L
 -96.3%
H
0.6
20
|
L
 -99.7%
H
0.6
276.8
|
L
 -100.0%
H
0.6
2812.5
|
L
 -100.0%
H
0.6
379518072.3
|
| GRI Bio Inc |
|
2.4
|
1.4
|
L
 -2.1%
H
1.4
1.5
|
L
 -4.8%
H
1.4
1.5
|
L
 -22.5%
H
1.4
1.9
|
L
 -36.7%
H
1.4
2.4
|
L
 -96.3%
H
1.4
80.4
|
L
 -100.0%
H
1.4
161135.5
|
L
 -100.0%
H
1.4
13462627.3
|
L
H
1.4
13462627.3
|
| Graphite Bio Inc |
|
308.7
|
5.3
|
L
 -8.0%
H
5.2
5.7
|
L
 -3.3%
H
5.2
6.1
|
L
 -8.5%
H
4.7
6.2
|
L
 -40.3%
H
4.7
10.6
|
L
 -82.3%
H
4.7
50.4
|
L
 -95.7%
H
4.7
413
|
L
 -99.5%
H
4.7
1145.1
|
L
H
4.7
1666
|
| GT Biopharma Inc |
|
10.5
|
0.3
|
L
 -6.5%
H
0.3
0.3
|
L
 -9.4%
H
0.3
0.3
|
L
 -40.8%
H
0.3
0.5
|
L
 -14.7%
H
0.3
0.6
|
L
 -84.0%
H
0.3
1.9
|
L
 11.5%
H
0.2
10.7
|
L
 -97.1%
H
0.2
11.8
|
L
 -100.0%
H
0.2
1519.8
|
| Galapagos NV (ADR) |
|
1,793.1
|
27.2
|
L
 -1.6%
H
27.1
28.0
|
L
 -2.3%
H
27.1
28.7
|
L
 -8.1%
H
27.1
30.9
|
L
 -2.8%
H
26.4
30.9
|
L
 -16.8%
H
26.4
37.8
|
L
 -35.2%
H
22.4
44.3
|
L
 -55.1%
H
22.4
72.1
|
L
 -48.8%
H
22.4
274.0
|
| Genmab (ADR) |
|
17,724.3
|
28.9
|
L
 0.8%
H
28.2
28.9
|
L
H
28.0
29.4
|
L
 4.5%
H
27.6
29.8
|
L
 9.2%
H
23.6
29.8
|
L
 32.6%
H
21
35.4
|
L
 -28.0%
H
17.2
39.8
|
L
 -35.9%
H
17.2
49.1
|
L
 58.6%
H
12.1
49.1
|
| Genenta Science SpA (ADR) |
|
71.8
|
1.5
|
L
 -1.3%
H
1.5
1.6
|
L
 -6.3%
H
1.3
1.7
|
L
 -14.9%
H
1.2
1.8
|
L
 104.1%
H
0.6
2.6
|
L
 -61.0%
H
0.6
10
|
L
 -72.3%
H
0.6
10
|
L
H
0.6
13.1
|
L
H
0.6
13.1
|
| Structure Therapeutics Inc (ADR) |
|
3,414.4
|
48.0
|
L
 -2.9%
H
46.8
49.5
|
L
 -2.2%
H
46.4
51.3
|
L
 -7.8%
H
44.8
57.1
|
L
 13.8%
H
35.8
57.1
|
L
 173.1%
H
15.8
94.9
|
L
 31.9%
H
13.2
94.9
|
L
H
13.2
94.9
|
L
H
13.2
94.9
|
| Grifols SA (ADR) - Level III |
|
5,356.2
|
7.9
|
L
 -4.0%
H
7.7
8.0
|
L
 3.8%
H
7.7
8.4
|
L
 12.6%
H
7
8.4
|
L
 -4.4%
H
7.0
8.5
|
L
 -27.0%
H
7.0
10.9
|
L
 -23.3%
H
5.3
12.2
|
L
 -48.3%
H
5.3
15.9
|
L
 -53.0%
H
5.3
25.7
|
| Halozyme Therapeutics Inc |
|
9,790.3
|
82.5
|
L
 -0.9%
H
81.5
83.3
|
L
 0.7%
H
81.2
84.4
|
L
 7.2%
H
73.9
84.4
|
L
 29.1%
H
63.1
84.4
|
L
 39.9%
H
58.7
84.4
|
L
 95.2%
H
32.8
84.4
|
L
 99.7%
H
29.9
84.4
|
L
 701.4%
H
8.2
84.4
|
| HCW Biologics Inc |
|
5.1
|
3.2
|
L
 1.6%
H
3.1
3.4
|
L
 28%
H
2.4
3.4
|
L
 -30.1%
H
2.4
5.0
|
L
 18.1%
H
1.8
23.9
|
L
 -87.1%
H
1.5
44.1
|
L
 -100.0%
H
1.5
24192
|
L
 -100.0%
H
1.5
67680
|
L
H
1.5
74640
|
| Hillstream BioPharma Inc |
|
22.7
|
1.9
|
L
 4.3%
H
1.8
2.0
|
L
 -0.5%
H
1.8
2.1
|
L
 -34.4%
H
1.8
3.0
|
L
 -40.3%
H
1.8
3.9
|
L
 55.7%
H
1.1
9.1
|
L
 -77.6%
H
1.1
132.8
|
L
H
1.1
132.8
|
L
H
1.1
132.8
|
| Hoth Therapeutics Inc |
|
17.9
|
0.8
|
L
 1.3%
H
0.8
0.8
|
L
 1.3%
H
0.7
0.8
|
L
 -15.8%
H
0.7
1.2
|
L
 9.6%
H
0.5
2.5
|
L
 -38.5%
H
0.5
2.5
|
L
 -69.3%
H
0.5
3.8
|
L
 -97.5%
H
0.5
43.8
|
L
H
0.5
347
|
| Werewolf Therapeutics Inc |
|
17.0
|
0.4
|
L
 -30%
H
0.3
0.5
|
L
 -18.6%
H
0.3
0.5
|
L
H
0.3
0.5
|
L
 -51.4%
H
0.3
0.8
|
L
 -69.8%
H
0.3
2.4
|
L
 -87.2%
H
0.3
8.2
|
L
 -98.0%
H
0.3
19.7
|
L
H
0.3
24.0
|
| Harmony Biosciences Holdings Inc |
|
2,040.1
|
35.2
|
L
 -1.7%
H
34.6
35.9
|
L
 -0.2%
H
34.6
37.1
|
L
 -2.1%
H
32.3
38.9
|
L
 10.7%
H
28.9
38.9
|
L
 2.4%
H
25.5
40.9
|
L
 3.7%
H
18.6
41.6
|
L
 34.7%
H
18.6
62.1
|
L
H
18.6
62.1
|
| Harrow Health Inc |
|
1,445.2
|
38.8
|
L
 -0.4%
H
37.2
39.0
|
L
 0.8%
H
36.3
39.9
|
L
 -9.8%
H
36.3
47.5
|
L
 -5.2%
H
28.5
47.5
|
L
 24.1%
H
28.5
54.9
|
L
 83.6%
H
7.6
59.2
|
L
 334.6%
H
5.4
59.2
|
L
 914.9%
H
1.4
59.2
|
| Heron Therapeutics Inc |
|
94.6
|
0.5
|
L
H
0.5
0.5
|
L
 8.7%
H
0.5
0.5
|
L
 19.1%
H
0.4
0.5
|
L
 -60.6%
H
0.4
1.3
|
L
 -70.4%
H
0.4
1.9
|
L
 -68.9%
H
0.4
3.9
|
L
 -96.0%
H
0.4
12.9
|
L
 -97.0%
H
0.4
42.9
|
| Quantum BioPharma Ltd (Class B) (Sub Voting) |
|
18.5
|
2.9
|
L
 1.8%
H
2.8
3.0
|
L
 -3.3%
H
2.7
3.1
|
L
 -14.0%
H
2.7
3.7
|
L
 -47.9%
H
2.7
10.8
|
L
 -87.8%
H
2.1
31.9
|
L
 -96.6%
H
2.1
109.2
|
L
 -97.5%
H
2.1
136.5
|
L
H
2.1
11431.9
|
| Humacyte Inc |
|
175.3
|
0.7
|
L
 -3.0%
H
0.6
0.7
|
L
 4.8%
H
0.6
0.7
|
L
 -3.0%
H
0.6
0.8
|
L
 -24.4%
H
0.6
1.5
|
L
 -71.5%
H
0.6
2.8
|
L
 -79.8%
H
0.6
10.0
|
L
 -93.5%
H
0.6
17.5
|
L
H
0.6
17.5
|
| HUTCHMED (China) Ltd (ADR) |
|
1,934.6
|
11.1
|
L
 3.3%
H
10.9
11.1
|
L
 1.1%
H
10.6
11.6
|
L
 3.3%
H
10.6
11.8
|
L
 -16.3%
H
9.8
13.6
|
L
 -35.6%
H
9.8
18.3
|
L
 -26.7%
H
9.8
21.9
|
L
 -73.5%
H
7.4
43.4
|
L
 -15.6%
H
7.4
43.9
|
| ImmunityBio Inc |
|
7,509.5
|
7.2
|
L
 -3.8%
H
7.1
7.6
|
L
 1.0%
H
6.7
7.6
|
L
 -22.1%
H
6.7
9.6
|
L
 0.8%
H
6.7
9.6
|
L
 202.5%
H
2.0
12.4
|
L
 251.5%
H
1.3
12.4
|
L
 -34.6%
H
1.2
12.4
|
L
H
1.2
40.8
|
| Immucell Corp |
|
101.4
|
11.2
|
L
 1.4%
H
11.0
11.4
|
L
 1.6%
H
10.8
11.4
|
L
 1.9%
H
9.9
12.1
|
L
 28.4%
H
8.0
12.1
|
L
 86.8%
H
4.5
12.1
|
L
 109.5%
H
3.3
12.1
|
L
 11.3%
H
3.3
12.1
|
L
 61.5%
H
3.3
13.2
|
| Ideaya Biosciences Inc |
|
3,417.8
|
35.5
|
L
 -2.5%
H
35.3
36.6
|
L
 0.3%
H
35.2
37.1
|
L
 -1.9%
H
34.0
40.6
|
L
 25.9%
H
26.8
40.6
|
L
 46.3%
H
22.1
40.6
|
L
 58.4%
H
13.5
47.7
|
L
 44.9%
H
8.1
47.7
|
L
H
3.0
47.7
|
| InflaRx N.V. |
|
250.4
|
1.7
|
L
 -1.2%
H
1.6
1.8
|
L
 -2.3%
H
1.6
1.8
|
L
 -27.0%
H
1.6
2.5
|
L
 -19.1%
H
1.5
3.0
|
L
 97.7%
H
0.7
3.0
|
L
 -59.3%
H
0.7
4.3
|
L
 -34.6%
H
0.7
7.3
|
L
H
0.7
53.1
|
| ImageneBio Inc |
|
63.0
|
5.5
|
L
 -6.3%
H
5.5
5.6
|
L
 -0.9%
H
5.5
5.9
|
L
 -4.0%
H
5.3
6.3
|
L
 -2.1%
H
5.1
6.3
|
L
 -67.9%
H
3.9
17.5
|
L
 -91.3%
H
3.9
65.8
|
L
 -95.3%
H
3.9
210
|
L
H
3.9
451.3
|
| Inhibikase Therapeutics Inc |
|
342.3
|
2.2
|
L
 -4.4%
H
2.1
2.3
|
L
 -6.4%
H
2.1
2.4
|
L
 12.4%
H
1.9
2.5
|
L
 14.1%
H
1.5
2.5
|
L
 43.4%
H
1.3
2.5
|
L
 -13.8%
H
0.8
4.2
|
L
 -84.0%
H
0.8
15.2
|
L
H
0.8
70.8
|
| Immix Biopharma Inc |
|
592.3
|
8.3
|
L
 -2.7%
H
8.2
8.7
|
L
 -2.4%
H
8.1
9.4
|
L
 -15.4%
H
8.1
12.1
|
L
 -10.5%
H
7.7
12.1
|
L
 214.0%
H
1.9
12.1
|
L
 305.9%
H
1.3
12.1
|
L
H
0.7
12.1
|
L
H
0.7
12.1
|
| Immunome Inc |
|
2,577.6
|
22.8
|
L
 -1.4%
H
22.5
23.7
|
L
 2.5%
H
22.2
23.8
|
L
 5.9%
H
21.3
25
|
L
 0.1%
H
17.8
25
|
L
 114.9%
H
8.7
27.7
|
L
 213.9%
H
5.2
31.0
|
L
 40.3%
H
2.1
31.0
|
L
H
2.1
63.8
|
| Imunon Inc |
|
6.7
|
1.6
|
L
 -0.6%
H
1.6
1.6
|
L
 5.3%
H
1.5
1.7
|
L
 -15.4%
H
1.5
2.2
|
L
 -43.2%
H
1.5
3.0
|
L
 -81.3%
H
1.5
9.4
|
L
 -91.7%
H
1.5
54.8
|
L
 -99.4%
H
1.5
265.5
|
L
 -100.0%
H
1.5
4410
|
| Immuneering Corp (Class A) |
|
267.2
|
4.1
|
L
 -2.4%
H
4.1
4.3
|
L
 -4.4%
H
4.0
4.5
|
L
 -18.2%
H
4.0
5.7
|
L
 -23.1%
H
3.9
6.9
|
L
 22.6%
H
2.9
10.1
|
L
 -61.2%
H
1
11.0
|
L
 -76.5%
H
1
34.0
|
L
H
1
34.0
|
| Immatics N.V |
|
1,183.6
|
8.7
|
L
 -5.9%
H
8.6
9.2
|
L
 -4.6%
H
8.2
9.6
|
L
 -12.1%
H
8.2
10.9
|
L
 -19.7%
H
8.2
11.9
|
L
 33.6%
H
5.1
12.4
|
L
 -31.4%
H
3.3
13.8
|
L
 -29.1%
H
3.3
16.3
|
L
H
3.3
18.4
|
| Immunic Inc |
|
190.3
|
14.0
|
L
 -0.1%
H
13.4
14.2
|
L
 4.3%
H
12.7
14.2
|
L
 -5.7%
H
12.7
15.8
|
L
 44.8%
H
9.7
15.8
|
L
 49.9%
H
5.1
15.8
|
L
 -40.0%
H
5.1
23.9
|
L
 -84.2%
H
5.1
145
|
L
 -99.4%
H
5.1
3900
|
| Immunovant Inc |
|
7,929.0
|
38.6
|
L
 -2.2%
H
38
39.3
|
L
 -2%
H
37.8
40.8
|
L
 1.3%
H
37.5
41.2
|
L
 42.4%
H
25.8
41.2
|
L
 145.8%
H
14.3
41.2
|
L
 67.4%
H
12.7
45.6
|
L
 269.2%
H
3.1
45.6
|
L
H
3.1
53.8
|
| IN8bio Inc |
|
10.0
|
1.0
|
L
 -3.7%
H
1.0
1.1
|
L
 -13.3%
H
1.0
1.2
|
L
 -26.8%
H
1.0
1.5
|
L
 -30.7%
H
1.0
1.9
|
L
 -50.7%
H
1.0
2.7
|
L
 -20.6%
H
0.1
4.2
|
L
 -89.6%
H
0.1
10.3
|
L
H
0.1
10.3
|
| Inhibrx Inc |
|
3,887.4
|
82.1
|
L
 -3.2%
H
80.4
85.6
|
L
 0.6%
H
77.5
86.1
|
L
 -13.6%
H
77.5
106.4
|
L
 -36.3%
H
77.5
151.0
|
L
 279.9%
H
20.6
155.3
|
L
 299.9%
H
10.8
155.3
|
L
 188.3%
H
7.7
155.3
|
L
H
7.7
155.3
|
| Incyte |
|
24,226.4
|
119.5
|
L
 -2.8%
H
118.4
122.8
|
L
 1.6%
H
117.3
132.6
|
L
 5.0%
H
110.6
132.6
|
L
 23.3%
H
92.2
132.6
|
L
 58.1%
H
75.5
132.6
|
L
 87.7%
H
50.3
132.6
|
L
 54.5%
H
50.3
132.6
|
L
 32.8%
H
50.3
153.2
|
| Indaptus Therapeutics Inc |
|
171.9
|
1.3
|
L
 -10.4%
H
1.3
1.5
|
L
 -50.6%
H
1.3
2.6
|
L
 -56.1%
H
1.3
3.2
|
L
 -39.7%
H
0.9
6.0
|
L
 -82.3%
H
0.9
8.7
|
L
 -38.6%
H
0.3
13.4
|
L
 -88.6%
H
0.3
28.8
|
L
 -99.7%
H
0.3
8800
|
| Indivior PLC |
|
4,729.4
|
40.0
|
L
 -0.5%
H
38.6
40.3
|
L
 -1.3%
H
38.6
41.7
|
L
 -0.6%
H
38.6
41.8
|
L
 6.2%
H
32.4
42.8
|
L
 90.1%
H
20.7
42.8
|
L
 75.9%
H
7.3
42.8
|
L
 1624.6%
H
2.2
42.8
|
L
 958.5%
H
0.4
42.8
|
| MiNK Therapeutics Inc |
|
52.3
|
10.5
|
L
 -0.9%
H
10.5
10.5
|
L
 -5.2%
H
10.4
11.3
|
L
 -8.4%
H
10.2
12.0
|
L
 -9.6%
H
9.5
13.4
|
L
 -28.7%
H
8.5
18.2
|
L
 -39.3%
H
0.9
76
|
L
H
0.9
221.6
|
L
H
0.9
221.6
|
| InMed Pharma Inc |
|
7.8
|
1.5
|
L
 -2%
H
1.4
1.6
|
L
 -14.0%
H
1.4
1.8
|
L
 -7.6%
H
1.4
2.3
|
L
 104.2%
H
0.6
2.3
|
L
 -38.5%
H
0.6
2.5
|
L
 -92.9%
H
0.6
41.6
|
L
 -99.9%
H
0.6
1475
|
L
 -99.9%
H
0.6
32175
|
| INmune Bio Inc |
|
46.5
|
1.8
|
L
 -1.1%
H
1.7
1.8
|
L
 8.0%
H
1.6
1.8
|
L
 4.2%
H
1.5
2.2
|
L
 15.9%
H
1.2
2.2
|
L
 -31.6%
H
1.1
3.0
|
L
 -79.5%
H
1.1
14.7
|
L
 -88.5%
H
1.1
30.4
|
L
H
1.1
30.4
|
| Inovio Pharma Inc |
|
55.9
|
0.7
|
L
 3.0%
H
0.6
0.7
|
L
 -29.9%
H
0.6
1.1
|
L
 -42.9%
H
0.6
1.3
|
L
 -38.2%
H
0.6
1.8
|
L
 -52.5%
H
0.6
3.0
|
L
 36%
H
0.3
14.8
|
L
 -91.9%
H
0.3
14.8
|
L
 -93.5%
H
0.3
33.8
|
| Insmed Inc |
|
21,371.8
|
98.6
|
L
 -2.9%
H
97.1
101.9
|
L
 -7.8%
H
97.1
107.4
|
L
 -7.9%
H
97.1
119.5
|
L
 -26.0%
H
90.4
142.9
|
L
 -9.3%
H
90.4
212.8
|
L
 345.5%
H
21.0
212.8
|
L
 300.8%
H
16.0
212.8
|
L
 748.5%
H
10.2
212.8
|
| Innoviva Inc |
|
1,547.8
|
21.0
|
L
 -1.2%
H
20.8
21.1
|
L
 -2.2%
H
20.8
22.0
|
L
 -4.3%
H
20.8
22.7
|
L
 -9.3%
H
20.8
24.2
|
L
 12.6%
H
16.5
25.1
|
L
 57.0%
H
12.2
25.1
|
L
 47.9%
H
10.6
25.1
|
L
 60.8%
H
7.6
25.1
|
| Ionis Pharma Inc |
|
8,603.4
|
51.8
|
L
 -2.8%
H
51.3
53.3
|
L
 -8.5%
H
51.3
57.1
|
L
 -34.6%
H
50
86.7
|
L
 -31.2%
H
50
86.7
|
L
 20.3%
H
40.0
86.7
|
L
 25.6%
H
24.0
86.7
|
L
 39.4%
H
24.0
86.7
|
L
 36.2%
H
24.0
86.7
|
| Iovance Biotherapeutics Inc |
|
1,817.3
|
4.1
|
L
 -13.2%
H
4.0
4.6
|
L
 -18.4%
H
4.0
5.2
|
L
 2.5%
H
3.8
5.6
|
L
 19.7%
H
3.3
5.6
|
L
 51.9%
H
1.8
5.6
|
L
 -43.4%
H
1.6
18.3
|
L
 -81.7%
H
1.6
28.0
|
L
 -54.9%
H
1.6
54.2
|
| MindWalk Holdings Corp |
|
60.6
|
1.3
|
L
 -4.4%
H
1.3
1.4
|
L
 -5.2%
H
1.3
1.5
|
L
 -20.4%
H
1.1
1.7
|
L
 6.6%
H
1.1
2.0
|
L
 -21.3%
H
1.0
3.3
|
L
 -44.4%
H
0.3
3.3
|
L
 -80.4%
H
0.3
8.7
|
L
 6350%
H
0.3
33.3
|
| Century Therapeutics Inc |
|
364.3
|
2.0
|
L
 -7.8%
H
2.0
2.2
|
L
 -4.3%
H
2.0
2.2
|
L
 -15.5%
H
2.0
2.5
|
L
 -12.6%
H
2.0
2.6
|
L
 281.1%
H
0.4
3.0
|
L
 -33.1%
H
0.3
5.5
|
L
 -93.1%
H
0.3
32.9
|
L
H
0.3
32.9
|
| Disc Medicine Inc |
|
2,956.2
|
77
|
L
 -2.8%
H
75.0
79.3
|
L
 3.9%
H
71.6
79.4
|
L
 2.7%
H
71.6
82.5
|
L
 15.1%
H
63.8
82.5
|
L
 30.6%
H
40
99.5
|
L
 52.9%
H
25.6
99.5
|
L
 89.2%
H
11.6
99.5
|
L
H
11.6
190.9
|
| Ironwood Pharma Inc (Class A) |
|
696.3
|
4.2
|
L
 13.4%
H
3.9
4.3
|
L
 14.0%
H
3.6
4.3
|
L
 2.7%
H
3.6
4.9
|
L
 -4.7%
H
3.1
4.9
|
L
 449.4%
H
0.7
5.8
|
L
 -62.4%
H
0.5
15.7
|
L
 -68.1%
H
0.5
15.7
|
L
 -63.8%
H
0.5
17.7
|
| Invivyd Inc |
|
159.1
|
0.5
|
L
 -6.9%
H
0.5
0.6
|
L
 -11.5%
H
0.5
0.6
|
L
 -36.5%
H
0.5
1
|
L
 -64.5%
H
0.5
1.6
|
L
 -26.0%
H
0.5
3.1
|
L
 -62.8%
H
0.4
5.2
|
L
H
0.4
78.8
|
L
H
0.4
78.8
|
| I-Mab (ADR) |
|
184.4
|
1.6
|
L
 -2.4%
H
1.6
1.7
|
L
 -9.6%
H
1.6
1.9
|
L
 -19.6%
H
1.6
2.3
|
L
 -32.8%
H
1.5
2.6
|
L
 -38.9%
H
1.5
6.8
|
L
 -42.2%
H
0.6
6.8
|
L
 -98.0%
H
0.6
81.1
|
L
H
0.6
85.4
|
| Immunocore Holdings PLC (ADR) |
|
1,719.8
|
33.8
|
L
 -0.2%
H
32.8
34.1
|
L
 -3.4%
H
32.8
35.9
|
L
 6.8%
H
30.3
36.3
|
L
 20.1%
H
27.6
36.3
|
L
 2.5%
H
27.6
40.7
|
L
 -49.2%
H
23.2
77.0
|
L
 3.3%
H
18.4
77.0
|
L
H
18.4
77.0
|
| Immutep Ltd (ADR) |
|
56.0
|
0.4
|
L
H
0.4
0.4
|
L
H
0.4
0.4
|
L
 -11.6%
H
0.4
0.5
|
L
 -13.6%
H
0.4
0.6
|
L
 -77.9%
H
0.3
3.5
|
L
 -82.5%
H
0.3
3.5
|
L
 -88.9%
H
0.3
5
|
L
 -87.4%
H
0.3
8.0
|
| Immuron Ltd (ADR) |
|
8.8
|
1.1
|
L
 -1.8%
H
1.1
1.1
|
L
 -1.8%
H
1.0
1.1
|
L
H
1.0
1.4
|
L
 38.0%
H
0.8
1.6
|
L
 -33.9%
H
0.7
2.4
|
L
 -43.8%
H
0.7
6.0
|
L
 -77.5%
H
0.7
6.0
|
L
H
0.7
29.0
|
| Innate Pharma (ADR) |
|
164.3
|
1.8
|
L
 0.6%
H
1.7
1.8
|
L
 -1.7%
H
1.7
1.9
|
L
 -3.3%
H
1.7
2.0
|
L
 21.5%
H
1.3
2.6
|
L
 -18.6%
H
1.2
2.6
|
L
 -41.3%
H
1.2
3.5
|
L
 -47.3%
H
1.2
12.0
|
L
H
1.2
12.0
|
| Inventiva (ADR) |
|
1,058.3
|
4.5
|
L
 -3.0%
H
4.3
4.6
|
L
 0.5%
H
4.3
4.7
|
L
 21.4%
H
3.7
4.7
|
L
 -9.9%
H
3.4
6.1
|
L
 39.1%
H
3.2
8.0
|
L
 9.8%
H
1.5
8.0
|
L
 -66.7%
H
1.5
15.8
|
L
H
1.5
19.1
|
| Jaguar Health Inc |
|
4.9
|
1
|
L
 -3.9%
H
1
1.1
|
L
 4.2%
H
0.9
1.1
|
L
 -67.1%
H
0.9
3
|
L
 -85.1%
H
0.9
5.9
|
L
 -98.6%
H
0.9
92.8
|
L
 -100.0%
H
0.9
33442.5
|
L
 -100.0%
H
0.9
17340750
|
L
 -100.0%
H
0.9
880621875
|
| Janux Therapeutics Inc |
|
925.1
|
15.2
|
L
 -2.6%
H
15
15.6
|
L
 -1.0%
H
14.6
16.0
|
L
 3.5%
H
14.6
16.9
|
L
 5.8%
H
13.0
16.9
|
L
 -35.6%
H
12.1
35.3
|
L
 14.6%
H
5.7
71.7
|
L
 -53.2%
H
5.7
71.7
|
L
H
5.7
71.7
|
| Jazz Pharma PLC |
|
15,884.1
|
252.9
|
L
 -2.1%
H
250.7
259.1
|
L
 -0.4%
H
250.7
261.3
|
L
 6.5%
H
233.5
261.3
|
L
 24.7%
H
203.1
261.3
|
L
 118.9%
H
105
261.3
|
L
 95.2%
H
95.5
261.3
|
L
 49.2%
H
95.5
261.3
|
L
 68.0%
H
86.9
261.3
|
| Jasper Therapeutics Inc |
|
21.0
|
0.6
|
L
 1.6%
H
0.6
0.6
|
L
 -8.7%
H
0.6
0.7
|
L
 37.0%
H
0.4
1.0
|
L
 -32.3%
H
0.3
1.0
|
L
 -78.1%
H
0.3
3.1
|
L
 -58.8%
H
0.3
31.0
|
L
H
0.3
31.0
|
L
H
0.3
31.0
|
| Jupiter Wellness Inc |
|
33.9
|
0.9
|
L
 -9%
H
0.9
1.0
|
L
 -18.8%
H
0.9
1.2
|
L
 -38.5%
H
0.9
1.5
|
L
 -64.5%
H
0.9
3.0
|
L
 -9.9%
H
0.1
7.2
|
L
 16.7%
H
0.1
7.5
|
L
 -53.1%
H
0.1
7.5
|
L
H
0.1
8.9
|
| Kala Pharma Inc |
|
14.1
|
0.8
|
L
 4.1%
H
0.7
0.8
|
L
 20.6%
H
0.6
0.8
|
L
 -57.3%
H
0.6
2.0
|
L
 -86.1%
H
0.6
5.9
|
L
 -99.8%
H
0.6
1030
|
L
 -99.9%
H
0.6
1030
|
L
 -100.0%
H
0.6
9172.8
|
L
H
0.6
66943.3
|
| Kamada Ltd |
|
411.9
|
7.1
|
L
 0.6%
H
7.1
7.3
|
L
 1.1%
H
6.9
7.3
|
L
 -5.1%
H
6.9
7.6
|
L
 -13.0%
H
6.9
8.7
|
L
 -1.1%
H
6.5
9.4
|
L
 41.9%
H
4.1
9.4
|
L
 31.3%
H
3.7
9.4
|
L
 76.7%
H
3.7
13.3
|
| Kiniksa Pharma Ltd (Class A) |
|
5,800.3
|
74.3
|
L
 -4.9%
H
73.7
78.0
|
L
 18.3%
H
62.8
82.9
|
L
 18.2%
H
60.1
82.9
|
L
 34.5%
H
46.1
82.9
|
L
 132.5%
H
31.8
82.9
|
L
 293.3%
H
14.1
82.9
|
L
 384.9%
H
7.4
82.9
|
L
H
5.0
82.9
|
| Kodiak Sciences Inc |
|
2,602.0
|
41.6
|
L
 -2.2%
H
40.4
42.9
|
L
 0.4%
H
38.1
43
|
L
 11.7%
H
35.8
44.9
|
L
 -5.4%
H
29.2
46.6
|
L
 525.3%
H
6.4
47.8
|
L
 1286%
H
1.4
47.8
|
L
 -50.4%
H
1.4
132.0
|
L
H
1.4
171.2
|
| Kiora Pharma Inc |
|
11.3
|
2.6
|
L
H
2.5
2.6
|
L
 0.4%
H
2.5
2.6
|
L
 -3.8%
H
2.3
2.7
|
L
 4.9%
H
2.3
2.9
|
L
 0.8%
H
1.8
3.0
|
L
 326.7%
H
0.4
5.6
|
L
 -97.5%
H
0.4
112
|
L
 -99.8%
H
0.4
2340
|
| Karyopharm Therapeutics Inc |
|
43.5
|
1.9
|
L
 -72.6%
H
1.8
2.4
|
L
 -74.1%
H
1.8
7.8
|
L
 -79.9%
H
1.8
10.9
|
L
 -78.1%
H
1.8
10.9
|
L
 -51.2%
H
1.8
11.0
|
L
 -92.9%
H
0.6
29.3
|
L
 -98.5%
H
0.6
221.0
|
L
 -98.2%
H
0.6
444.2
|
| Keros Therapeutics Inc |
|
199.3
|
10.1
|
L
 -1.5%
H
9.8
10.2
|
L
 0.1%
H
9.8
10.5
|
L
 -7.4%
H
9.8
12.2
|
L
 -12.4%
H
9.7
12.2
|
L
 -29.7%
H
9.7
22.6
|
L
 -75.5%
H
9.1
73
|
L
 -72.6%
H
9.1
73
|
L
H
9.1
88.8
|
| Krystal Biotech Inc |
|
10,056.1
|
341.1
|
L
 -7.0%
H
340.6
367.3
|
L
 1.8%
H
334.4
369
|
L
 -8.2%
H
325
382.1
|
L
 28.2%
H
252.0
382.5
|
L
 117.3%
H
130.5
382.5
|
L
 162.0%
H
94.0
382.5
|
L
 483.7%
H
38.9
382.5
|
L
H
8.0
382.5
|
| TuHURA Biosciences Inc |
|
138.2
|
2.2
|
L
H
2.1
2.2
|
L
 2.8%
H
2
2.2
|
L
 -11.4%
H
2
2.6
|
L
 -6.9%
H
1.9
2.8
|
L
 -9.6%
H
0.4
3.9
|
L
 -98.5%
H
0.2
175
|
L
 -99.9%
H
0.2
2887.5
|
L
 -100.0%
H
0.2
138565
|
| Pasithea Therapeutics Corp |
|
15.4
|
0.5
|
L
 4.6%
H
0.4
0.5
|
L
H
0.4
0.5
|
L
 -19.3%
H
0.4
0.6
|
L
 -45.2%
H
0.4
1.0
|
L
 -34.3%
H
0.3
2.1
|
L
 -23.3%
H
0.3
9.3
|
L
H
0.3
9.3
|
L
H
0.3
9.3
|
| Kura Oncology Inc |
|
799.9
|
9.0
|
L
 -3.2%
H
8.9
9.5
|
L
 -13.3%
H
8.8
10.8
|
L
 -16.4%
H
8.8
12.2
|
L
 2.7%
H
8.4
12.2
|
L
 49.7%
H
5.5
12.5
|
L
 -12.9%
H
5.4
24.2
|
L
 -52.4%
H
5.4
24.2
|
L
 109.0%
H
3.9
43
|
| Kymera Therapeutics Inc |
|
8,505.4
|
103.4
|
L
 -3.4%
H
102.1
106.7
|
L
 -6.5%
H
102.1
113
|
L
 -9.5%
H
102.1
120.9
|
L
 28.1%
H
69.5
130.1
|
L
 140.7%
H
36.7
130.1
|
L
 376.9%
H
9.6
130.1
|
L
 71.8%
H
9.6
130.1
|
L
H
9.6
130.1
|
| Kazia Therapeutics Ltd (ADR) |
|
144.2
|
12.6
|
L
 -1.6%
H
12.5
13.6
|
L
 2.9%
H
11.5
13.6
|
L
 -5.8%
H
11.5
14.7
|
L
 -5.8%
H
10.6
15.3
|
L
 54.3%
H
4.9
17.4
|
L
 -76.8%
H
2.9
79
|
L
 -97.2%
H
2.9
614
|
L
 -96.6%
H
2.9
792.5
|
| Lexaria Bioscience Corp |
|
0.6
|
0.4
|
L
 -2.5%
H
0.4
0.4
|
L
 -30.4%
H
0.4
0.6
|
L
 -31.6%
H
0.4
0.7
|
L
 -45.1%
H
0.4
0.7
|
L
 -54.1%
H
0.4
1.6
|
L
 -53.6%
H
0.4
6.9
|
L
 -93.7%
H
0.4
7.2
|
L
 -90%
H
0.4
76.2
|
| Lifecore Biomedical Inc |
|
165.8
|
4.4
|
L
 1.4%
H
4.3
4.5
|
L
 2.1%
H
4.2
4.6
|
L
 -16.1%
H
4.2
5.5
|
L
 -16.0%
H
4.2
6.0
|
L
 -36.8%
H
3.6
9.0
|
L
 -57.5%
H
3.6
11.5
|
L
 -59.6%
H
1.5
12.0
|
L
 -62.2%
H
1.5
15.6
|
| Lifevantage Corp |
|
81.1
|
6.4
|
L
 2.2%
H
6.2
6.5
|
L
 -1.5%
H
6.2
6.6
|
L
 2.9%
H
5.8
6.6
|
L
 18.4%
H
4.6
11.7
|
L
 -48.9%
H
3.9
15
|
L
 27.6%
H
3.9
27.4
|
L
 -20.8%
H
3.0
27.4
|
L
 -52.5%
H
2.9
27.4
|
| Ligand Pharma Inc (Class B) |
|
5,762.6
|
287.5
|
L
 -3.0%
H
286.2
301.9
|
L
 -4.3%
H
286.2
305.0
|
L
 -7.8%
H
286.2
326.6
|
L
 26.4%
H
200.0
326.6
|
L
 116.7%
H
131.7
326.6
|
L
 331.1%
H
49.3
326.6
|
L
 292.5%
H
46.8
326.6
|
L
 221.7%
H
36.9
326.6
|
| Longeveron Inc (Class A) |
|
22.1
|
0.7
|
L
 2.9%
H
0.7
0.8
|
L
 16.7%
H
0.6
0.8
|
L
 -4.1%
H
0.6
0.8
|
L
 -17.7%
H
0.6
0.9
|
L
 -57.3%
H
0.5
1.8
|
L
 -97.9%
H
0.5
43.0
|
L
 -98.8%
H
0.5
450
|
L
H
0.5
450
|
| Atyr Pharma Inc |
|
48.0
|
0.5
|
L
 2.1%
H
0.5
0.5
|
L
 4.3%
H
0.5
0.5
|
L
 -17.0%
H
0.5
0.7
|
L
 -41.0%
H
0.4
1.1
|
L
 -89.6%
H
0.4
6.5
|
L
 -75.1%
H
0.4
7.3
|
L
 -89.5%
H
0.4
13.1
|
L
 -98.9%
H
0.4
90.9
|
| Lixte biotech Holdings Inc |
|
81.9
|
4.5
|
L
 7.4%
H
4.1
4.7
|
L
 -7.4%
H
4.0
5.2
|
L
 -41.6%
H
4.0
8.0
|
L
 32.9%
H
3.3
8.4
|
L
 -8.0%
H
2.4
8.4
|
L
 30.2%
H
0.6
8.4
|
L
 -83.7%
H
0.6
49.5
|
L
 -81.3%
H
0.6
110.4
|
| Lipocine Inc |
|
17.5
|
2.1
|
L
 0.5%
H
2.1
2.2
|
L
 1.9%
H
2.1
2.3
|
L
 -13.8%
H
2.1
2.5
|
L
 -9.0%
H
1.9
2.7
|
L
 -32.7%
H
1.8
12.4
|
L
 -57.4%
H
1.8
12.4
|
L
 -90.6%
H
1.8
32.1
|
L
 -96.4%
H
1.8
100.3
|
| Leap Therapeutics Inc |
|
62.8
|
0.6
|
L
 -6.4%
H
0.6
0.7
|
L
 -4.8%
H
0.6
0.7
|
L
 -7.8%
H
0.6
0.8
|
L
 -39.2%
H
0.5
1.4
|
L
 90.3%
H
0.2
3.7
|
L
 -76.8%
H
0.2
5
|
L
 -95.8%
H
0.2
41.7
|
L
H
0.2
102.5
|
| Liquidia Corp |
|
7,479.7
|
84.1
|
L
 -3.1%
H
82.5
87.5
|
L
 -2.5%
H
82.5
89.7
|
L
 6.0%
H
69.7
91.1
|
L
 120.5%
H
37.5
91.1
|
L
 375.7%
H
17.8
91.1
|
L
 978.3%
H
5.7
91.1
|
L
 3557.0%
H
2.3
91.1
|
L
H
2.3
91.1
|
| Larimar Therapeutics Inc |
|
396.8
|
3.8
|
L
H
3.7
3.9
|
L
 -4.5%
H
3.6
4.1
|
L
 19%
H
3.2
4.3
|
L
 -3.1%
H
2.9
4.3
|
L
 11.1%
H
2.7
6.4
|
L
 -6.1%
H
1.6
13.7
|
L
 -61.6%
H
1.5
15.3
|
L
 -90.0%
H
1.5
148.3
|
| Lisata Therapeutics Inc |
|
9.0
|
1.0
|
L
 -3.9%
H
1.0
1.1
|
L
 -40.7%
H
1.0
1.6
|
L
 -70.5%
H
1.0
3.9
|
L
 -68.4%
H
1.0
4.0
|
L
 -60.2%
H
1.0
5.1
|
L
 -69.1%
H
1.0
5.1
|
L
 -95.0%
H
1.0
20.4
|
L
 -98.8%
H
1.0
174.8
|
| Lantern Pharma Inc |
|
33.6
|
2.6
|
L
 -0.8%
H
2.6
2.9
|
L
 -4.4%
H
2.5
2.9
|
L
 -34.6%
H
2.5
4.2
|
L
 24.1%
H
2
4.3
|
L
 -44.9%
H
1.1
5.7
|
L
 -46.2%
H
1.1
12.0
|
L
 -79.6%
H
1.1
14.8
|
L
H
1.1
24.8
|
| Lexicon Pharma Inc |
|
1,026.1
|
2.3
|
L
 -1.3%
H
2.2
2.4
|
L
 0.9%
H
2.2
2.4
|
L
 -1.3%
H
2.0
2.4
|
L
 41.7%
H
1.5
2.7
|
L
 115.9%
H
1.0
2.7
|
L
 19.1%
H
0.3
3.7
|
L
 -34.7%
H
0.3
6.3
|
L
 -86.2%
H
0.3
19.6
|
| Lyell Immunopharma Inc |
|
317.1
|
12.9
|
L
 -5.7%
H
12.9
13.7
|
L
 2.5%
H
12.6
13.7
|
L
 -0.2%
H
12.5
16.8
|
L
 -37.9%
H
11.5
21.5
|
L
 17.4%
H
9.3
45
|
L
 -76.8%
H
7.7
65.1
|
L
 -95.5%
H
7.7
396.8
|
L
H
7.7
396.8
|
| Legend Biotech Corp (ADR) |
|
3,588.3
|
18.6
|
L
 -2.6%
H
18.3
19
|
L
 -16.5%
H
18.3
20.8
|
L
 -37.9%
H
18.3
30.3
|
L
 -21.4%
H
18.3
37.5
|
L
 -52.2%
H
16.2
39.2
|
L
 -75.1%
H
16.2
75.7
|
L
 -56.9%
H
16.2
77.3
|
L
H
16.2
77.3
|
| Mustang Bio Inc |
|
4.3
|
0.6
|
L
 -3.4%
H
0.6
0.6
|
L
 1.8%
H
0.5
0.7
|
L
 -18.6%
H
0.5
0.7
|
L
 -24%
H
0.5
0.9
|
L
 -61.2%
H
0.5
1.9
|
L
 -99.8%
H
0.1
262
|
L
 -100.0%
H
0.1
2317.5
|
L
H
0.1
10012.5
|
| Microbot Medical Inc |
|
115.5
|
1.7
|
L
 -1.2%
H
1.7
1.8
|
L
 0.6%
H
1.7
1.8
|
L
 -10.0%
H
1.7
2.0
|
L
 -18.1%
H
1.7
2.3
|
L
 -32.6%
H
1.6
4.7
|
L
 -29.2%
H
0.8
4.7
|
L
 -75.6%
H
0.8
9.6
|
L
 -96.6%
H
0.8
403.7
|
| Moleculin Biotech Inc |
|
2.8
|
0.4
|
L
 -60.8%
H
0.3
1.1
|
L
 -81.1%
H
0.3
2.3
|
L
 -85.1%
H
0.3
2.8
|
L
 -84.1%
H
0.3
3.7
|
L
 -97.6%
H
0.3
18.3
|
L
 -99.8%
H
0.3
3318.8
|
L
 -100.0%
H
0.3
3318.8
|
L
 -100.0%
H
0.3
15840
|
| Seres Therapeutics Inc |
|
46.8
|
4.8
|
L
 1.1%
H
4.6
5.0
|
L
 -2.6%
H
4.6
5.3
|
L
 -39.2%
H
4.6
8.3
|
L
 -36.5%
H
4.6
8.3
|
L
 -65.5%
H
4.6
30.0
|
L
H
0.4
30.0
|
L
 -32.0%
H
0.4
30.0
|
L
 -50.4%
H
0.4
38.5
|
| Madrigal Pharma Inc |
|
10,797.0
|
467.3
|
L
 -5.2%
H
460.1
490.2
|
L
 -14.2%
H
447.0
566.2
|
L
 -9.2%
H
447.0
569.4
|
L
 -9.0%
H
445.2
569.4
|
L
 54.7%
H
299.2
615
|
L
 131.0%
H
119.8
615
|
L
 435.2%
H
52.3
615
|
L
 6682.6%
H
6.6
615
|
| MediWound Ltd |
|
181.5
|
14.1
|
L
 0.1%
H
13.9
14.6
|
L
 -0.8%
H
13.9
14.9
|
L
 -4.7%
H
13.9
15.2
|
L
 -15.1%
H
13.5
17.6
|
L
 -23.8%
H
13.5
20.3
|
L
 47.1%
H
7.1
24
|
L
 -46.9%
H
7.1
28.4
|
L
 -72.0%
H
7.1
60.1
|
| MEI Pharma Inc |
|
32.7
|
1.0
|
L
 -3.0%
H
0.9
1.0
|
L
 -3.0%
H
0.9
1.0
|
L
 -1.0%
H
0.9
1.1
|
L
 -15.0%
H
0.7
1.3
|
L
 -80.3%
H
0.7
5.6
|
L
 -87.1%
H
0.7
9
|
L
 -98.2%
H
0.7
71
|
L
 -96.7%
H
0.7
102.8
|
| Macrogenics Inc |
|
234.5
|
3.7
|
L
 -2.4%
H
3.6
3.8
|
L
 -0.3%
H
3.6
4.1
|
L
 -20.1%
H
3.4
5.1
|
L
 17.9%
H
2.9
5.1
|
L
 133.5%
H
1.3
5.1
|
L
 -24.4%
H
1.0
21.9
|
L
 -85.2%
H
1.0
28.1
|
L
 -88.1%
H
1.0
36.5
|
| Mangoceuticals Inc |
|
9.6
|
0.6
|
L
 93.1%
H
0.5
1.3
|
L
 7.7%
H
0.3
1.3
|
L
 30.2%
H
0.3
1.3
|
L
 75%
H
0.3
1.3
|
L
 -67.3%
H
0.2
2.8
|
L
 -61.4%
H
0.1
6.2
|
L
H
0.1
6.2
|
L
H
0.1
6.2
|
| Magenta Therapeutics Inc |
|
-
|
106.9
|
L
 -5.1%
H
105.7
114.6
|
L
 2.9%
H
100
114.6
|
L
 18.5%
H
87.4
114.6
|
L
 22.3%
H
68.9
114.6
|
L
 419.3%
H
18.1
114.6
|
L
 735.3%
H
10.9
114.6
|
L
 -6.1%
H
5.1
135.8
|
L
H
5.1
336
|
| MeiraGTx Holdings PLC |
|
1,091.9
|
11.8
|
L
 -1.6%
H
11.4
12.0
|
L
 0.2%
H
11.4
12.8
|
L
 -7.9%
H
11.4
15.4
|
L
 25.3%
H
8.9
15.4
|
L
 54.1%
H
6.6
15.4
|
L
 94.2%
H
3.5
15.4
|
L
 -15.7%
H
3.5
24.9
|
L
H
3.5
30.2
|
| Mirum Pharma Inc |
|
6,461.0
|
106.0
|
L
 -5.9%
H
105.7
113.5
|
L
 -6.3%
H
105.7
116.4
|
L
 -12.1%
H
105.7
130
|
L
 9.8%
H
88.3
130
|
L
 103.7%
H
50.3
130
|
L
 324.3%
H
23.1
130
|
L
 633.2%
H
12.8
130
|
L
H
6.5
130
|
| Milestone Pharma Inc |
|
138.2
|
1.1
|
L
 -3.5%
H
1.1
1.2
|
L
 -4.3%
H
1.0
1.2
|
L
 -15.9%
H
1.0
1.4
|
L
 -40.6%
H
1.0
2.0
|
L
 -22.4%
H
1
3.1
|
L
 -65.0%
H
0.6
3.6
|
L
 -80.5%
H
0.6
9.9
|
L
H
0.6
28.0
|
| MoonLake Immunotherapeutics (Class A) |
|
1,568.5
|
18.4
|
L
 -2.9%
H
18.4
19.0
|
L
 -3.1%
H
18.3
20
|
L
 -3.6%
H
18.3
21.3
|
L
 10.2%
H
15.8
23.3
|
L
 -65.2%
H
6.0
62.8
|
L
 -68.1%
H
6.0
65.0
|
L
 85.9%
H
4.3
65.0
|
L
H
4.3
65.0
|
| Mineralys Therapeutics Inc |
|
2,249.8
|
25.5
|
L
 -2.6%
H
25.2
27.0
|
L
 -4.5%
H
25.2
28.2
|
L
 -5.1%
H
25.2
31.1
|
L
 -12.8%
H
22.3
32.1
|
L
 86.8%
H
12.6
47.7
|
L
 84.3%
H
5.9
47.7
|
L
H
5.9
47.7
|
L
H
5.9
47.7
|
| Mannkind Corp |
|
1,208.0
|
3.9
|
L
 -4.9%
H
3.9
4.1
|
L
 -5.3%
H
3.8
4.2
|
L
 -3.5%
H
3.7
4.6
|
L
 37.7%
H
2.8
4.6
|
L
 4.3%
H
2.2
6.5
|
L
 -12.9%
H
2.2
7.6
|
L
 -4.6%
H
2.2
7.6
|
L
 -23.3%
H
0.7
7.6
|
| Mind Medicine Inc |
|
5,777.0
|
43.5
|
L
 -2.2%
H
42.8
45
|
L
 0.8%
H
40.3
45.4
|
L
 0.3%
H
40.3
48.5
|
L
 100.6%
H
19.3
49.2
|
L
 415.6%
H
8.6
49.2
|
L
 790.0%
H
2.4
49.2
|
L
 -5.2%
H
2.1
49.2
|
L
H
0.0
154.8
|
| Medicinova Inc |
|
65.5
|
1.3
|
L
 -0.8%
H
1.3
1.4
|
L
 0.8%
H
1.3
1.4
|
L
 -6.3%
H
1.3
1.5
|
L
 -5%
H
1.2
1.6
|
L
 -7.0%
H
1.2
2.0
|
L
 -43.2%
H
1.1
2.6
|
L
 -63.4%
H
1.1
4.7
|
L
 -78.8%
H
1.1
14.5
|
| Monopar Therapeutics Inc |
|
725.8
|
108.4
|
L
 -5.5%
H
107.1
116.7
|
L
 -1.4%
H
105.0
116.7
|
L
 14.0%
H
88.3
116.7
|
L
 103.5%
H
51.8
116.7
|
L
 166.3%
H
29.2
116.7
|
L
 2893.1%
H
1.4
116.7
|
L
 308.1%
H
1.4
116.7
|
L
H
1.4
240
|
| Marker Therapeutics Inc |
|
18.8
|
1.1
|
L
 0.9%
H
1.1
1.2
|
L
 -7.4%
H
1.1
1.3
|
L
 -22.1%
H
1.1
1.7
|
L
 -22.6%
H
1.1
1.7
|
L
 -16.3%
H
0.8
2.5
|
L
 -79.5%
H
0.8
7.0
|
L
 -94.6%
H
0.7
21.8
|
L
 -97.9%
H
0.7
135.5
|
| Moderna |
|
21,751.8
|
54.8
|
L
 -5.4%
H
54.7
59.5
|
L
 1.4%
H
53.3
59.5
|
L
 -24.4%
H
53.3
85.6
|
L
 20.8%
H
43.9
85.6
|
L
 98.6%
H
22.3
85.6
|
L
 -51.9%
H
22.3
170.5
|
L
 -84.5%
H
22.3
497.5
|
L
H
11.5
497.5
|
| Maravai LifeSciences Holdings Inc (Class A) |
|
969.1
|
6.6
|
L
 -2.7%
H
6.5
6.8
|
L
 -2.8%
H
6.5
7.0
|
L
 6.8%
H
5.7
7.4
|
L
 76.1%
H
3.6
7.4
|
L
 196.0%
H
2.0
7.4
|
L
 -40.4%
H
1.7
12.1
|
L
 -85.1%
H
1.7
63.6
|
L
H
1.7
63.6
|
| Mannatech Inc |
|
9.2
|
4.8
|
L
 -1.8%
H
4.5
5.2
|
L
 6.4%
H
4.5
5.3
|
L
 -6.1%
H
4.0
5.5
|
L
 9.4%
H
3.8
6.5
|
L
 -41.6%
H
3.8
12.5
|
L
 -59.1%
H
3.8
16.5
|
L
 -81.8%
H
3.8
43.1
|
L
 -73.1%
H
3.8
49.1
|
| MaxCyte Inc |
|
112.5
|
1.1
|
L
H
1
1.1
|
L
 -2.8%
H
1.0
1.1
|
L
 -14.6%
H
1.0
1.5
|
L
 19.3%
H
0.8
1.5
|
L
 -48.5%
H
0.6
2.2
|
L
 -76.7%
H
0.6
5.5
|
L
 -93.8%
H
0.6
17.3
|
L
H
0.6
17.4
|
| TNF Pharma Inc |
|
20.5
|
2.6
|
L
 -3.7%
H
2.5
2.8
|
L
 -19.2%
H
2.5
3.4
|
L
 -34.1%
H
2.5
4.1
|
L
 -30.0%
H
2.5
5.5
|
L
 -74.2%
H
2.5
12.2
|
L
 -99.9%
H
2.5
6387
|
L
 -100.0%
H
2.5
29850
|
L
 -100.0%
H
2.5
29850
|
| Mainz Biomed N.V. |
|
26.0
|
1.1
|
L
 2.7%
H
1.1
1.2
|
L
 5.6%
H
1.0
1.2
|
L
 -26.0%
H
1.0
1.5
|
L
 178.1%
H
0.3
4.9
|
L
 -14.3%
H
0.3
4.9
|
L
 -99.3%
H
0.3
175.2
|
L
H
0.3
1200
|
L
H
0.3
1200
|
| Mesoblast Ltd (ADR) |
|
1,837.8
|
14.2
|
L
 -2.6%
H
14.0
14.5
|
L
 -7.5%
H
14.0
15.1
|
L
 0.6%
H
13.7
19.4
|
L
 -10.0%
H
13.1
19.4
|
L
 -6.6%
H
12.7
21.5
|
L
 255.1%
H
1.0
22
|
L
 102.4%
H
1.0
22
|
L
 242.3%
H
1.0
22
|
| Molecular Partners AG (ADR) |
|
147.4
|
3.9
|
L
H
3.9
3.9
|
L
 1.0%
H
3.8
4
|
L
H
3.7
4.2
|
L
 -7.3%
H
3.7
4.4
|
L
 11.3%
H
3.5
5.4
|
L
 -34.3%
H
3.3
12.7
|
L
 -80.7%
H
3.3
32.0
|
L
 -84.6%
H
3.3
32.0
|
| Mereo Biopharma Grp PLC (ADR) |
|
54.3
|
0.3
|
L
 6.3%
H
0.3
0.4
|
L
 17.2%
H
0.3
0.4
|
L
 6.3%
H
0.3
0.4
|
L
 30.8%
H
0.2
0.4
|
L
 -79.5%
H
0.2
2.4
|
L
 -74.8%
H
0.2
5.0
|
L
 -86.8%
H
0.2
5.0
|
L
H
0.2
8.5
|
| Natural Alternatives Intl Inc |
|
14.4
|
2.3
|
L
 -5.8%
H
2.3
2.5
|
L
 -4.6%
H
2.2
2.6
|
L
 -4.2%
H
2.1
2.6
|
L
 -15.8%
H
2.1
2.8
|
L
 -36.6%
H
2.1
5.0
|
L
 -69.3%
H
2.1
7.5
|
L
 -87.1%
H
2.1
19.9
|
L
 -78.7%
H
2.1
19.9
|
| NewAmsterdam Pharma Co NV |
|
3,248.8
|
27.8
|
L
 -2.4%
H
27.3
28.8
|
L
 -6.2%
H
27.0
31.3
|
L
 -21.0%
H
27.0
37.4
|
L
 -2.3%
H
27.0
42.2
|
L
 30.6%
H
21.2
42.2
|
L
 145.9%
H
5.6
42.2
|
L
 187.1%
H
5.6
42.2
|
L
H
5.6
42.2
|
| Nature`s Sunshine Products Inc |
|
354.3
|
20.2
|
L
 -0.7%
H
19.9
20.3
|
L
 -1.2%
H
19.9
21.3
|
L
 -8.2%
H
19.9
22.4
|
L
 -24.4%
H
19.4
27.1
|
L
 27.5%
H
13.0
28.1
|
L
 46.4%
H
10.8
28.1
|
L
 14.6%
H
7.9
28.1
|
L
 69.2%
H
5.5
28.1
|
| Nautilus biotech Inc |
|
124.7
|
1.0
|
L
 -4.9%
H
1.0
1.1
|
L
 -42.0%
H
1.0
1.7
|
L
 -46.7%
H
1.0
2.1
|
L
 -63.7%
H
1.0
3.2
|
L
 29.0%
H
0.6
4.3
|
L
 -68.9%
H
0.6
4.3
|
L
 -87.5%
H
0.6
12.4
|
L
H
0.6
25.9
|
| Neurocrine Biosciences Inc |
|
16,771.7
|
166.8
|
L
 -10.1%
H
164.6
185.6
|
L
 -5.1%
H
164.6
186.1
|
L
 -0.6%
H
164.6
186.1
|
L
 26.6%
H
131.8
186.1
|
L
 29.4%
H
122.1
186.1
|
L
 61.3%
H
84.2
186.1
|
L
 79.0%
H
71.9
186.1
|
L
 223.8%
H
37.3
186.1
|
| Minerva Neurosciences Inc |
|
185.4
|
4.0
|
L
 -1%
H
3.9
4.1
|
L
 -1.5%
H
3.9
4.4
|
L
 -22.7%
H
3.9
5.4
|
L
 -34.4%
H
3.9
6.4
|
L
 108.4%
H
1.8
12.5
|
L
 -61.7%
H
1.2
13.5
|
L
 -73.0%
H
1.2
17.0
|
L
 -95.6%
H
1.2
121.7
|
| Nektar Therapeutics |
|
2,387.7
|
70.7
|
L
 -1.1%
H
69.5
71.4
|
L
 -0.1%
H
67.5
74.0
|
L
 9.8%
H
64.2
77.2
|
L
 -18.3%
H
54.1
88.1
|
L
 207.8%
H
21.6
109
|
L
 803.7%
H
6.2
109
|
L
 -70.2%
H
6.2
290.6
|
L
 -73.5%
H
6.2
1670.4
|
| Nkarta Inc |
|
149.5
|
2.1
|
L
 -2.8%
H
2.0
2.2
|
L
 -7.9%
H
2.0
2.4
|
L
 -26.7%
H
2.0
3.7
|
L
 -28.7%
H
2.0
3.7
|
L
 -1.4%
H
1.7
3.7
|
L
 -7.5%
H
1.3
16.2
|
L
 -93.4%
H
1.3
40.6
|
L
H
1.3
79.2
|
| NLS Pharmaceutics Ltd |
|
18.8
|
3.5
|
L
 3.9%
H
3.4
3.7
|
L
 -7.2%
H
3.2
3.8
|
L
 -9.4%
H
3.2
4.6
|
L
 -9.4%
H
2.8
4.6
|
L
 -80.6%
H
1.8
28.0
|
L
 -99.0%
H
1.2
482
|
L
 -99.7%
H
1.2
1240
|
L
H
1.2
2940
|
| Neoleukin Therapeutics Inc |
|
-
|
32.9
|
L
 -2.1%
H
31.8
33.6
|
L
 -5.8%
H
31.8
35.9
|
L
 -2.9%
H
31.8
43.7
|
L
 22.5%
H
24.9
43.7
|
L
 51.0%
H
15.9
43.7
|
L
 141.8%
H
12.2
43.7
|
L
 -76.5%
H
7.5
169.6
|
L
 -81.0%
H
7.5
399.4
|
| 9 Meters Biopharma Inc |
|
-
|
9.1
|
L
 1.5%
H
8.8
9.3
|
L
 4.9%
H
8.6
9.4
|
L
 -2.3%
H
8.5
9.4
|
L
 2.0%
H
8.5
9.6
|
L
 37.8%
H
6.4
9.6
|
L
 45250%
H
0.0
9.6
|
L
 -58.0%
H
0.0
29.2
|
L
 -98.6%
H
0.0
1010
|
| MetaVia Inc |
|
7.3
|
1.4
|
L
 -1.4%
H
1.4
1.5
|
L
 -4.1%
H
1.4
1.5
|
L
 -2.1%
H
1.4
2.6
|
L
 -1.4%
H
1.0
4.3
|
L
 -78.8%
H
1.0
19.0
|
L
 -96.7%
H
1.0
74.3
|
L
 -100.0%
H
1.0
13068
|
L
H
1.0
1424940
|
| Nurix Therapeutics Inc |
|
2,408.8
|
23.2
|
L
 -1.6%
H
23.1
23.8
|
L
 -0.7%
H
22.6
24.6
|
L
 -2.9%
H
21.2
25.1
|
L
 38.1%
H
14.2
25.1
|
L
 110.2%
H
8.2
25.1
|
L
 144.3%
H
4.2
29.6
|
L
 -24.5%
H
4.2
37.4
|
L
H
4.2
52.4
|
| NeuroSense Therapeutics Ltd |
|
16.6
|
0.5
|
L
 -4.2%
H
0.4
0.5
|
L
 -23.3%
H
0.4
0.6
|
L
 -36.1%
H
0.4
0.7
|
L
 -48.9%
H
0.4
1.0
|
L
 -57.4%
H
0.4
2.0
|
L
 -63.5%
H
0.4
2.6
|
L
H
0.4
8.2
|
L
H
0.4
8.2
|
| NRX Pharma Inc |
|
134.8
|
3.2
|
L
 1.0%
H
3.0
3.3
|
L
 -16%
H
2.8
3.9
|
L
 -18.4%
H
2.8
4.6
|
L
 1.9%
H
2.7
5.1
|
L
 21.6%
H
1.6
5.1
|
L
 -21.1%
H
1.1
54
|
L
 -97.9%
H
1.1
197.5
|
L
H
1.1
769.9
|
| Intellia Therapeutics Inc |
|
1,492.2
|
10.7
|
L
 -3.7%
H
10.6
11.2
|
L
 -0.5%
H
10.2
11.3
|
L
 -38.1%
H
10.2
18.5
|
L
 -19.5%
H
10.2
18.5
|
L
 -7.1%
H
8.0
28.3
|
L
 -73.9%
H
5.9
41.0
|
L
 -92.5%
H
5.9
180.6
|
L
 -42.5%
H
5.9
202.7
|
| Natera Inc |
|
38,347.4
|
267.8
|
L
 -0.7%
H
262.3
275.1
|
L
 2.2%
H
248.0
275.1
|
L
 -3.1%
H
248.0
288.0
|
L
 29.2%
H
184.8
288.0
|
L
 99.0%
H
133.0
288.0
|
L
 490.3%
H
36.9
288.0
|
L
 133.8%
H
26.1
288.0
|
L
 1953.4%
H
7.4
288.0
|
| Novavax Inc |
|
1,203.7
|
7.3
|
L
 -1.6%
H
7.2
7.5
|
L
 -1.9%
H
7.2
7.8
|
L
 -22.6%
H
7.2
10.1
|
L
 -9.0%
H
7.2
11.6
|
L
 11.6%
H
6.2
12.0
|
L
 -16.3%
H
3.5
23.9
|
L
 -95.9%
H
3.5
277.8
|
L
 -95.0%
H
3.5
331.7
|
| Nuvectis Pharma Inc |
|
678.4
|
21.5
|
L
 -5.5%
H
21.2
23.1
|
L
 11.4%
H
19
23.1
|
L
 10.3%
H
18.0
23.1
|
L
 152.0%
H
8.5
29.3
|
L
 216.5%
H
5.6
29.3
|
L
 56.3%
H
4.4
29.3
|
L
H
3.1
29.3
|
L
H
3.1
29.3
|
| Nextcure Inc |
|
16.8
|
4.1
|
L
 -17.7%
H
4.1
5.1
|
L
 -2.4%
H
4.1
5.8
|
L
 112.3%
H
1.6
9.9
|
L
 -55.8%
H
1.6
11.1
|
L
 -15.3%
H
1.6
15.7
|
L
 -79.7%
H
1.6
30.8
|
L
 -95.0%
H
1.6
110.2
|
L
H
1.6
1308
|
| Nanobiotix (ADR) |
|
1,949.2
|
38.4
|
L
 -4.4%
H
38.0
40.1
|
L
 -3.3%
H
36.4
40.8
|
L
 -2.8%
H
35
42.9
|
L
 9.3%
H
30.3
57.1
|
L
 464.4%
H
6.1
57.1
|
L
 416.6%
H
2.8
57.1
|
L
 160.6%
H
1.8
57.1
|
L
H
1.8
57.1
|
| NuCana PLC (ADR) |
|
5.5
|
1.3
|
L
 4.8%
H
1.3
1.3
|
L
 2.3%
H
1.2
1.4
|
L
 -8.3%
H
1.2
1.6
|
L
 -41.3%
H
1.2
2.4
|
L
 -99.9%
H
1.2
2000
|
L
 -100.0%
H
1.2
818000
|
L
 -100.0%
H
1.2
3319720
|
L
H
1.2
32000000
|
| Ocugen Inc |
|
416.4
|
1.2
|
L
 -2.4%
H
1.2
1.3
|
L
 1.7%
H
1.2
1.3
|
L
 -16.9%
H
1.2
1.6
|
L
 -31.7%
H
1.2
1.9
|
L
 24.2%
H
0.9
2.7
|
L
 105%
H
0.3
2.7
|
L
 -81.7%
H
0.3
17.7
|
L
 -99.0%
H
0.2
268.2
|
| Ocular Therapeutix Inc |
|
1,788.9
|
8.2
|
L
 -3.5%
H
8.2
8.6
|
L
 -3.9%
H
8.2
8.9
|
L
 -13.7%
H
8.2
10.9
|
L
 -13.4%
H
7.9
10.9
|
L
 -31.5%
H
6.2
16.4
|
L
 86.1%
H
2
16.4
|
L
 -25.8%
H
2
16.4
|
L
 86.5%
H
2
24.3
|
| Opus Genetics Inc |
|
306.3
|
3.7
|
L
 -3.4%
H
3.6
3.9
|
L
 20.5%
H
3.1
3.9
|
L
 -11.2%
H
2.8
4.4
|
L
 -27.8%
H
2.8
5.4
|
L
 246.7%
H
1.0
5.8
|
L
 -11.0%
H
0.7
5.8
|
L
 -11.7%
H
0.7
6.6
|
L
 -97.1%
H
0.7
340.8
|
| Insight Molecular Diagnostics Inc |
|
150.1
|
4.7
|
L
 1.1%
H
4.5
4.7
|
L
 -1.9%
H
4.4
4.9
|
L
 -18.3%
H
4.3
6.0
|
L
 11.2%
H
4.2
6.9
|
L
 81.6%
H
2.3
8.5
|
L
 12.6%
H
1.9
8.5
|
L
 -95.5%
H
1.9
109.6
|
L
 -93.7%
H
1.9
159
|
| OKYO Pharma Ltd - Ordinary Shares - New |
|
88.2
|
1.7
|
L
 1.2%
H
1.6
1.7
|
L
 8.4%
H
1.5
1.8
|
L
 12%
H
1.3
1.9
|
L
 1.2%
H
1.3
1.9
|
L
 -45.8%
H
1.3
3.4
|
L
 3.7%
H
0.8
3.4
|
L
H
0.8
7
|
L
H
0.8
7
|
| Olema Pharma Inc |
|
1,000.1
|
11.5
|
L
 -3.1%
H
11.4
11.9
|
L
 -2.1%
H
11.0
12.5
|
L
 -5.2%
H
10.7
13.1
|
L
 -20.0%
H
9.1
15.6
|
L
 114.8%
H
4.5
36.3
|
L
 26.1%
H
2.9
36.3
|
L
 -51.2%
H
2
36.3
|
L
H
2
60.3
|
| Omeros Corp |
|
856.9
|
11.8
|
L
 -0.8%
H
11.4
12.0
|
L
 20.9%
H
10.5
12.2
|
L
 25.8%
H
9
12.2
|
L
 -21.4%
H
6.7
15.3
|
L
 228.0%
H
3.4
17.7
|
L
 183.9%
H
0.9
17.7
|
L
 -18.3%
H
0.9
17.7
|
L
 0.3%
H
0.9
27.1
|
| Oncolytics Biotech Inc |
|
89.5
|
0.8
|
L
H
0.7
0.8
|
L
 -7.4%
H
0.7
0.8
|
L
 -16.7%
H
0.7
1.1
|
L
 -13.8%
H
0.7
1.2
|
L
 -24.2%
H
0.7
1.5
|
L
 -68.4%
H
0.3
2.5
|
L
 -67.7%
H
0.3
3.4
|
L
 -76.8%
H
0.3
8.5
|
| Traws Pharma Inc |
|
6.9
|
0.5
|
L
 2.3%
H
0.4
0.5
|
L
 -8.2%
H
0.4
0.5
|
L
 -44.4%
H
0.4
0.9
|
L
 -69.8%
H
0.4
3.2
|
L
 -69.2%
H
0.4
3.3
|
L
 -98.3%
H
0.4
27.5
|
L
 -99.6%
H
0.4
169.3
|
L
 -100.0%
H
0.4
23175
|
| VivoSim Labs Inc |
|
1.2
|
0.3
|
L
 -12.8%
H
0.3
0.4
|
L
 -19.1%
H
0.3
0.4
|
L
 -67.9%
H
0.3
1.6
|
L
 -76.4%
H
0.3
1.6
|
L
 -81.6%
H
0.3
5.3
|
L
 -98.2%
H
0.3
24.6
|
L
 -99.6%
H
0.3
99.6
|
L
 -100.0%
H
0.3
1197.6
|
| ORIC Pharma Inc |
|
1,145.9
|
11.1
|
L
 -4.9%
H
11.0
11.7
|
L
 -8.5%
H
11.0
12.6
|
L
 1.7%
H
10.3
12.6
|
L
 13.3%
H
7.3
12.6
|
L
 9.4%
H
7.2
14.9
|
L
 36.5%
H
3.9
16.7
|
L
 -33.5%
H
2.4
26.7
|
L
H
2.4
40.8
|
| Oramed Pharma Inc |
|
166.6
|
4.1
|
L
 -1.2%
H
3.9
4.1
|
L
 1.0%
H
3.9
4.2
|
L
 -11.7%
H
3.9
4.8
|
L
 2.3%
H
3.6
5.2
|
L
 92.0%
H
2.0
5.2
|
L
 23.0%
H
1.7
5.2
|
L
 -71.3%
H
1.7
31.5
|
L
 -50.1%
H
1.7
31.5
|
| Outlook Therapeutics Inc |
|
183.3
|
1.0
|
L
 -5.8%
H
0.9
1.0
|
L
 -30%
H
0.8
1.4
|
L
 -33.3%
H
0.8
1.9
|
L
 276.9%
H
0.2
1.9
|
L
 -49.2%
H
0.2
3.0
|
L
 -99.9%
H
0.2
680
|
L
 -99.9%
H
0.2
1308
|
L
 -100.0%
H
0.2
17568
|
| Ovid Therapeutics Inc |
|
414.3
|
2.2
|
L
 -6.3%
H
2.2
2.4
|
L
 -4.7%
H
2.2
2.5
|
L
 -17.2%
H
2.2
2.8
|
L
 -20.4%
H
2.2
3.0
|
L
 344%
H
0.5
3.1
|
L
 -37.6%
H
0.2
4.1
|
L
 -40.5%
H
0.2
4.2
|
L
H
0.2
15.9
|
| Phibro Animal Health Corp (Class A) |
|
1,473.7
|
36.3
|
L
 -0.3%
H
35.3
36.6
|
L
 6.7%
H
34.5
37.9
|
L
 13.2%
H
30.6
37.9
|
L
 -33.8%
H
28.3
58.7
|
L
 39.1%
H
26.1
60.1
|
L
 145.0%
H
9.4
60.1
|
L
 53.5%
H
9.4
60.1
|
L
 74.4%
H
9.4
60.1
|
| Palisade Bio Inc |
|
330.2
|
1.9
|
L
 -3.1%
H
1.9
2.0
|
L
 -2.6%
H
1.9
2.0
|
L
 -3.6%
H
1.8
2.2
|
L
 -4.5%
H
1.6
2.3
|
L
 88.1%
H
0.5
2.9
|
L
 -94.0%
H
0.4
32.1
|
L
 -99.9%
H
0.4
2400
|
L
 -100.0%
H
0.4
594000
|
| Passage Bio Inc |
|
14.4
|
4.5
|
L
 -0.5%
H
4.5
4.6
|
L
 -9.5%
H
4.4
5.0
|
L
 -2.4%
H
4.3
5.1
|
L
 -10.1%
H
3.3
6.3
|
L
 -22.1%
H
3.3
20
|
L
 -74.9%
H
3.3
35.8
|
L
 -98.1%
H
3.3
261.5
|
L
H
3.3
764.6
|
| Paranovus Entertainment Tech Ltd (Class A) |
|
4.1
|
4.8
|
L
 -1.9%
H
4.6
4.9
|
L
 -1.0%
H
4.4
5.4
|
L
 -32.5%
H
3.8
9.5
|
L
 -96.0%
H
3.8
2669
|
L
 -100%
H
3.8
148800
|
L
 -100.0%
H
3.8
580800
|
L
 -100.0%
H
3.8
3504000
|
L
H
3.8
14640000
|
| Puma biotech Inc |
|
403.6
|
7.9
|
L
 0.5%
H
7.6
7.9
|
L
 -0.6%
H
7.6
8.2
|
L
 -0.8%
H
7.6
8.8
|
L
 5.9%
H
6.6
8.8
|
L
 158.3%
H
3.0
8.8
|
L
 123.4%
H
2.1
8.8
|
L
 5.5%
H
1.6
8.8
|
L
 -83.8%
H
1.6
136.9
|
| Pacira BioSciences Inc |
|
1,039.2
|
26.4
|
L
 -2.1%
H
26.0
27.0
|
L
 2.1%
H
25.8
27.2
|
L
 5.5%
H
24.4
27.2
|
L
 8.1%
H
21.9
27.2
|
L
 19.7%
H
18.8
27.6
|
L
 -26.6%
H
11.2
40.2
|
L
 -55.2%
H
11.2
82.2
|
L
 -29.7%
H
11.2
82.2
|
| Processa Pharma Inc |
|
6.0
|
2.2
|
L
 5.4%
H
1.9
2.2
|
L
 -17.3%
H
1.8
3.1
|
L
 9.7%
H
1.7
3.1
|
L
 -15.7%
H
1.7
3.4
|
L
 -59.4%
H
1.7
14.3
|
L
 -99%
H
1.7
450
|
L
 -99.9%
H
1.7
4495.5
|
L
 -100.0%
H
1.7
17937.5
|
| Vaxcyte Inc |
|
7,809.0
|
54.1
|
L
 -3.4%
H
53.5
56.4
|
L
 -1.1%
H
52.5
57.0
|
L
 -3.6%
H
52.5
61.8
|
L
 -5.0%
H
45.3
61.8
|
L
 63.8%
H
29.1
65
|
L
 9.7%
H
27.7
121.1
|
L
 149.4%
H
16.8
121.1
|
L
H
15.5
121.1
|
| PDS biotech Corp |
|
38.6
|
0.7
|
L
 -1.4%
H
0.7
0.7
|
L
 1.5%
H
0.7
0.7
|
L
 -20.7%
H
0.7
0.9
|
L
 -29.6%
H
0.7
1.6
|
L
 -36.7%
H
0.5
1.6
|
L
 -87.9%
H
0.5
6.9
|
L
 -93.5%
H
0.5
17.9
|
L
 -99.6%
H
0.5
355.4
|
| PepGen Inc |
|
121.7
|
1.8
|
L
 -1.1%
H
1.7
1.9
|
L
 -8.8%
H
1.7
2
|
L
 -2.8%
H
1.7
2.6
|
L
 0.6%
H
1.3
2.6
|
L
 33.3%
H
1.0
7.8
|
L
 -70.4%
H
0.9
19.3
|
L
H
0.9
20
|
L
H
0.9
20
|
| Precigen Inc |
|
2,235.3
|
6.3
|
L
 5.6%
H
5.9
6.3
|
L
 16.1%
H
5.2
6.3
|
L
 19.4%
H
4.8
6.3
|
L
 53.7%
H
3.5
6.3
|
L
 275.5%
H
1.7
6.3
|
L
 386.0%
H
0.7
6.3
|
L
 14.2%
H
0.7
6.5
|
L
 -77.1%
H
0.7
32.9
|
| Phathom Pharma Inc |
|
707.9
|
8.8
|
L
 -3.1%
H
8.7
9.5
|
L
 -23.5%
H
8.7
12.2
|
L
 -17.0%
H
8.7
12.6
|
L
 -27.1%
H
8.7
13.4
|
L
 4.8%
H
8.0
18.3
|
L
 -42.1%
H
2.2
19.7
|
L
 -72.7%
H
2.2
37.2
|
L
H
2.2
64.5
|
| Phio Pharma Corp |
|
11.8
|
1.0
|
L
 -1.0%
H
1
1.1
|
L
 -1.9%
H
1.0
1.1
|
L
 2%
H
0.8
1.1
|
L
 -10.5%
H
0.8
1.2
|
L
 -56.2%
H
0.8
4.2
|
L
 -95.8%
H
0.6
29.1
|
L
 -99.5%
H
0.6
261.4
|
L
 -100.0%
H
0.6
174042
|
| Pharvaris NV |
|
2,279.5
|
32.6
|
L
 -3.7%
H
32
33.8
|
L
 -4.5%
H
32
34.9
|
L
 -3.9%
H
32
36.6
|
L
 10.8%
H
28.3
36.6
|
L
 63.1%
H
19.6
36.6
|
L
 91.3%
H
11.5
36.6
|
L
 83.6%
H
1.8
36.6
|
L
H
1.8
42.9
|
| Pliant Therapeutics Inc |
|
64.4
|
1.0
|
L
 -1.9%
H
1.0
1.1
|
L
 -4.6%
H
1.0
1.1
|
L
 -6.3%
H
1.0
1.2
|
L
 -13.3%
H
1.0
1.3
|
L
 -34.2%
H
1.0
2.0
|
L
 -94.1%
H
1.0
20.2
|
L
 -94.9%
H
1.0
36.6
|
L
H
1.0
43.9
|
| Pluri Inc |
|
16.7
|
1.6
|
L
 -0.6%
H
1.5
1.6
|
L
 -12.9%
H
1.5
1.8
|
L
 -25.8%
H
1.5
2.4
|
L
 -53.7%
H
1.5
3.9
|
L
 -70.0%
H
1.5
5.7
|
L
 -74.2%
H
0.7
8.5
|
L
 -94.1%
H
0.7
26.8
|
L
 -98.7%
H
0.7
169.6
|
| PharmaCyte Biotech Inc |
|
6.2
|
0.6
|
L
 -3.3%
H
0.6
0.6
|
L
 -3.3%
H
0.6
0.6
|
L
 -21.6%
H
0.6
0.8
|
L
 -23.7%
H
0.6
1.0
|
L
 -42%
H
0.6
1.5
|
L
 -78.3%
H
0.6
2.7
|
L
 -95.2%
H
0.6
12.0
|
L
 -99.2%
H
0.6
253.4
|
| ProMIS Neurosciences Inc |
|
123.0
|
13.7
|
L
 -8.0%
H
13.5
14.9
|
L
 12.5%
H
11.3
17.3
|
L
 2.0%
H
11.3
17.3
|
L
 24.6%
H
9.1
17.3
|
L
 -28.5%
H
6.3
27.4
|
L
 -81.1%
H
6.3
87.5
|
L
 -94.2%
H
6.3
322.8
|
L
 -91.8%
H
6.3
1050
|
| PMV Pharmaceuticals Inc |
|
59.2
|
1.1
|
L
 -1.8%
H
1.1
1.1
|
L
 -10.5%
H
1.1
1.3
|
L
 -10.5%
H
1.1
1.5
|
L
 -20.1%
H
1.0
1.5
|
L
 -20.7%
H
1.0
1.9
|
L
 -83.2%
H
0.8
9.7
|
L
 -96.7%
H
0.8
37.3
|
L
H
0.8
63.2
|
| Praxis Precision Medicines Inc |
|
8,581.9
|
307.8
|
L
 0.0%
H
293.2
310.2
|
L
 -5.4%
H
287.9
330
|
L
 -3.7%
H
287.9
343.1
|
L
 -5.1%
H
238.8
366.5
|
L
 469.1%
H
37.2
366.5
|
L
 2042.2%
H
12.9
366.5
|
L
 31.6%
H
11.9
366.5
|
L
H
11.9
914.3
|
| PainReform Ltd |
|
3.0
|
1
|
L
 -2.9%
H
1.0
1.0
|
L
 -12.3%
H
1.0
1.3
|
L
 -26.5%
H
1.0
1.5
|
L
 -47.1%
H
1.0
5.4
|
L
 -24.2%
H
0.6
5.4
|
L
 -97.7%
H
0.2
45.3
|
L
 -99.4%
H
0.2
208.2
|
L
H
0.2
471
|
| Prelude Therapeutics Inc |
|
366.4
|
4.6
|
L
 -8.9%
H
4.6
5.2
|
L
 20.1%
H
3.9
5.2
|
L
 -6.3%
H
3.8
5.3
|
L
 -2.1%
H
3.4
5.7
|
L
 454.2%
H
0.8
5.7
|
L
 24.7%
H
0.6
6.8
|
L
 -85.6%
H
0.6
43.6
|
L
H
0.6
95.4
|
| Prime Medicine Inc |
|
527.4
|
2.9
|
L
 -3.3%
H
2.9
3.0
|
L
 -1.0%
H
2.9
3.2
|
L
 -24.9%
H
2.9
4.8
|
L
 -14.4%
H
2.7
4.8
|
L
 -27.7%
H
2.7
6.9
|
L
 -80.3%
H
1.1
15.0
|
L
H
1.1
21.7
|
L
H
1.1
21.7
|
| ProKidney Corp Ordinary |
|
316.0
|
1.5
|
L
 -2.5%
H
1.5
1.6
|
L
 2.7%
H
1.5
1.6
|
L
 -18.5%
H
1.5
2.2
|
L
 -20.2%
H
1.5
2.2
|
L
 -45.4%
H
1.5
3.6
|
L
 -88.2%
H
0.5
13.5
|
L
H
0.5
14.2
|
L
H
0.5
14.2
|
| ProQR Therapeutics NV |
|
242.7
|
1.7
|
L
 -3.4%
H
1.7
1.8
|
L
H
1.7
1.8
|
L
 -1.7%
H
1.5
2
|
L
 11.0%
H
1.4
2
|
L
 -17.3%
H
1.3
3.1
|
L
 6.8%
H
1.1
4.6
|
L
 -67.1%
H
0.5
9.1
|
L
 -64.9%
H
0.5
24
|
| Prothena Corporation plc |
|
425.1
|
8.1
|
L
 -3.5%
H
8
8.5
|
L
 -7.2%
H
8
9.1
|
L
 -15.2%
H
8
10.2
|
L
 -23.7%
H
7.7
11.8
|
L
 19.2%
H
6.7
11.8
|
L
 -88.2%
H
4.3
70.1
|
L
 -83.8%
H
4.3
79.8
|
L
 -85.7%
H
4.3
79.8
|
| Plus Therapeutics Inc |
|
26.6
|
3.9
|
L
 6.0%
H
3.6
4.0
|
L
 1.0%
H
3.6
4.0
|
L
 -7.0%
H
3.6
4.4
|
L
 -36.5%
H
3.6
7.3
|
L
 -73.5%
H
2.9
23.4
|
L
 -93.8%
H
2.9
80.3
|
L
 -99.5%
H
2.9
870
|
L
 -100.0%
H
2.9
429375
|
| PTC Therapeutics Inc |
|
5,676.2
|
68.0
|
L
 -9.9%
H
64.6
73.7
|
L
 -11.5%
H
64.6
79.3
|
L
 -16.4%
H
64.6
90.9
|
L
 4.4%
H
63.6
90.9
|
L
 30.5%
H
43.2
90.9
|
L
 67.2%
H
17.5
90.9
|
L
 77.4%
H
17.5
90.9
|
L
 1014.9%
H
4.0
90.9
|
| Protagonist Therapeutics Inc |
|
8,787.5
|
136.6
|
L
 -1.4%
H
131.7
138.4
|
L
 0.4%
H
130.6
139.9
|
L
 9.2%
H
125.2
143.3
|
L
 38.9%
H
92.8
143.3
|
L
 153.8%
H
50.5
143.3
|
L
 618.4%
H
13.7
143.3
|
L
 176.4%
H
6.9
143.3
|
L
H
4.5
143.3
|
| Pulmatrix Inc |
|
6.4
|
1.7
|
L
 2.4%
H
1.6
1.7
|
L
 5.5%
H
1.6
1.8
|
L
H
1.6
1.9
|
L
 34.9%
H
1.2
1.9
|
L
 -67.4%
H
1.2
5.6
|
L
 -34.8%
H
1.2
10.4
|
L
 -89.7%
H
1.2
20.8
|
L
 -99.6%
H
1.2
1396
|
| Polypid Ltd |
|
82.3
|
4.3
|
L
 -1.8%
H
4.2
4.5
|
L
 10%
H
3.7
4.5
|
L
 -15.1%
H
3.7
5.7
|
L
 -3.4%
H
3.7
5.7
|
L
 25.8%
H
3.1
5.7
|
L
 -61.4%
H
2.3
12
|
L
 -98.2%
H
2.3
289.2
|
L
H
2.3
583.5
|
| Pyxis Oncology Inc |
|
167.9
|
2.7
|
L
 -7.7%
H
2.6
2.9
|
L
 1.5%
H
2.6
3.1
|
L
 -7.0%
H
2.1
3.2
|
L
 54.1%
H
1.5
3.4
|
L
 140.9%
H
1.0
5.6
|
L
 3.1%
H
0.8
6.9
|
L
H
0.8
19
|
L
H
0.8
19
|
| Pharming Grp N.V. (ADR) |
|
713.4
|
10.1
|
L
 -6.2%
H
9.7
10.5
|
L
 -20.1%
H
9.6
13.0
|
L
 -26.2%
H
9.6
14.8
|
L
 -40.6%
H
9.6
16.8
|
L
 -8.0%
H
9.6
21.3
|
L
 -16%
H
6.7
21.3
|
L
 -11.0%
H
6.1
21.3
|
L
H
6.1
22.0
|
| Purple Biotech Ltd (ADR) |
|
1.3
|
1.4
|
L
 2.2%
H
1.3
1.5
|
L
 -2.1%
H
1.3
1.5
|
L
 -20%
H
1.3
1.7
|
L
 -66.7%
H
1.3
4.5
|
L
 -93.6%
H
1.3
24
|
L
 -100.0%
H
1.3
7200
|
L
 -100.0%
H
1.3
22600
|
L
 -100.0%
H
1.3
182000
|
| Qilian Intl Holding Grp ltd (Class A) |
|
112.2
|
0.3
|
L
 3.7%
H
0.3
0.3
|
L
 -3.5%
H
0.3
0.3
|
L
 -22.2%
H
0.3
0.5
|
L
 -6.7%
H
0.3
0.5
|
L
 -96.7%
H
0.3
11.8
|
L
 -93.5%
H
0.3
17.2
|
L
 -98.7%
H
0.3
22.5
|
L
H
0.3
110
|
| Quince Therapeutics Inc |
|
22.9
|
23.4
|
L
 1.6%
H
21.6
24.6
|
L
 31.0%
H
17.4
24.6
|
L
 39.6%
H
16.1
24.6
|
L
 1658.7%
H
0.8
24.6
|
L
 39.2%
H
0.8
45.5
|
L
 93.3%
H
0.8
45.5
|
L
 -95.9%
H
0.8
1219.8
|
L
H
0.8
1219.8
|
| uniQure NV |
|
3,026.5
|
43.6
|
L
 3.4%
H
43
45.0
|
L
 12.0%
H
35.3
45.0
|
L
 -3.4%
H
35.3
46.1
|
L
 128.1%
H
19.4
50.5
|
L
 218.5%
H
8.7
71.5
|
L
 310.8%
H
3.7
71.5
|
L
 50.4%
H
3.7
71.5
|
L
 492.0%
H
3.7
82.5
|
| Quoin Pharma Ltd (ADR) |
|
8.9
|
4.5
|
L
 1.1%
H
4.2
4.5
|
L
 4.0%
H
4.0
4.5
|
L
 -5.5%
H
4.0
4.9
|
L
 -28.3%
H
3.3
6.7
|
L
 -34.8%
H
3.3
41.8
|
L
 -99.9%
H
3.3
5439.7
|
L
 -100.0%
H
3.3
3003840
|
L
 -100.0%
H
3.3
3003840
|
| Rani Therapeutics Holdings Inc |
|
86.5
|
0.8
|
L
 -6.1%
H
0.8
0.8
|
L
 -9.4%
H
0.8
0.9
|
L
H
0.6
0.9
|
L
 -18.1%
H
0.6
1.1
|
L
 45.3%
H
0.4
3.9
|
L
 -82.2%
H
0.4
8.8
|
L
 -93%
H
0.4
36.3
|
L
H
0.4
224.5
|
| Ultragenyx Pharmaceutical Inc |
|
2,453.4
|
24.9
|
L
 -4.3%
H
24.6
26.1
|
L
 -7.4%
H
24.5
28
|
L
 -23.1%
H
24.5
36.6
|
L
 0.6%
H
21.3
36.6
|
L
 -12.4%
H
18.3
39.9
|
L
 -42.0%
H
18.3
60.4
|
L
 -68.8%
H
18.3
104.4
|
L
 -60.8%
H
18.3
179.7
|
| Rocket Pharmaceuticals Inc |
|
339.6
|
3.1
|
L
 -3.1%
H
3.1
3.2
|
L
 -2.5%
H
3.0
3.4
|
L
 -11.7%
H
3.0
4.3
|
L
 -12.6%
H
2.5
4.3
|
L
 4.0%
H
2.5
5.5
|
L
 -82.6%
H
2.2
32.5
|
L
 -91.3%
H
2.2
37.7
|
L
 -88.4%
H
2.2
67.5
|
| Regeneron Pharma |
|
78,516.6
|
762.6
|
L
 3.3%
H
724.8
764.8
|
L
 16.3%
H
659.5
764.8
|
L
 22.1%
H
625.7
764.8
|
L
 8.7%
H
591.5
764.8
|
L
 36.5%
H
541
821.1
|
L
 3.2%
H
476.5
1211.2
|
L
 32.7%
H
476.5
1211.2
|
L
 75.7%
H
271.4
1211.2
|
| Replimune Grp Inc |
|
941.1
|
11.2
|
L
 107.0%
H
9.4
12.5
|
L
 15.5%
H
4.8
12.5
|
L
 -0.2%
H
4.8
12.5
|
L
 348%
H
2.5
12.5
|
L
 47.4%
H
1.5
12.5
|
L
 -45.5%
H
1.5
21.6
|
L
 -65.8%
H
1.5
37.0
|
L
H
1.5
54.9
|
| Revelation Biosciences Inc |
|
3.7
|
1.0
|
L
 -5%
H
1.0
1.0
|
L
 -10.4%
H
0.9
1.1
|
L
 -8.7%
H
0.9
1.2
|
L
 -15.2%
H
0.9
1.2
|
L
 -90.3%
H
0.9
11.7
|
L
 -100.0%
H
0.9
5417.6
|
L
 -100.0%
H
0.9
2276064
|
L
H
0.9
2276064
|
| Regencell Bioscience Holdings Ltd |
|
3,055.9
|
6.2
|
L
 4.0%
H
5.6
6.2
|
L
 8.0%
H
5.3
6.4
|
L
 -23.0%
H
4.5
8.2
|
L
 -78.8%
H
4.5
32
|
L
 -52.4%
H
4.5
69
|
L
 1161.2%
H
0.1
83.6
|
L
 2475%
H
0.1
83.6
|
L
H
0.1
83.6
|
| Repligen Corp |
|
7,958.0
|
141.0
|
L
 -1.8%
H
139.4
145
|
L
 6.9%
H
130.0
154
|
L
 1.5%
H
129
154
|
L
 20.3%
H
101.0
154
|
L
 18.6%
H
101.0
175.8
|
L
 -15.6%
H
101.0
211.1
|
L
 -42.6%
H
101.0
327.3
|
L
 372.1%
H
26.2
327.3
|
| Regenxbio Inc |
|
620.4
|
9.7
|
L
 -4.3%
H
9.6
10.4
|
L
 -0.4%
H
9.2
10.5
|
L
 -26.0%
H
8.4
15.9
|
L
 6.3%
H
5.5
15.9
|
L
 18.3%
H
5.5
16.2
|
L
 -49.4%
H
5.0
28.8
|
L
 -70.0%
H
5.0
46.5
|
L
 16.6%
H
5.0
85.1
|
| Rigel Pharma |
|
681.1
|
36.8
|
L
 -3.3%
H
36.1
37.8
|
L
 0.2%
H
36.1
40.0
|
L
 -3.9%
H
35.0
44.0
|
L
 25.2%
H
25.5
44.0
|
L
 68.0%
H
21.8
52.2
|
L
 2667.7%
H
0.7
52.2
|
L
 820.3%
H
0.6
52.2
|
L
 1366.5%
H
0.6
52.2
|
| Relay Therapeutics Inc |
|
4,103.8
|
18.8
|
L
 -3.2%
H
18.5
19.8
|
L
 2.1%
H
17.7
19.8
|
L
 6.0%
H
17.7
20.8
|
L
 48.0%
H
11.6
20.8
|
L
 460.4%
H
3.0
20.8
|
L
 58.1%
H
1.8
20.8
|
L
 -42.0%
H
1.8
38.2
|
L
H
1.8
64.4
|
| Relmada Therapeutics Inc |
|
557.5
|
5.3
|
L
 -0.8%
H
5
5.4
|
L
 2.5%
H
5
5.4
|
L
 -16.9%
H
4.9
6.7
|
L
 -30.5%
H
4.9
8
|
L
 800%
H
0.6
8
|
L
 107.4%
H
0.2
8
|
L
 -79.6%
H
0.2
38.7
|
L
 -28.6%
H
0.2
54
|
| Rallybio Corp |
|
84.5
|
15.9
|
L
 -0.9%
H
15.9
16.1
|
L
 -2.3%
H
15.9
16.5
|
L
 -0.1%
H
15.6
17.1
|
L
 69.3%
H
13.2
17.6
|
L
 272.2%
H
3.2
17.6
|
L
 -66.8%
H
1.8
50.6
|
L
 -88.3%
H
1.8
192.8
|
L
H
1.8
206.2
|
| TransCode Therapeutics Inc |
|
4.8
|
4.6
|
L
 -13.1%
H
4.5
5.4
|
L
 -23.1%
H
4.5
6.1
|
L
 -40.4%
H
4.5
10.7
|
L
 -41.8%
H
3.8
10.7
|
L
 -60.4%
H
3.8
21.0
|
L
 -100.0%
H
3.8
118272
|
L
 -100.0%
H
3.8
3901941.1
|
L
H
3.8
5174400
|
| RenovoRx Inc |
|
43.3
|
1.0
|
L
 2.1%
H
0.9
1.0
|
L
 11.6%
H
0.9
1.0
|
L
H
0.8
1.0
|
L
 9.1%
H
0.8
1
|
L
 -20.7%
H
0.7
1.5
|
L
 -52.2%
H
0.6
2.4
|
L
H
0.6
16.7
|
L
H
0.6
16.7
|
| Roivant Sciences Ltd |
|
24,496.8
|
33.9
|
L
 -1.8%
H
33.5
34.5
|
L
 -3.1%
H
32.8
35.6
|
L
 -3.2%
H
32.8
37
|
L
 21.9%
H
27.5
37
|
L
 199.8%
H
10.9
37
|
L
 184.2%
H
8.2
37
|
L
 242.2%
H
2.5
37
|
L
H
2.5
37
|
| Royalty Pharma PLC (Class A) |
|
25,900.5
|
58.4
|
L
 -1%
H
58.3
59.1
|
L
 -0.7%
H
58.3
60.4
|
L
 4.8%
H
55.0
60.4
|
L
 18.1%
H
49.1
60.4
|
L
 57.5%
H
34.1
60.4
|
L
 89.1%
H
24.1
60.4
|
L
 53.0%
H
24.1
60.4
|
L
H
24.1
60.4
|
| Revolution Medicines Inc |
|
39,868.2
|
187.5
|
L
 -2.4%
H
186.2
192
|
L
 -0.9%
H
178.1
194.6
|
L
 0.0%
H
176
194.6
|
L
 34.5%
H
140.5
194.6
|
L
 412.0%
H
34
194.6
|
L
 495.3%
H
15.5
194.6
|
L
 554.8%
H
14.1
194.6
|
L
H
14.1
194.6
|
| Recursion Pharma Inc (Class A) |
|
1,592.3
|
3
|
L
 -1.3%
H
3.0
3.1
|
L
 1.4%
H
2.9
3.1
|
L
 -18.3%
H
2.8
4.1
|
L
 -11.5%
H
2.8
4.1
|
L
 -47.2%
H
2.8
7.2
|
L
 -78.3%
H
2.8
15.7
|
L
 -90.1%
H
2.8
31.8
|
L
H
2.8
42.8
|
| Rhythm Pharma Inc |
|
6,807.9
|
99.3
|
L
 -6.1%
H
98.4
106.9
|
L
 -2.8%
H
98.4
111.0
|
L
 -10.1%
H
98.4
115.9
|
L
 21.3%
H
81.1
115.9
|
L
 12.4%
H
74.5
122.2
|
L
 336.3%
H
21.0
122.2
|
L
 474.0%
H
3.0
122.2
|
L
H
3.0
122.2
|
| Rezolute Inc |
|
454.5
|
4.7
|
L
 -3.3%
H
4.5
4.9
|
L
 -5.4%
H
4.5
5.1
|
L
 -4.7%
H
4.1
5.4
|
L
 43.0%
H
2.8
5.4
|
L
 -19.6%
H
1.1
11.5
|
L
 166.7%
H
0.7
11.5
|
L
 -57.6%
H
0.7
11.8
|
L
 -90.4%
H
0.7
100
|
| Redhill Biopharma (ADR) |
|
4.0
|
0.7
|
L
 3.2%
H
0.6
0.7
|
L
 3.2%
H
0.6
0.7
|
L
 -21.7%
H
0.6
0.9
|
L
 -39.8%
H
0.6
1.1
|
L
 -45.8%
H
0.6
2.8
|
L
 -97.9%
H
0.6
82
|
L
 -100.0%
H
0.6
11180
|
L
 -100.0%
H
0.6
16540
|
| SAB Biotherapeutics Inc |
|
273.0
|
3.6
|
L
 0.3%
H
3.4
3.6
|
L
 1.7%
H
3.4
3.6
|
L
 -8.0%
H
3.4
4.1
|
L
 2.9%
H
3.3
4.6
|
L
 60.1%
H
1.9
5.2
|
L
 320%
H
0.4
6.6
|
L
 -64.0%
H
0.4
12.9
|
L
H
0.4
12.9
|
| Sana biotech Inc |
|
871.1
|
3.1
|
L
 -3.7%
H
3.1
3.3
|
L
 -1.6%
H
3.0
3.5
|
L
 -12.1%
H
3.0
4.2
|
L
 -4.3%
H
2.6
4.2
|
L
 -20.0%
H
2.6
6.6
|
L
 -45.4%
H
1.3
12
|
L
 -80.8%
H
1.3
26.6
|
L
H
1.3
44.6
|
| Filana Therapeutics Inc |
|
48.8
|
1.0
|
L
 5.2%
H
0.9
1.0
|
L
 13.5%
H
0.9
1.0
|
L
 -19.2%
H
0.9
1.4
|
L
 -33.1%
H
0.9
1.6
|
L
 -52.4%
H
0.9
5.0
|
L
 -95.4%
H
0.9
42.2
|
L
 -98.5%
H
0.9
126.5
|
L
 -94.6%
H
0.8
146.2
|
| Sunshine Biopharma Inc |
|
2.8
|
1.2
|
L
 -4.9%
H
1.2
1.2
|
L
 -29.5%
H
1.1
1.7
|
L
 -46.3%
H
1.1
2.2
|
L
 -88.9%
H
1.1
23.2
|
L
 -91.7%
H
1.1
24.3
|
L
 -100.0%
H
1.1
12900
|
L
 -100.0%
H
1.1
596000
|
L
 -100.0%
H
1.1
45037037.0
|
| Scilex Holding Co |
|
46.8
|
6.7
|
L
 0.9%
H
6.4
6.9
|
L
 -2.6%
H
6.4
7.3
|
L
 -15.5%
H
6.4
10.4
|
L
 -37.1%
H
5.4
12.3
|
L
 -50.3%
H
4.2
34.3
|
L
 27.6%
H
0.2
34.3
|
L
 -33.1%
H
0.2
34.3
|
L
H
0.2
34.3
|
| Scynexis Inc |
|
48.1
|
4.8
|
L
 29.8%
H
3.6
5.0
|
L
 29.8%
H
3.5
5.0
|
L
 14.4%
H
3.5
5.1
|
L
 -38.9%
H
3.5
8.2
|
L
 -11.2%
H
3.5
10.5
|
L
 -79.3%
H
3.5
31.0
|
L
 -91.3%
H
3.5
64.8
|
L
 -97.0%
H
3.5
440.8
|
| Seer Inc (Class A) |
|
122.1
|
2.2
|
L
 7.8%
H
2.2
2.3
|
L
 12.7%
H
1.8
2.3
|
L
 36.2%
H
1.6
2.3
|
L
 9.4%
H
1.6
2.3
|
L
 4.2%
H
1.6
2.4
|
L
 -54.2%
H
1.5
5.0
|
L
 -93.0%
H
1.5
45.9
|
L
H
1.5
86.6
|
| Selecta Biosciences Inc |
|
1,207.9
|
7.8
|
L
 0.9%
H
7.3
7.8
|
L
 -1.0%
H
7.3
8.4
|
L
 -23.4%
H
7.3
11.0
|
L
 25.4%
H
5.8
11
|
L
 -36.7%
H
5.6
12.6
|
L
 -24.0%
H
5.6
15.6
|
L
 -24.0%
H
5.6
15.6
|
L
 -24.0%
H
5.6
15.6
|
| Shuttle Pharma Holdings Inc |
|
2.2
|
3.8
|
L
 23.0%
H
2.9
4.4
|
L
 31.5%
H
2.6
4.4
|
L
 11.8%
H
2.6
5.1
|
L
 450.7%
H
0.4
6.2
|
L
 8.6%
H
0.4
6.2
|
L
 -97.9%
H
0.4
186.0
|
L
H
0.4
25252
|
L
H
0.4
25252
|
| SIGA Tech Inc |
|
234.5
|
3.3
|
L
 0.6%
H
3.2
3.3
|
L
 5.1%
H
3.0
3.4
|
L
 -12.1%
H
3.0
3.9
|
L
 -28.9%
H
3.0
4.9
|
L
 -49.4%
H
3.0
9.6
|
L
 -41.9%
H
3.0
12.8
|
L
 -48.7%
H
3.0
27.0
|
L
 48.6%
H
1.9
27.0
|
| SILO Pharma Inc |
|
4.7
|
4.2
|
L
 -1.4%
H
4.2
4.4
|
L
 -6.3%
H
4.2
4.7
|
L
 -32.1%
H
4.2
8.0
|
L
 810.9%
H
0.3
8.0
|
L
 474.0%
H
0.2
8.0
|
L
 95.8%
H
0.2
8.0
|
L
 -46.8%
H
0.2
496
|
L
 -91.6%
H
0.2
496
|
| Solid Biosciences Inc |
|
793.5
|
8.1
|
L
 -5.1%
H
8
8.6
|
L
 2.9%
H
7.7
8.6
|
L
 -21.0%
H
7.7
11.5
|
L
 13.0%
H
6
11.5
|
L
 18.0%
H
3.8
11.5
|
L
 95.2%
H
1.8
15.1
|
L
 -80.7%
H
1.8
51.3
|
L
H
1.8
822.6
|
| Sol-Gel Tech Ltd |
|
268.9
|
82.3
|
L
 -3.5%
H
82.3
90.4
|
L
 0.4%
H
77.1
90.4
|
L
 14.3%
H
71
93.7
|
L
 8.8%
H
62.5
93.7
|
L
 532.7%
H
12.5
98.0
|
L
 2014.4%
H
0.3
98.0
|
L
 632.4%
H
0.3
98.0
|
L
H
0.3
98.0
|
| Decoy Therapeutics Inc |
|
2.2
|
4.1
|
L
 4.9%
H
3.9
4.1
|
L
 -18.5%
H
3.5
4.5
|
L
 -46.1%
H
3.5
8.3
|
L
 -30.3%
H
3.5
13.5
|
L
 -96.4%
H
3.5
120.6
|
L
 -99.7%
H
3.5
1425.6
|
L
 -100.0%
H
3.5
43200
|
L
 -100.0%
H
3.5
11412000
|
| SELLAS Life Sciences Grp Inc |
|
1,968.3
|
10.0
|
L
 -2.7%
H
9.9
10.5
|
L
 -11.6%
H
9.2
11.5
|
L
 -24.6%
H
9.2
15.6
|
L
 103.0%
H
4.8
15.9
|
L
 503.0%
H
1.4
15.9
|
L
 510.4%
H
0.5
15.9
|
L
 16.9%
H
0.5
15.9
|
L
 -99.9%
H
0.5
15300
|
| Summit Therapeutics Inc |
|
10,386.7
|
13.0
|
L
 -3.1%
H
13.0
13.6
|
L
 -4.7%
H
12.3
14.2
|
L
 -9.5%
H
12.3
16.1
|
L
 -19.2%
H
12.3
19.4
|
L
 -51.9%
H
12.3
31.0
|
L
 523.0%
H
1.5
36.9
|
L
 77.6%
H
0.7
36.9
|
L
 95.8%
H
0.7
36.9
|
| Syndax Pharma Inc |
|
1,688.0
|
19.1
|
L
 -2.2%
H
18.6
19.5
|
L
 -8.5%
H
18.6
21.6
|
L
 -8.8%
H
18.6
25.2
|
L
 -0.3%
H
16.7
25.2
|
L
 90.9%
H
9.7
25.6
|
L
 -9.8%
H
8.6
25.6
|
L
 30.7%
H
8.6
29.9
|
L
 55.9%
H
3.4
29.9
|
| Soligenix Inc |
|
5.5
|
0.4
|
L
 -2.6%
H
0.4
0.4
|
L
H
0.4
0.4
|
L
 -7.5%
H
0.3
0.4
|
L
 8.8%
H
0.3
1.1
|
L
 -86.5%
H
0.3
6.2
|
L
 -96.3%
H
0.3
85.3
|
L
 -99.8%
H
0.3
295.2
|
L
 -100.0%
H
0.3
2040.1
|
| Sonoma Pharma Inc |
|
5.3
|
1.1
|
L
 -2.7%
H
1.1
1.1
|
L
 -3.5%
H
1.1
1.2
|
L
 -9.1%
H
1.1
1.3
|
L
 -8.3%
H
1
1.3
|
L
 -63.2%
H
0.9
6.9
|
L
 3.8%
H
0.1
6.9
|
L
 -83.6%
H
0.1
13.4
|
L
 -96.9%
H
0.1
74.2
|
| Sensei Biotherapeutics Inc |
|
702.2
|
27.2
|
L
 -5.5%
H
26.3
30.1
|
L
 -3.7%
H
26.3
31.6
|
L
 15.1%
H
21.2
37.9
|
L
 1.0%
H
10.8
37.9
|
L
 164.0%
H
7.2
37.9
|
L
 4.8%
H
5
38.8
|
L
 -82.7%
H
5
247.4
|
L
H
5
530
|
| Senti Biosciences Inc |
|
10.6
|
0.3
|
L
 -5.6%
H
0.3
0.4
|
L
 -15%
H
0.3
0.4
|
L
 -67.9%
H
0.3
1.1
|
L
 -66.7%
H
0.3
1.2
|
L
 -79.8%
H
0.3
2.9
|
L
 -96.4%
H
0.3
16.9
|
L
 -65.3%
H
0.3
87.7
|
L
H
0.3
87.7
|
| Spruce Biosciences Inc |
|
117.9
|
42.8
|
L
 -1.3%
H
42
43.3
|
L
 -0.6%
H
40.3
45.5
|
L
 -18.5%
H
40.3
55.2
|
L
 -25.2%
H
40.3
60.3
|
L
 387.3%
H
7.3
240
|
L
 -75.2%
H
4.3
446.3
|
L
 -93.8%
H
4.3
702.8
|
L
H
4.3
2670
|
| SciSparc Ltd |
|
4.1
|
7.1
|
L
 -18.2%
H
6.6
8
|
L
 33.6%
H
4.8
11.5
|
L
 38.3%
H
4.2
11.5
|
L
 -10.0%
H
4
15.8
|
L
 -86.1%
H
3.0
80.1
|
L
 -99.7%
H
3.0
2997.5
|
L
H
3.0
41769
|
L
H
3.0
41769
|
| Spero Therapeutics Inc |
|
67.7
|
1.2
|
L
 -2.5%
H
1.2
1.2
|
L
 -1.7%
H
1.2
1.3
|
L
 -47.3%
H
1.1
2.3
|
L
 -52.8%
H
1.1
3.1
|
L
 -49.1%
H
1.1
3.1
|
L
 -23.0%
H
0.5
3.2
|
L
 -91.2%
H
0.5
19.9
|
L
H
0.5
23.6
|
| ARS Pharma Inc |
|
509.4
|
5.1
|
L
 -8.9%
H
5.1
5.6
|
L
 -13.6%
H
5.1
6.1
|
L
 -35.4%
H
5.1
8.7
|
L
 -40.1%
H
5.1
10.9
|
L
 -70.1%
H
5.1
18
|
L
 -28.6%
H
2.6
18.9
|
L
 -83.1%
H
2.6
31.7
|
L
H
2.6
63.4
|
| SeqLL Inc |
|
36.1
|
0.7
|
L
H
0.7
0.7
|
L
 -8.9%
H
0.7
0.8
|
L
 -20%
H
0.6
1.0
|
L
 -48.6%
H
0.4
1.8
|
L
 -53.9%
H
0.4
5.3
|
L
 100%
H
0.3
35.4
|
L
H
0.2
35.4
|
L
H
0.2
35.4
|
| Sarepta Therapeutics Inc |
|
1,568.9
|
14.9
|
L
 -4.5%
H
14.8
15.6
|
L
 -5.2%
H
14.8
16.7
|
L
 -18.4%
H
14.8
20.9
|
L
 -30.9%
H
14.7
23.5
|
L
 -6.6%
H
14.7
25.3
|
L
 -86.2%
H
10.4
173.3
|
L
 -78.1%
H
10.4
173.3
|
L
 -42.6%
H
10.4
181.8
|
| Scholar Rock Holding Corp |
|
5,667.9
|
47.3
|
L
 -3.5%
H
46.9
49.3
|
L
 -0.8%
H
46.9
50.1
|
L
 -10.5%
H
46.9
58.5
|
L
 2.0%
H
43.2
58.5
|
L
 30.1%
H
27.1
58.5
|
L
 590.5%
H
5.9
58.5
|
L
 51.4%
H
4.3
58.5
|
L
H
4.3
70
|
| Surrozen Inc |
|
257.9
|
22.2
|
L
 6.6%
H
20.8
22.6
|
L
 12.6%
H
18.1
22.6
|
L
 -13.0%
H
18.1
26.8
|
L
 -33.9%
H
18.1
35
|
L
 101.9%
H
9.0
35
|
L
 2544.0%
H
0.3
35
|
L
H
0.3
35
|
L
H
0.3
35
|
| Stoke Therapeutics Inc |
|
1,797.4
|
28.9
|
L
 -3.9%
H
28.7
30
|
L
 -1.5%
H
28.5
30.9
|
L
 -11.8%
H
27.2
33.7
|
L
 -12.8%
H
27.2
35.2
|
L
 123.6%
H
12.7
40.2
|
L
 352.4%
H
3.4
40.2
|
L
 0.8%
H
3.4
40.2
|
L
H
3.4
71.6
|
| Sutro Biopharma Inc |
|
400.5
|
24.2
|
L
 -2.6%
H
23.8
25.1
|
L
 5.6%
H
22.8
25.1
|
L
 -20.1%
H
21.7
33.4
|
L
 -32.1%
H
21.7
43.9
|
L
 198.4%
H
7.2
43.9
|
L
 -45.7%
H
5.2
61.3
|
L
 -85.8%
H
5.2
237
|
L
H
5.2
283
|
| Shattuck Labs Inc |
|
675.2
|
7.1
|
L
 -1.7%
H
6.9
7.4
|
L
 -4.9%
H
6.6
7.7
|
L
 8.6%
H
6.1
7.8
|
L
 1.1%
H
3.3
7.8
|
L
 868.5%
H
0.7
8.3
|
L
 207.4%
H
0.7
11.8
|
L
 -67.9%
H
0.7
23.0
|
L
H
0.7
60.5
|
| Supernus Pharma Inc |
|
2,590.3
|
44.6
|
L
 -2.2%
H
44.4
45.7
|
L
 -3.4%
H
44.4
48.5
|
L
 -5.9%
H
44.4
51.4
|
L
 -6.7%
H
42.5
53.0
|
L
 25.7%
H
35.5
59.7
|
L
 40.8%
H
22
59.7
|
L
 69.5%
H
22
59.7
|
L
 100.9%
H
13.1
61.3
|
| Savara Inc |
|
1,118.9
|
5.5
|
L
 -1.4%
H
5.4
5.6
|
L
 -0.9%
H
5.2
5.7
|
L
 -9.9%
H
5.2
6.5
|
L
 6.6%
H
4.7
6.5
|
L
 110.8%
H
2.4
7
|
L
 52.9%
H
1.9
7
|
L
 326.6%
H
1.0
7
|
L
 -78.1%
H
0.7
49.6
|
| China SXT Pharma Inc |
|
2.3
|
0.1
|
L
 -14.3%
H
0.1
0.1
|
L
H
0.1
0.1
|
L
 -97.6%
H
0.1
2.9
|
L
 -97.1%
H
0.1
2.9
|
L
 -96.5%
H
0.0
7.0
|
L
 -98.7%
H
0.0
9.4
|
L
 -99.8%
H
0.0
57
|
L
H
0.0
2335
|
| 60 Degrees Pharma Inc |
|
3.1
|
1.2
|
L
 -6.4%
H
1.1
1.2
|
L
 -21.0%
H
1.1
1.7
|
L
 -33.1%
H
1.1
1.8
|
L
 -29.5%
H
1.1
1.9
|
L
 -78.0%
H
1.1
8.6
|
L
 -99.8%
H
1.1
516
|
L
H
1.1
2076
|
L
H
1.1
2076
|
| Sanofi (ADR) |
|
103,225.6
|
43.1
|
L
 0.4%
H
42.5
43.1
|
L
 -0.6%
H
41.4
45.7
|
L
 3.5%
H
41.4
45.7
|
L
 -1.3%
H
40.9
45.7
|
L
 -7.9%
H
40.9
52.7
|
L
 -18.8%
H
40.9
60.1
|
L
 -16.4%
H
36.9
60.1
|
L
 1.4%
H
36.8
60.1
|